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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by amyloid
plaques that are comprised of aggregated amyloid- peptides. These toxic proteins
promote mitochondrial dysfunction and neuronal cell death. A shift in metabolism away
from oxidative phosphorylation and toward aerobic glycolysis, with the concomitant
production of lactate, affords neurons a survival advantage against amyloid- toxicity.
Recent evidence now suggests that aerobic glycolysis in the brain plays a critical role in
supporting synaptic plasticity, learning, and memory. However, the role of aerobic
glycolysis and lactate metabolism in AD-mediated cognitive decline is unknown. My
objective was to test the hypotheses that aerobic glycolysis is upregulated in neurons to
mediate amyloid- resistance and promote memory processes in vivo using the APP/PS1
mouse model of AD. Cerebral lactate levels within the frontal cortex of control mice
were found to decline with age, whereas lactate levels remained unaltered in APP/PS1
mice. An age-dependent decline in levels of key aerobic glycolysis enzymes and an
increase in lactate transporter expression were detected in control mice. Increased
expression of lactate-producing enzymes correlated with improved memory performance
in control mice, yet the opposite effect was detected in APP/PS1 mice. To determine if
aerobic glycolysis plays a role in mediating spatial memory processes, mice were injected
with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Dichloroacetate
caused a reduction in conversion of pyruvate to lactate in the brain and a decline in
phosphorylation of pyruvate dehydrogenase, the target of dichloroacetate, yet there was
no significant effect on memory. In agreement with previous observations, a correlation
analysis of cortical extracts revealed that increased phosphorylation of pyruvate
dehydrogenase correlated with better spatial memory in control mice. These observations
indicate that production of lactate, via aerobic glycolysis, is beneficial for memory
function during normal aging, yet is not explicitly required for spatial memory tasks. In
addition, elevated lactate levels in APP/PS1 mice indicate perturbed lactate processing, a
factor that may contribute to memory impairment in AD. Collectively, this research
demonstrates several novel observations that will lead to a better understanding of
cerebral lactate metabolism in the AD brain and aid in the development of metabolic
strategies to treat this devastating disease.
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Chapter 1

1

Literature review

The motivation for this work comes primarily from two research questions that I aim to
answer: does lactate metabolism in the brain mediate resistance to amyloid- plaques,
and does lactate metabolism in the brain contribute to memory? This literature review
will provide background information on three main areas of research that all converge in
this thesis: (1) Alzheimer’s disease, (2) the link between cerebral metabolism and
Alzheimer’s disease, and (3) the link between cerebral metabolism and memory. First, I
provide a background of the underlying causes of Alzheimer’s disease and the current
state of Alzheimer’s disease research, which is shifting toward early diagnosis and
prevention. Second, I introduce the link between Alzheimer’s disease and glucose
metabolism, as well as the metabolic phenotype of aerobic glycolysis and associated
lactate metabolism that is central to this work. I also introduce relevant components of
the metabolic pathways involved in aerobic glycolysis because they are integral to several
experiments performed. Third, I review neuron and astrocyte metabolic coupling and the
role of lactate in memory. Finally, I provide the rationale for the questions driving this
research, as well as the specific aims of this work, and the central hypotheses.

1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disease that
affects the elderly and is the most common form of dementia worldwide. AD represents a
considerable challenge to the Canadian health care system due to its high prevalence in
the population (564,000 Canadians in 2016, or 1.5% of the population), rising incidence
(projected 937,000 Canadians in 2032, or 2.8% of the population), and high cost of care
for individuals with dementia ($10.4 billion in annual cost to Canadians in 2016)1. There
are two different types of AD: early-onset (familial) and late-onset (sporadic). Familial
AD affects less than 1% of all cases of AD and is directly caused by a genetic mutation
resulting in the development of AD before the age of 65, sometimes as early as 302,3. The
vast majority of AD patients have the sporadic version, in which the exact cause is
unknown although several risk factors have been identified including age, genetics, diet,
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and lifestyle4. Diagnosis of dementia is based on a physician’s evaluation of cognitive
tests and criteria given in the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV), yet an individual with AD will progress through different
stages of the disease as cognitive and functional abilities decline. Symptoms of AD
commonly begin with mild cognitive impairment (MCI) characterized by confusion or
loss of memory that disrupts daily life and eventually leads to loss of executive functions
including speaking, swallowing, and walking. As the disease progresses, more
pronounced dementia arises leading to physical complications, such as immobility and
malnutrition, which can increase the risk of other serious complications, including
pneumonia, ultimately leading to death of the individual5. The median survival time of
individuals with AD depends on age and is approximately 8 years from diagnosis to death
for individuals over 65 years of age, and less than 4 years for individuals aged over 90
years6.

1.1.1

Causes of Alzheimer’s disease

AD was first characterized in 1906 by Alois Alzheimer after post-mortem analysis of a
55 year old woman with pre-senile dementia revealed the presence of dense protein
deposits in both the intracellular and extracellular regions of the brain7. The intracellular
deposits, commonly known as neurofibrillary tangles (NFTs), are composed of
aggregates of the microtubule-associating protein tau (tubulin-associated unit), that arise
from abnormal hyperphosphorylation8–10. The extracellular deposits are known as
amyloid plaques and are primarily comprised of an aggregated peptide called the
amyloid- peptide (A) derived from the proteolytic cleavage of the amyloid precursor
protein (APP)11,12. These two distinct pathologies, amyloid plaques and neurofibrillary
tangles, have formed the neuropathological criteria for post-mortem diagnosis of AD13.
The etiology of AD has evolved over the past 100 years and has now been attributed to
the accumulation of several different pathological features in the brain that collectively
lead to neurodegeneration and dementia. Researchers have attempted to understand the
causes of AD by focusing on the specific mechanisms that lead to AD pathology in order
to design effective interventions for the prevention, attenuation, or reversal of disease
progression.
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Tau Protein
In 1986, a link between tau and neurodegenerative diseases was established with the
extraction and subsequent identification of hyperphosphorylated tau as the primary
component of NFTs in the AD brain8–10,14. The tau protein, also known as the
microtubule-associating protein tau (MAPT), is one member of a family of microtubuleassociating proteins, including MAP1(A/B) and MAP2, that are functionally redundant
and widely expressed, especially in the central nervous system15. The tau protein
functions to promote assembly and organization of microtubules, which are important for
growth of axons and dendrites in neurons16. Tau is regulated by phosphorylation; the
degree of which can lead to a conformational change that impairs its ability to promote
microtubule assembly17,18. Mutations in the tau gene MAPT cause Frontotemporal
dementia and Parkinsonism linked to chromosome 17 (FTDP-17), a neurogenerative
disease known as a “taupathy”19–21. While hyperphosphorylation of tau and accumulation
of NFTs are common in taupathies, they lack the characteristic amyloid plaques of AD,
suggesting that NFTs alone cannot cause AD. In addition, no mutations in MAPT have
been found associated with familial AD, suggesting that A is the initiator of AD
pathogenesis22. Human genetic and biomarker studies have suggested A deposition
precedes tau hyperphosphorylation and that neurofibrillary tangles are a late-stage
pathology correlating more closely with symptom severity in AD patients than amyloid
plaques23–26. A recent study using transgenic mice expressing a human tau repeat domain
demonstrated that amyloid plaques are necessary but not sufficient for the conversion of
wild-type to pathological tau, suggesting that a second risk determinant (risk
alleles/factors) is required to drive the pathological conversion of tau27.

Amyloid precursor protein processing to generate amyloid- peptides
The most prevalent theory for the root cause of AD is the amyloid cascade hypothesis,
which posits that AD arises from the abnormal deposition, or improper clearance, of A
in the brain28. This was largely supported by the discovery that all of the familial versions
of AD are caused by mutations within the APP gene itself or within genes that directly
affect APP processing in favor of A production29. In contrast, a mutation in APP that
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results in a reduction of A was found to be protective against AD and age-related
cognitive decline30. The discovery of the APP gene was made possible by the
identification of the amino acid sequence of the A peptide isolated from the AD
brain11,31 and was subsequently used to clone the APP gene and map the location to
chromosome 2132. Consistent with this discovery, individuals with trisomy 21 (Down
syndrome) develop dementia at an early age and display plaques and tangles consistent
with AD pathology33.
APP is one member of a family of single-pass transmembrane proteins that includes the
amyloid precursor-like proteins (APLP1 and APLP2) in mammals, all of which are
highly homologous and functionally redundant34. APP and APLP2 are ubiquitously
expressed but APLP1 expression is restricted to the nervous system35. The biological
function of the APP is still unclear although several studies have suggested that APP
participates in cell adhesion, neurite outgrowth, synaptogenesis, and neuron survival36–39.
Knockout mice individually lacking APP, APLP1, or APLP2 are viable and fertile with a
small growth deficit, minor behavioural phenotypes, and a reduced number of synaptic
vesicles at presynaptic terminals40–42. Mice lacking both APP and APLP2, or APLP1 and
APLP2, display perinatal lethality41. Yet mice lacking APP and APLP1 are viable and
fertile, indicating a key physiological role for APLP241. Despite the functional
redundancy of the APP family, APP itself is the only member that generates the
amyloidogenic peptide, due to sequence differences at the internal A cleavage site43.
APP is highly expressed in neurons and is processed in the Golgi apparatus and
transported in vesicles down the axon where it collects at the cell surface of the
synapse44.
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Figure 1. Schematic of amyloid precursor protein processing
APP is a transmembrane protein that is cleaved in two distinct
pathways: non-amyloidogenic (left) or amyloidogenic (right). Cleavage
by the -secretase followed by the -secretase generates the nonamyloidogenic P3 fragment. In contrast, cleavage by the -secretase
followed by the -secretase results in the generation of the
amyloidogenic A peptide, which can subsequently form oligomers and
fibrils that are neurotoxic.
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In the non-amyloidogenic pathway, APP is first cleaved by the -secretase to release the
extracellular secreted -APP (sAPP) ectodomain. APP is then cleaved by the secretase, which generates the non-amyloidogenic extracellular P3 fragment and the APP
intracellular domain (AICD) C-terminal fragment . In the amyloidogenic pathway, APP
is first cleaved by the -site APP-cleaving enzyme 1 (BACE1), which produces the
extracellular secreted -APP cleavage product (sAPP). Subsequent cleavage of APP by
the -secretase then generates the intracellular AICD fragment and releases the
extracellular A (pathogenic) fragment. The -secretase cuts at one of several different
sites to produce A peptides of varying sizes with A(1-40) and A(1-42) being most
common. Presenilin 1 (PSEN1) and presenilin 2 (PSEN2) are homologous proteins that
form the active site of the -secretase complex. Autosomal dominant mutations have
been identified in both PSEN1 and PSEN2 that favor the cleavage of A(1-42) in familial
AD46–48. The A1-42) peptide in particular is hydrophobic and highly prone to undergo
self-aggregation forming insoluble fibers leading to the development of amyloid
plaques49,50. Until recently there was no known biological function of the A peptides,
but a recent study reported that injection of Salmonella typhimurium in a mouse model of
severe amyloid pathology accelerated amyloid plaque deposition which co-localized to
invading bacteria and prevented their attachment to host cells, suggesting that A might
play a role in antimicrobial defense51. A is actively metabolized and cleared in the
normal brain, however individuals with AD have increased production or reduced
clearance which leads to an age-dependent accumulation of A and deposition of plaque
in the brain52,53.

Apolipoprotein E
Aside from the characteristic plaques and tangles of AD pathology, several genetic and
environmental risk-factors have been shown to be directly associated with AD onset. The
most prominent genetic risk factor for sporadic AD is the 4 polymorphism in the
apolipoprotein E (APOE) gene, which increases the risk of AD 5- to 15-fold depending
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on the allelic dosage54–56. The prevalence of the 4 allele in AD patients is greater than
50%, while individuals homozygous for 4 have a 95% chance of developing AD by the
age of 80 years old57. Although the epidemiological link between APOE-4 and AD is
well established, the mechanism by which 4 is a risk factor for AD remains largely
unclear. APOE is a 34 kDa lipid binding protein that transports cholesterol and
triglycerides throughout the body by binding to cell surface lipoprotein receptors58. In
humans, there are three different APOE isoforms (2, 3, and 4), which differ from each
other by a single amino acid affecting lipid association and receptor binding59,60. The 4
allele is the only variant that increases risk of AD, while the 2 allele is associated with
protection against AD and the 3 allele has no correlation with AD55,61. The link between
APOE and AD is likely through clearance mechanisms of A. APOE is a chaperone
molecule that binds directly with amyloid plaques54. The 3 isoform binds to A with
higher affinity and clears more efficiently than 462. Accordingly, APOE-3 mice
displayed fewer amyloid plaques than 4 mice63,64. AD patients with APOE-4 display
increased plaque load in both sporadic and familial variants, as well as in subjects with
amyloid load but are cognitively normal 65–67. Interestingly, the 4 iosoform has also been
implicated as a transcription factor that promotes the activation of genes associated with
programmed cell death, microtubule disassembly, synaptic function, and insulin
resistance68. It is also a known risk factor for other neurodegenerative diseases including
cerebral amyloid angiopathy (CAA), taupathies, Parkinson’s disease, and multiple
sclerosis, suggesting it plays a general role in susceptibility to neurodegeneration69–72.

Age
The single greatest risk factor for AD is age. Epidemiological evidence suggests that
beyond the age of 60 the incidence of sporadic AD rises exponentially with the risk
doubling every 5 years after 6573–75. Even in individuals afflicted with familial AD, the
disease rarely develops before the age of 45, suggesting significant A accumulation or
age-associated brain changes are necessary before the onset of cognitive decline2,3. The
aging process itself carries an inherent risk of cognitive dysfunction. Normal aging is
associated with reductions in gross brain volume76–79, accelerated atrophy in the
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hippocampus and cortex76,80–82, and disruption of episodic memory83,84. In fact,
significant A accumulation also occurs in cognitively normal elderly individuals and
may simply be a part of normal aging85–87. These features of the aging brain make it
difficult to tease apart the relative contributions of aging and AD-pathology to cognitive
decline88, which has led to a new proposed diagnostic criteria for AD that incorporates
the use of biomarkers showing underlying pathogenesis89–92. The link between aging and
AD likely involves the progressive accumulation of A either through over production in
familial AD or through reduced ability to clear A in sporadic AD52,93,94. Evidence in
support of this model comes from preclinical investigation using multi-modal imaging
strategies to demonstrate that abnormal A biomarkers are the earliest indicators of AD95.
Yet at some point a pathological threshold of A accumulation is reached which triggers
a cascade of downstream processes that mediates neurodegeneration96,97.

1.1.2

Toward Alzheimer’s disease prevention

Since 2002, there have been over 400 clinical trials for AD therapeutics with an overall
failure rate of 99.6%98. Current FDA-approved treatment options for AD patients are
limited to acetylcholinesterase inhibitors for mild-to-moderate dementia and the Nmethyl-D-aspartate (NMDA)-receptor antagonist Memantine for moderate to severe
dementia99–103. These therapies reduce the severity of symptoms for AD patients but do
not alter the course of the disease progression. In fact, there are currently no FDAapproved therapies that prevent or reverse cognitive decline in AD104. A growing
consensus has emerged that the problem with failed clinical trials may not be related to
the strategy of targeting AD pathology, or even the animal models for testing pre-clinical
candidate drugs, but that the therapies are applied to human patients too late to alter the
course of sustained brain damage105,106. In recent years a large initiative toward
prevention of AD has been undertaken, in which the goal is to discover the earliest
reliable biomarker for probable AD in order to implement therapeutic or lifestyle
interventions for at-risk individuals before the onset of neurodegeneration and
dementia107. In 2005, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) was
launched with the goal of tracking the progression of AD and establishing criteria for
early diagnosis108,109. In 2008 an international partnership called the Dominantly
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Inherited Alzheimer’s Network (DIAN) was initiated to develop a database of AD
individuals carrying familial mutations while their non-carrier siblings act as genetically
similar controls110. The goal is to determine a temporal sequencing of preclinical AD
biomarkers in order to identify the most ideal therapeutic window for treatment of at-risk
AD patients. More recently an initiative called the Alzheimer’s Prevention Initiative
(API) was started with the goal of evaluating the extent to which AD-modifying
treatments predict clinical benefit in at-risk individuals111,112. Despite the fact that all
individuals registered with the DIAN carry autosomal dominant mutations for AD, the
pathological phenotype of familial AD is largely similar to sporadic AD, which has
prompted some to suggest that they are the same disease just with an age delay in
sporadic individuals113,114. Another reason why subjects with autosomal dominant AD
mutations are recruited for these clinical trials is because defining preclinical AD in
sporadic individuals is difficult even when significant A is detected in the brain by
positron emission tomography (PET) and in the cerebrospinal fluid (CSF) by ELISA
analysis115–117.
These neuroimaging initiatives use a variety of techniques to measure pathological
changes in the brain, of which the two most reliable biomarkers of AD pathophysiology
are measurements of the CSF and PET imaging. The CSF can be used to detect
alterations in A and tau as a reflection of physiological changes to amyloid plaques and
neurofibrillary tangles occurring in the brain. Reductions in A(1-42) and increased
phosphorylated-tau or total tau in the CSF correlate well with late-stage
neurodegeneration and cognitive decline115,118–121. PET scans are a useful imaging
technique to measure a wide variety of parameters depending on the radio-labelled tracer
used in the analysis. The two most commonly used tracers are the 11C-labeled Pittsburgh
compound B (PiB) that binds with high specificity and high affinity to fibrillar-A found
predominantly in amyloid plaques122, and the
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F-fluorodeoxyglucose (FDG) compound

that is an analog of glucose used to measure glucose metabolism in the brain123,124.
Biomarker research from the ADNI and DIAN programs provided a clear picture of
preclinical AD progression that begins with A accumulation in the brain and follows in
a sequence of cerebral inflammation, oxidative stress, synaptic loss, regional
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hypometabolism, tau pathology accumulation, and finally atrophy, neurodegeneration,
and dementia125–132. These studies also identified an interesting phenomenon in AD
pathogenesis: A accumulation begins decades before clinical diagnosis of AD-dementia.
PiB-PET scans suggest that deposition of amyloid plaque can begin 20 to 30 years before
the onset of cognitive decline, while reductions of A(1-42) in CSF are present up to 25
years before symptom onset25,131,133,134. Pathological changes in CSF tau were detected up
to 15 years before the onset of clinical symptoms, while individuals with both abnormal
A and tau CSF biomarkers were associated with a more rapid progression to a clinical
state25,133,135–137. Cerebral hypometabolism and impaired episodic memory also occurred
10 years before expected symptom onset, suggesting that neurodegeneration precedes
clinical diagnosis by up to a decade25.

Non-demented individuals with Alzheimer’s disease neuropathology
Although A accumulation and tau hyperphosphorylation have been consistent
pathological features of AD, the presence of these biomarkers is also observed in
cognitively normal elderly people138. This group of individuals, which have been called
non-demented individuals with AD neuropathology (NDANs), were first discovered in
1968 after autopsy of cognitively normal individuals found 8 of 28 brains to have
amyloid plaque deposition and neurofibrillary tangles similar to AD patients139. Since
then it has been established that approximately 30-50% of the elderly (aged 57 to 102)
are cognitively normal yet have A and tau pathology indistinguishable from AD patients
of the same age140–143,85,144–148. In fact, the distribution of amyloid plaques and NFTs
matches the pattern in AD patients and the sequence of pathological events is the same as
AD irrespective of cognitive status149–151. However, it is currently unclear if all
cognitively normal individuals with AD biomarkers will eventually develop AD-related
dementia. Some have argued that NDAN individuals are in the preclinical stages of AD
and will eventually progress to AD with increased age152–156, while others suggest that
AD pathology may be a normal part of the aging process157. Several studies have shown
that CSF A(1-42) and tau can predict cognitive decline in healthy individuals with a mean
follow up of at least 3 years158–160. One study demonstrated that NDAN individuals
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meeting criteria for intermediate likelihood or high likelihood of AD displayed subtle
deficits in episodic memory after adjusting for age, sex, and education161. Yet, another
study found that measures of cognition did not correlate with any of the measured AD
biomarkers within cognitively normal individuals162. In addition, some longitudinal
studies showed only about 20% of individuals positive for AD biomarkers will progress
from cognitively normal to MCI or AD-related dementia with a mean follow-up of 2.8
years25,131. Due to an estimated lag time of 15 to 20 years between the appearance of AD
biomarkers and onset of cognitive impairment, it is still unknown if all individuals
positive for AD biomarkers will progress to AD. However, it is clear that certain
environmental and lifestyle factors can either increase or reduce the risk of developing
AD-related dementia in cognitively normal individuals.
Epidemiological evidence suggests that several different environmental factors can
reduce or increase the risk of developing dementia163. The dementia risk reducing factors
include: higher education, aerobic exercise, cognitive training, social engagement, and
healthy diet; while the dementia risk increasing factors include: smoking, diabetes,
obesity, hypertension, traumatic brain injury, depression, and sleep disturbances163.
Collectively these findings suggest that certain adjustable lifestyle choices can impact the
healthy aging of the brain despite the presence of neuropathology and has led to the
argument that a greater emphasis should be placed on preventative measures to treat AD
in at-risk individuals164. While it is clear that environmental factors can alter the risk of
developing dementia, the biological mechanisms underlying this effect are still unknown.
The association between lifestyle effects and progression of AD pathology has been
inconsistent. It has been shown that physical activity and cognitive engagement can
reduce A and tau pathology in middle-aged at-risk individuals165–167, yet this finding
was not replicated in a follow up study168. In addition, these observations do not explain
how some individuals can tolerate AD neuropathology and remain cognitively normal.
One prevalent theory that explains the discrepancy between neuropathological changes
and their clinical expression is called “cognitive reserve”, which refers to the capacity of
the brain to tolerate pathological insult169. The proposed mechanism involves both
passive and active models170. The passive model simply refers to an anatomical

12

difference in brain size with increased neuron count and a higher threshold for AD
pathology or neurodegeneration. The active model refers to the adaptive use of
underlying neurological networks to compensate for neuropathology and localized insult.
Taken together, individuals with higher cognitive reserve will tolerate an overall higher
burden of AD pathology before succumbing to cognitive impairment171,172. In fact,
cognitive decline is delayed in individuals with higher reserve173–175, yet progresses more
rapidly than lower reserve individuals once a pathological threshold is reached173,176–179.
Several studies have shown associations between higher cognitive reserve and structural
changes in the brain, including neurogenesis, synaptic density, synaptic protein
expression, neuronal density, dendritic complexity, and neuronal hypertrophy180–186. Yet,
a causal mechanism underlying cognitive reserve and maintenance of brain function in
the presence of AD pathology has yet to be demonstrated.

1.2 Glucose metabolism and Alzheimer’s disease
A progressive decline in brain glucose metabolism, called cerebral hypometabolism, is a
common feature of AD that correlates temporally with symptom severity and has high
predictive value for onset of dementia153,187–191. Current estimates suggest that cerebral
glucose metabolism is 20-25% lower in the AD brain192. Cerebral hypometabolism has
been traditionally perceived as a result of decreased energy demand due to synaptic
dysfunction and neuronal loss at later stages of the disease193. However, there is a
growing consensus that impaired glucose metabolism precedes clinical symptoms in AD
and may serve as a preclinical biomarker153,188,190,191,194–196. Impaired glucose metabolism
is likely due to mitochondrial dysfunction, which is directly caused by A interference
with mitochondrial enzymes. The A peptide has been shown to progressively
accumulate in the mitochondria of CNS neurons in both AD patients and AD transgenic
mice prior to amyloid plaque deposition and cognitive deficits197–200. In addition,
embryonic neurons derived from the hippocampus of triple-transgenic AD female mice
displayed reduced mitochondrial respiration and increased glycolysis, suggesting that
mitochondrial dysfunction occurs early in AD pathogenesis199. Defects in mitochondrial
metabolism are also well documented in the human AD brain201.
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Amyloid- and the mitochondrion
The mitochondrion is a vital organelle responsible for producing the majority of cellular
ATP and regulating cell survival. Several in vitro and in vivo studies have directly linked
A exposure to mitochondrial dysfunction including the inhibition of respiratory chain
complexes, reduced membrane potential and ATP levels, and increased reactive oxygen
species (ROS) production, as well as mitochondrial swelling and depolarization leading
to the induction of apoptosis202–211. Consistent with the targeted production of A in
synaptic terminals, A preferentially accumulates in synaptic mitochondria and likely
contributes to early synaptic dysfunction in AD212. Certain soluble species of oligomeric
A are amphipathic in nature and have the ability to permeabilize lipid bilayers thereby
passively entering the mitochondria213–216. APP also contains a mitochondrial targeting
signal and can be actively imported into the mitochondria by the translocase of the outer
membrane (TOM) machinery217,218. Once inside the mitochondria, A directly binds to
and impairs the activity of the pyruvate dehydrogenase (PDH) complex, which is
responsible for converting pyruvate to acetyl-coenzyme A (acetyl-CoA) and is the first
committed step for pyruvate to oxidative phosphorylation in the mitochondria204. Aalso
impairs activity of proteins in the tricarboxylic acid (TCA) cycle and the electron
transport chain (ETC), including the -ketoglutarate dehydrogenase complex (KGDHC) and cytochrome oxidase (COX)204,219. Reduced activity and expression of these
enzymes in the AD brain has been well documented220–222. This diminished enzyme
activity leads to a reduction in oxygen consumption rate and ATP production, suggesting
a direct link between defective mitochondrial and preclinical hypometabolism in AD209.
Defective mitochondria can produce high levels of ROS, which can lead to a state of
oxidative stress and is a common feature of AD. Under normal circumstances,
physiological levels of ROS function as important redox-dependent signaling molecules
that regulate cellular growth and homeostasis223. The ETC of the mitochondria is the
main source of cellular ROS via the reduction of oxygen to the superoxide free radical
anion and subsequent conversion to hydrogen peroxide by superoxide dismutase224. An
overproduction of ROS or a decline in antioxidant response can lead to oxidative damage
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and ultimately cell death. The AD brain displays several markers of oxidative damage to
biomacromolecules including proteins, nucleic acids and lipids225,226. In vitro work has
demonstrated a dose-dependent effect between A and mitochondrial-derived oxidative
stress and neuronal toxicity227,228. Synergistic effects between A and tau have been
observed in the mitochondria of triple-transgenic AD mice leading to reduced ATP
production and an increase in oxidative stress229. Moreover, mitochondrial-derived
oxidative stress has been shown to potentiate A formation and suggests a feed-forward
mechanism in AD pathogenesis230. This has led to the oxidative stress hypothesis of AD,
which posits that the generation of oxygen free radicals from the mitochondria participate
in the cascade of events that lead to neuronal death in AD231.

Cerebral hypermetabolism in Alzheimer’s disease
In contrast to cerebral hypometabolism in AD, the exact opposite effect (cerebral
hypermetabolism) has also been observed in the AD brain at very early stages of the
disease. This may represent an early compensatory mechanism in response to A
accumulation and mitochondrial dysfunction. A recent PET study of autosomal dominant
AD mutation carriers revealed regionally higher glucose uptake ~25 years before the
estimated age of onset232. PET imaging of cognitively normal people at risk for AD
revealed area-specific increases in both Aβ deposition and glucose metabolism in
individuals before MCI233. Although reduced glucose metabolism was observed 5 to 10
years before the estimated age of onset in many cortical areas with Aβ deposition, a
divergent pattern was observed subcortically; the caudate and pallidum did not show
either metabolic decline or atrophy, despite markedly elevated PiB uptake232. APP/PS1
transgenic-AD mice display an age-dependent increase in glucose uptake in the
hippocampus and cortex that precedes cognitive impairment and correlates spatially with
amyloid plaque deposition234. In addition to these observations, the same enzymes that
were shown to be inhibited by A at later stages of the disease, COX and -KGDHC, can
also be up-regulated before the appearance of amyloid plaques in the APP(Tg2576) mouse
model of AD235.
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Cerebral hypermetabolism in the preclinical AD brain may be accounted for by the
compensatory up-regulation of glycolytic machinery in response to mitochondrial
damage. Glycolysis is the metabolic pathway in the cytosol that breaks down glucose to
pyruvate with the concomitant production of ATP and NADH. The specific activity of
the glycolytic rate-limiting enzymes phosphofructokinase-1 (PFK), hexokinase (HK), and
pyruvate kinase (PK) were found to be increased in the frontal and temporal cortex of AD
patients236–238. Increased activity was also found for lactate dehydrogenase (LDH), the
enzyme responsible for the production of lactate as the end-product of glycolysis238.
Embryonic neurons derived from the triple-transgenic AD mouse hippocampus displayed
reduced mitochondrial respiration but increased rates of glycolysis199. In addition, recent
evidence has revealed that nerve cells can be made to be resistant to A toxicity by
undergoing a metabolic shift toward enhanced glycolysis and reduced oxidative
phosphorylation in the mitochondria239,240. Thus, glycolytic metabolism may be elevated
in certain regions of the brain as a compensatory mechanism in response to A
accumulation and mitochondrial dysfunction. Loss of this protective mechanism may
render certain areas of the brain susceptible to A-induced neurotoxicity.

1.2.1

Aerobic glycolysis and amyloid- resistance

Under normal conditions, the majority of glucose consumed by the cell is oxidized to
carbon dioxide and water in the mitochondria to yield large amounts of ATP to support
cellular functions. Glycolysis can be up-regulated in a state of low oxygen (hypoxia) or
mitochondrial dysfunction in order to compensate for energy demand with the production
of lactic acid (lactate) as an end-product241,242. However, a characteristic feature of
rapidly proliferating cells is the extensive reliance on glycolysis for energy needs, even
under normoxic conditions. In cancer cells, this type of metabolism is known as the
Warburg effect in recognition of its discovery by Otto Warburg243. The reliance on
glycolysis in the presence of oxygen is commonly referred to as “aerobic glycolysis” and
is a characteristic feature of cancer cells and stem cells244. It is now understood that
aerobic glycolysis occurs in many different cell types including: endothelial cells, skeletal
muscle, vascular smooth muscle, monocytes and leukocytes of the immune system, as
well as astrocytes and neurons of the brain245–252. The relative contribution of glycolysis
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to ATP production highly depends on the cell type, growth environment, and phase of
cell cycle. Through precise measurements of oxygen consumption and lactate production
rates, it has been estimated that glycolysis can account for between 0.94% to 65% of total
ATP produced in the cell with an average of approximately 17% in most tissues 253.
Interestingly, aerobic glycolysis has been estimated to account for up to 85% of ATP
produced in endothelial cells despite their direct contact with oxygenated blood251.
A high glycolytic rate has several advantages for energy-demanding cells. First, despite
its low efficiency at producing energy (2 ATP per glucose) compared to oxidative
phosphorylation in the mitochondria (34 ATP per glucose), glycolysis can generate ATP
at a faster rate when the supply of glucose is abundant254. This feature has obvious
benefits for cellular processes that have a rapid energy demand, such as in maintaining
resting membrane potential via the ATP-dependent Na+/K+-ATPase pump. For neurons,
the Na+/K+-ATPase pump can account for up to 50% of total expended energy255.
Second, proliferating cells require metabolites to support the biosynthetic requirements of
mitosis and glycolytic intermediates can provide the carbon building blocks for the de
novo synthesis of nucleotides, lipids, and non-essential amino acids256,257. In addition to
glycolysis in the cytosol, the supply of acetyl-CoA and glutamine to the TCA cycle
within mitochondria drives the production of metabolites that can be siphoned off to the
cytosol and participate in the anabolic metabolism of amino acids and lipids257. Finally,
the conversion of pyruvate to lactate produces NAD+, which is an important cofactor for
continued glycolytic flux and biosynthesis of nucleotides and amino acids, in addition to
maintaining the NAD+/NADH redox balance of the cytosol258,259. These metabolic
pathways will be described in greater detail in later sections. Thus, when glucose is not
rate-limiting, aerobic glycolysis provides several advantages to the cell and may persist
as the predominant metabolic phenotype despite the presence of oxygen.
Our lab has previously demonstrated that nerve cells selected for resistance to A toxicity
undergo metabolic reprogramming and shift toward aerobic glycolysis through the
stabilization of the transcription factor hypoxia-inducible factor 1 (HIF-1) and upregulation of pyruvate dehydrogenase kinase-1 (PDK1) and lactate dehydrogenase-A
(LDHA)260. Over-expression of either PDK1 or LDHA enzymes in nerve cell lines
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represses mitochondrial respiration and confers resistance to A and other neurotoxins,
whereas chemical or genetic inhibition of these enzymes results in re-sensitization of
resistant lines to A toxicity239,240. Moreover, mitochondrial-derived ROS, which are
closely associated with A toxicity, are markedly diminished in resistant relative to
sensitive cells. By repressing mitochondrial respiration, A-resistant cells are less likely
to produce ROS and are more resistant to mitochondrial depolarization; two events
tightly linked to induction of apoptosis261. In support of this discovery, a recent
multimodal PET imaging study has revealed a strong correlation between the spatial
distribution of elevated aerobic glycolysis in healthy resting individuals and A
deposition in the brains of both healthy individuals and AD patients262. In contrast, brain
regions that rely primarily on oxidative phosphorylation for energy needs displayed little
amyloid burden. The observation that A deposition in the AD brain closely matches the
spatial pattern of elevated aerobic glycolysis in both the healthy and AD brain suggests
that aerobic glycolysis may arise as a mechanism to counter the toxic effects of A in the
AD brain.

1.2.2

Cerebral glucose metabolism

Glucose is nearly the sole fuel source of the human brain263. The metabolism of glucose
in the brain is a complex process integrating several different cell types and competing
biochemical pathways in order to sustain the energy needs of neuronal activation. Here I
describe each step of glucose metabolism as it relates to aerobic glycolysis, the shuttling
of metabolites between astrocytes and neurons, as well as any connections to AD
pathophysiology. Considering the tight connection between aerobic glycolysis and
proliferation, many of the properties of glycolytic enzymes and regulators were
characterized in cancer cells. The first rate-limiting step in cerebral glucose metabolism is
the facilitated transport of glucose across the blood brain barrier. This is mediated by the
glucose transporter (GLUT)-family of integral membrane proteins of which there are 14
members in humans, each with different affinities for glucose and related sugars264.
GLUT-1 is primarily expressed in astrocytes and the capillary endothelium that form the
blood-brain barrier265. Astrocytes are generally believed to act as an intermediary cell
between glucose uptake from the blood and delivery to neurons, yet current models
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suggest that glucose can also diffuse from endothelial cells through the basal lamina and
interstitial fluid (ISF) to neurons where it is directly imported via GLUT-3266–268. GLUT1 and GLUT-3 expression is decreased in the AD brain which correlates spatially with
cerebral hypometabolism269–272. GLUT-1 expression can also be up-regulated by HIF-1
in response to hypoxia273–275. Once glucose is taken into the cell it is irreversibly
phosphorylated by HK1 to form glucose-6-phosphate (glucose-6P), which traps it in the
cell by adding a negative charge to prevent it from diffusing back through the
membrane276. Glucose-6P is the precursor to three main metabolic pathways: glycolysis,
the pentose phosphate pathway (PPP), and glycogenesis (Figure 2).
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Figure 2. Schematic representation of cerebral glucose metabolism
Glucose enters cells via glucose transporters and is phosphorylated by
hexokinase to produce glucose-6-phosphate (Glucose-6P). In
astrocytes, glucose-6P can be reversibly converted to glycogen by
glycogen phosphorylase. Glucose-6P can also enter the pentose
phosphate pathway (PPP) to generate two molecules of NADPH and
Ribose-5-phosphate for the biosynthesis of nucleotides, fatty acids, and
amino acids. Glucose-6P is further metabolized in the cytosol through
glycolysis giving rise to two molecules of pyruvate, ATP, and NADH.
Pyruvate is further processed in the mitochondria through the
tricarboxylic acid (TCA) cycle to produce NADH which fuels oxidative
phosphorylation thereby generating ATP and CO2 while consuming
oxygen. The complete oxidation of glucose produces far larger amounts
of energy in the form of ATP in the mitochondria (34 ATP) compared
to glycolysis (2 ATP). During aerobic glycolysis pyruvate is reduced to
lactate by lactate dehydrogenase which is subsequently released in the
extracellular space.
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The pentose phosphate pathway
The main fate of glucose-6P is to continue through the glycolytic pathway to generate
pyruvate, NADH, and ATP, but it can also be funnelled into the PPP depending on the
redox and energy status of the cell. The PPP is a metabolic branch that runs parallel to
glycolysis and is primarily responsible for generating reducing equivalents in NADPH
and biosynthetic precursors for growing or dividing cells. The first committed step to the
PPP is catalyzed by the enzyme glucose 6-phosphate dehydrogenase (G6PDH), which
oxidizes glucose-6P to 6-phosphogluconolactone while reducing NADP+ to NADPH277.
G6PDH is strongly inhibited by NADPH, while NADP+ is a cofactor for its proper
conformation, thus the cytosolic ratio of NADP+/NADPH is the main modulator of
G6PDH and entry to the PPP278,279. The NADP+/NADPH ratio is also a redox sensor.
NADPH is a necessary cofactor for the reduction of glutathione (GSH) molecules, which
are the primary reducing agents for the cell. Consequently, the PPP is upregulated in
response to oxidative stress in order to replenish depleted glutathione levels280,281. The
PPP is also important for the synthesis of nucleotides and fatty acids. Ribose-5-phosphate
(R5P), an intermediate metabolite of the PPP, is the requisite building block for
nucleotides, while NADPH is a necessary reducing agent for the synthesis of nucleotides,
fatty acids, and amino acids257. Therefore, the PPP is also up-regulated in highly
proliferating cells, including cancer cells, in order to meet the increased demands for
synthesis of biological building blocks282.

Glycogenesis
In astrocytes, glucose-6P can also be converted to glycogen, a polymer composed of
glucose residues that serves as a fuel reserve of the brain283. The prominent role of
glycogen storage in astrocytes is to act as an energy buffer in times of glucose
deprivation or high glucose consumption284–287. Yet, in recent years it has been
hypothesized that the storage and mobilization of astrocytic glycogen serves to enhance
the availability of glucose for neuronal metabolism286,288–291. Neuronal activation can
trigger glycogen breakdown in astrocytes by as much as 20%292, while decreased
neuronal activity during anesthesia is accompanied by an increase in glycogen storage by

21

up to 85%293. Recent evidence also points to a direct association between glycogen
mobilization and functional memory through synthesis of glutamate in astrocytes294,295. In
addition, glycogen-derived lactate has also been shown to contribute to memory
processing via shuttling between astrocytes and neurons296. However, the role of lactate
in brain energy metabolism is still unresolved. Another study has suggested that glycogen
mobilization in astrocytes functions primarily to preserve glucose supply for neurons,
rather than provide neurons with glycogen-derived lactate297. Thus, glycogen storage and
metabolic coupling between astrocytes and neurons are important for proper metabolic
homeostasis during neuronal activity or in cases of severe energy crisis.

Glycolysis
The final rate-limiting step in glycolysis is the conversion of phosphoenolpyruvate (PEP)
and ADP into pyruvate and ATP. This is catalyzed by the enzyme pyruvate kinase (PK),
of which there are four isoforms (M1, M2, L, and R). The L and R isoforms of PK are
exclusively expressed in liver and red blood cells, respectively, while PKM1 and PKM2
are expressed in most adult tissues and arise from alternative splicing of the same M-gene
under regulation of the oncogene C-MYC298,299. The PKM1 isoform assembles as a
constitutively active tetramer for rapid substrate turnover300. In contrast, PKM2 is among
the most tightly regulated enzymes of the glycolytic pathway and is important for
controlling levels of ATP and glycolytic intermediates in the cell. PKM2 can exist as a
tetramer (high activity), or as a dimer (low activity). The dimeric form of PKM2 is
characterized by low affinity for PEP which results in accumulation of glycolytic
intermediates and increased flux through the PPP301. The ratio of PKM2/PKM1 is an
indication of the metabolic phenotype of the cell, whereby high levels of PKM2 promote
aerobic glycolysis and high levels of PKM1 promote oxidative phosphorylation299.
Consistent with this observation, cancer cells preferentially splice the M2 isoform over
M1 through the action of C-MYC in order to promote aerobic glycolysis and
proliferation302. Replacing PKM2 expression with PKM1 effectively inhibited the growth
of xenograft tumors by impairing nucleotide production and promoting cell cycle
arrest303,304. PKM2 is also sensitive to oxidative stress as it can be inhibited by cysteine

22

oxidation to divert more glucose-6P toward the PPP to generate NADPH as an
antioxidant response305.
As the end product of glycolysis, pyruvate has two major fates: conversion to acetyl-CoA
in order to fuel oxidative phosphorylation in the mitochondria, or conversion to lactate to
regenerate NAD+ in the cytosol. The breakdown of pyruvate in the mitochondria occurs
over a series of successive reactions in the citric acid cycle that ultimately produces
NADH and FADH2 as reducing equivalents to drive the proton gradient necessary for
oxidative phosphorylation and ATP production. The first committed step in this process
is the irreversible decarboxylation and acetylation of pyruvate to acetyl-CoA with the
concomitant reduction of NAD+ to NADH. This is catalyzed by PDH, which is a
ubiquitously expressed protein complex composed of four sub-complex proteins (E1, E2,
E3, and the E3 binding protein)306. The PDH complex serves as a critical link between
glycolysis and the citric acid cycle, and thus its activity is highly regulated at the
transcriptional and post-translational levels. For example, during starvation, the genes of
the PDH complex are repressed in the liver in order to reduce pyruvate metabolism and
maintain glucose levels in the blood stream307. In addition, the products of the PDH
reaction, acetyl-CoA, NADH, and ATP, can exhibit direct feedback inhibition when their
concentrations are sufficiently elevated in the mitochondria308,309. Yet, the principal mode
of PDH regulation is reversible phosphorylation. The E1 subunit of the PDH complex
forms the active site for the oxidative decarboxylation of pyruvate and contains three
target serine residues (at positions Serine-232, -293, and -300) that are susceptible for
post-translational modification by phosphorylation310. Phosphorylation of any serine is
sufficient to completely inhibit the activity of the PDH complex, which allows for the
rapid and reversible regulation of pyruvate metabolism or to maintain energy
homeostasis311.

Pyruvate dehydrogenase kinase
Pyruvate dehydrogenase kinase (PDK) phosphorylates the regulatory serine residues of
PDH, while the pyruvate dehydrogenase phosphatase (PDP) removes the phosphate
groups. There are four isoforms of PDK (PDK1-4), each with unique and overlapping
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tissue expression. PDK1 and PDK2 are expressed ubiquitously while predominantly in
the heart and nervous system, respectively. PDK3 is found only in heart and skeletal
muscle, and PDK4 is expressed in the kidneys, brain, liver, heart and skeletal muscle312.
The PDK isoforms also have different specificity to the PDH-E1 serine residues. All
PDK isoforms are able to phosphorylate Serine-232 and Serine-293, while only PDK1
can phosphorylate all three sites313. The PDK enzymes are themselves tightly regulated at
the transcriptional and post-translational levels. All PDK isoforms are allosterically
activated by high levels of acetyl-CoA, NADH, and ATP (the opposite effect occurs with
the PDH complex), and are inhibited by the mitochondrial accumulation of pyruvate,
NAD+, and ADP314. The expression of PDK2 and PDK4 are upregulated in the heart,
liver, and kidneys during starvation, yet this trend is not observed in the brain315,316. More
recently a growing body of evidence links the expression of PDK1 to cancer cells through
transcriptional activation by HIF-1 as a means of reducing mitochondrial metabolism
and preventing ROS production317–319. Less is known about the role of pyruvate
metabolism in aging or AD. One study has shown that aged rats display a reduction in the
expression of PDK1 and PDK2 in the brain320. Alzheimer’s patients also typically show a
reduction in PDH activity, and increased pyruvate levels in the cerebrospinal fluid may
be a potential biomarker of AD321,322.

Lactate dehydrogenase
Pyruvate that is not imported into the mitochondria can be converted to lactate in the
cytosol. Lactate dehydrogenase (LDH) is the enzyme complex that catalyzes the
reversible conversion of pyruvate to lactate with the concomitant oxidation of NADH to
NAD+. LDH is a ubiquitously expressed tetramer composed of two different subunits,
LDHA and LDHB, which can assemble into five different combinations (LDH-1 through
LDH-5) depending on the relative expression levels of each subunit in the cytosol 323,324.
LDH-1 is comprised entirely of LDHB subunits while LDH-5 is comprised entirely of
LDHA subunits. LDHA favors the forward reaction of pyruvate and NADH to lactate and
NAD+, while LDHB favors the reverse reaction of lactate and NAD+ back to pyruvate
and NADH. The LDHA gene promoter contains two hypoxia response elements, the
essential binding sites of HIF-1, which implicates a role of LDHA in cellular response to
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hypoxia and oxidative stress325. LDHA is also commonly over-expressed in many
tumours and is a promising target for cancer therapy326,327. Previous evidence has
suggested that neurons exclusively express LDHB, while astrocytes can express both
LDHA and LDHB328. However, a more recent report has demonstrated that primary
cultures of rat neurons and astrocytes both preferentially express LDHA, yet are capable
of expressing all isofoms of LDH329. In addition, LDHB expression was higher in freshly
isolated synaptic terminals, which implicates that lactate conversion to pyruvate in
neurons is specific to synapses329. A recent study using a mouse model of advanced aging
demonstrated a progressive shift toward higher LDHA/LDHB ratio resulting in higher
cortical lactate levels with age330. Yet, it has been suggested that the observed elevation
in lactate is unlikely to be caused by a shift in the isoform ratio of LDH due to the near
steady-state conditions of the reaction331. The age-dependent change in LDH expression
and its effect on cerebral lactate metabolism and AD remains to be elucidated.

Hypoxia-inducible factor
Cellular metabolism is a complex process regulated by many intrinsic and extrinsic
factors. Shifts in metabolic states occur naturally in order to meet the energy demands of
active cellular processes while responding to a dynamic environment and changing
nutrient availability. Hypoxia inducible factor-1 (HIF-1) is the master transcriptional
regulator of anaerobic respiration and also plays a key role in promoting aerobic
glycolysis. HIF-1 is a heterodimeric transcription factor comprised of two subunits that
are constitutively expressed: a stable  subunit, and an  subunit that is highly regulated
by changing oxygen levels332. Under normal oxygen conditions, HIF-1 is hydroxylated
by prolyl hydroxylases and targeted for ubiquitin-mediated degradation333.

Under

hypoxic conditions, HIF-1 is stabilized and translocates to the nucleus where it
dimerizes with HIF-1 and induces expression of genes regulated by hypoxic response
elements334. These genes include glucose transporters GLUT-1 and GLUT-3, as well as
glycolytic enzymes and regulators LDHA, and PDK1335. HIF-1 activation represents a
well-characterized mechanism by which the cell can quickly respond to hypoxic
environments by up-regulating glycolysis and inhibiting mitochondrial respiration in
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order to meet cellular energy demands. However, even when oxygen is abundant, HIF-1
can be stabilized and transcriptionally active during periods of rapid proliferation and
increased metabolic demand. HIF-1 expression can be elevated under normoxic
conditions through the PI3K/Akt/mTOR pathway, which results in transcriptional upregulation of PKM2 and promotes cell proliferation336. Expression of HIF-1 is induced
by the glycolytic intermediates pyruvate, lactate and NAD+, in addition to other TCA
cycle metabolites319,335. This feed-forward mechanism perpetuates HIF-1 activity and
contributes to prolonged aerobic glycolysis commonly associated with proliferating cells.
HIF-1 is over-expressed in many human cancers and loss of HIF-1 dramatically slows
tumor growth in nude mice337–340. HIF-1α activation promotes several cellular responses
that are beneficial for a growing tumor, including vascular remodelling, increased
glucose uptake, oxidative stress response, and cell survival. As such, it also directly
opposes known deleterious effects of AD pathophysiology, including reduced cerebral
blood flow, impaired glucose uptake and metabolism, increased oxidative stress, and
uncontrolled cell death341. A has also been shown to decrease HIF-1 expression in
activated astrocytes resulting in a reduced rate of glycolysis342. In addition, nerve cell
lines and primary cortical neurons can be made resistant to A toxicity by activating HIF1 resulting in enhanced glycolysis260.

1.3 Cerebral metabolism and memory
The brain is a very energetically demanding organ. Despite being 2% of the total body
weight, the human brain accounts for approximately 20% of basal metabolism in healthy
adults343,344. An updated account of ATP consumed in the cerebral cortex predicts that
most of the energy is directed at the maintenance of post-synaptic receptors, which
includes the energy used to reverse glutamate-evoked Na+ and Ca2+ fluxes255. The
remaining energy is directed at pumping Na+ ions out of neurons for the maintenance of
resting membrane potentials and the generation of action potentials, while only a small
fraction of total energy consumed is used for neurotransmitter recycling255,345. Current
estimates suggest that approximately 10-12% of the total glucose consumed by the
resting brain is in excess of oxygen consumption, suggesting a role for non-oxidative
(glycolytic) metabolism346–351. Different regions of the resting brain also display different
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levels of glycolytic metabolism. Aerobic glycolysis accounts for nearly 25% of glucose
consumed in two distinct cortical systems: the default mode network (DMN) and areas of
the frontal and parietal cortex351. The DMN is defined as the region of the brain that
shows high levels of activity when no explicit task is performed, while the frontal and
parietal cortex are associated with task control processes352–355. In contrast to these brain
regions displaying higher levels of aerobic glycolysis, the cerebellum relies almost
entirely on oxidative phosphorylation for energy needs. These observations could be
explained by the ratio of neurons to astrocytes in each brain region. The cerebral cortex
contains only about 19% of the brains’ total neurons and 72% of non-neuronal cells,
while the cerebellum contains approximately 80% of the brains’ neurons and only 19% of
non-neuronal cells, which supports the hypothesis that neurons preferentially exhibit a
phenotype of oxidative metabolism356.

Cerebral activation and aerobic glycolysis
The brain must also rapidly respond to changing energy demand and supply, as reflected
by task-dependent cerebral activation, changes in localized blood flow, and glucose
utilization357. It was traditionally perceived that most of the energy needed for brain
function is derived by the complete oxidation of glucose to carbon dioxide and water.
Therefore, it was postulated that blood-flow increases accompanied by cerebral activation
must be related to an increased demand for oxygen358. However, several early
observations during cerebral activation suggested regional cerebral blood flow (rCBF)
and cerebral metabolic rate of glucose (CMRglc) increase in excess oxygen
consumption346,359,360. In fact, there is a very close correlation between rCBF and
CMRglc, but not between rCBF and oxygen consumption346,361,362. It is now known that
during cerebral activation, aerobic glycolysis is quickly up-regulated and can account for
up to 40% of the glucose consumed by activated regions361,363. A recent multimodal PET
analysis identified high rates of aerobic glycolysis in cortical regions of the adult brain
known to participate in cognitive control networks351. Local aerobic glycolysis can also
persist for up to 40 minutes following activation despite the return of physiological
conditions back to baseline349. Correspondingly, it is well documented that there is an
increase in local brain lactate efflux during cerebral activation363–368. Yet, this lactate
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efflux accounts for only about 50% of the excess glucose consumed by glycolysis and
suggests that some of the lactate is also recycled as a fuel source.
Recent work has provided a potential mechanism between rCBF and glycolytic
metabolism through changes to the lactate/pyruvate ratio and the cytosolic NADH/NAD+
ratio. Experiments in support of this hypothesis are based on lactate and pyruvate
injections, whereby the intravenous injection of lactate augmented rCBF in response to
visual stimulus, while the injection of pyruvate attenuated this response369–371. The
NADH/NAD+ ratio is a sensor of the redox state of the cell that increases when NADH is
produced by glycolysis and the citric acid cycle at a faster rate than can be used by the
mitochondria to synthesize ATP. The excess electrons from NADH can be transferred to
oxygen by NADPH oxidase (NOX) to generate superoxide, which elevates cytosolic Ca2+
levels and activates nitric oxide production by nitric oxide synthase (NOS)372,373. Nitric
oxide is a signaling molecule in endothelial cells that causes cerebral vasodilation and
increases local blood flow374. Lactate has also been shown to directly promote the ability
of astrocytes to induce vasodilation through accumulation of prostaglandin E2 (PGE2), a
well characterized vasodilating agent375. The induction of rCBF serves to remove excess
lactate and promotes the delivery of glucose and oxygen to activated tissues. Taken
altogether, under resting conditions, glucose is almost entirely oxidized to carbon dioxide
to generate large amounts of ATP. Cerebral activation triggers the up-regulation of
aerobic glycolysis to rapidly synthesize ATP with the concomitant production of lactate
as an end product. The rapid increase in glycolysis raises the NADH/NAD+ ratio and
promotes an increase in rCBF. The increased blood flow serves to remove the excess
lactate and promotes the delivery of glucose and oxygen to activated tissues in order to
sustain metabolic flux.

1.3.1

Neuron-astrocyte metabolic coupling

The question of how glucose is utilized by the different cell types of the brain, namely
neurons and astrocytes, has been extensively investigated yet remains to be fully
characterized. Astrocytes are the most common non-neuronal cell in the brain and play a
key role in cerebral homeostasis, including neurotransmitter recycling, ion and water
regulation, defense against oxidative stress, and synapse formation and remodeling376.
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Despite the general assumption that the human brain contains about 100 billion neurons
and ten-times as many astrocytes, it was recently calculated that the human brain contains
approximately equal numbers of neurons and astrocytes with a total of 86.1 ± 8.1 billion
neurons and 84.6 ± 9.8 billion astrocytes356. While neurons traditionally account for the
majority of energy consumed in the brain, astrocytes are thought to regulate the energy
supply from the blood stream to neurons in a process called “metabolic coupling”.

The astrocyte-neuron lactate shuttle hypothesis
In 1994, a seminal discovery by Pellerin and Magistretti identified glutamate as the
molecular trigger for glucose uptake and up-regulation of aerobic glycolysis in response
to brain activation377. Glutamate is the principal excitatory neurotransmitter of the central
nervous system, accounting for well over 80% of all synaptic activity in the human
brain378. In response to axon depolarization, glutamate is released into the synapse from
the pre-synaptic terminal and propagates the action potential in the post-synaptic neuron
by binding to specific ionotropic and metabotropic receptors379. Glutamate is then quickly
removed by glutamate transport 1 (GLT-1), located on astrocytes and neurons, in order to
terminate signal propagation and prevent excitotoxicity. Glutamate transport is coupled
with the import of three Na+ ions into the cell, which leads to the activation of the Na+/K+
-ATPase to restore the osmotic balance380. This is an energetically demanding process
that increases ATP consumption and triggers an increase in glucose uptake to compensate
for energy demand. Pellerin and Magistretti observed an increase in glucose uptake and
lactate released by primary mouse cortical astrocytes in response to glutamate
stimulation377. It is proposed that the increased lactate production implicates aerobic
glycolysis in astrocytes as the key mechanism coupling neuronal activity to glucose
utilization. The discovery led to the long-standing hypothesis called the astrocyte-neuron
lactate shuttle hypothesis (ANLSH). The ANLSH posits that astrocytes can rapidly
mobilize glucose from either glycogen stores, or directly from cerebral blood vessels, and
process it through glycolysis to generate lactate which is exported and subsequently used
as a fuel source for oxidative phosphorylation in the mitochondria of neurons (Figure
3)377,381–383.
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Figure 3. The astrocyte-neuron lactate shuttle model
The astrocyte-neuron lactate shuttle model proposes that astrocytes
readily take up glucose from cerebral blood vessels, via glucose
transporters (GLUT-1) and process it at a high capacity, by aerobic
glycolysis, to produce lactate by lactate dehydrogenase A (LDHA)
which is released into the extracellular space via monocarboxylate
transporters 1 or 4 (MCT1/4). Extracellular lactate is then taken up by
neurons (via MCT2) and converted to pyruvate by LDHB, which enters
the TCA cycle followed by oxidative phosphorylation in the
mitochondria. Lactate may also be transported and oxidized in the
mitochondria through an unknown process. Recent studies suggest that
extracellular lactate may also bind GPR81 (a G-protein coupled
receptor) on neurons and trigger a phosphorylation of ERK and possibly
activate downstream signaling events, including phosphorylation of the
cAMP-binding protein (CREB), that may affect memory. In addition,
astrocytes remove the excitatory neurotransmitter glutamate from
synapses via glutamate transporters (GLT-1) and convert it to glutamine
as part of a recycling of the neurotransmitter. In doing so, glutamate
triggers a cascade of molecular events leading to an enhancement of
glucose utilization by astrocytes. Astrocytes can also breakdown
glycogen for entry into glycolysis. Neurons also have the capacity to
fully oxidize glucose following uptake by the neuron-specific glucose
transporter (GLUT-3).
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Monocarboxylate transporters
The shuttling of lactate and other monocarboxylates, including pyruvate and ketone
bodies, is dependent on the proton-linked monocarboxylate transporter (MCT) family of
transmembrane proteins384. There are a total of 14 members of MCT, yet only four
isoforms are well-characterized (MCT1 to MCT4), each with different tissue-specific
expression patterns and substrate specificity. Among the three MCTs that are known to
be expressed in the brain, MCT2 is almost exclusively expressed in neurons, while
MCT4 is almost exclusively expressed in astrocytes, and MCT1 is expressed in
astrocytes, oligodendrocytes, and endothelial cells of cerebral blood vessels385–390. In
addition to neurons, MCT2 has also been observed specifically in the foot processes of
astrocytes and has a ten-fold higher affinity for substrates than MCT1 and MCT4,
suggesting it is particularly suited to lactate import391,392. The transport of lactate via
MCTs is dependent on H+ co-transport and thus movement of lactate is pH-sensitive,
whereby lactate transport is enhanced at low pH on the H+ binding side or high pH on the
opposite side393. In this manner, the export of lactate out of the cell is regulated by the
redox potential and is enhanced by a high glycolytic rate394. The transport of lactate is
also freely reversible with a trans-acceleration effect, which means that shuttling is
accelerated if the lactate concentration is increased on the opposite side395. Given the
tissue-specific expression and the kinetic characteristics of each, the distribution of MCTs
in the brain supports the ANLSH whereby astrocytes are a lactate ‘source’ and neurons
are a lactate ‘sink’396,397. The low lactate-affinity of MCT1 and MCT4 in astrocytes
would ensure that lactate is exported to continue a high glycolytic rate and prevent lactate
accumulation inside the cell. In contrast, the high lactate-affinity of MCT2 in neurons
would ensure a high degree of lactate import and consumption.

Support for the astrocyte-neuron lactate shuttle hypothesis
Several lines of evidence support the ANLSH. First, from an anatomical standpoint,
astrocytes are positioned in such a manner to support the coupling between glucose
supply from blood vessels and energetic demand in neurons. Astrocytes project
specialized processes called perivascular end-feet to surround cerebral blood vessels in
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order to form the blood-brain-barrier and express GLUT-1 at the surface to promote
glucose import into the brain398,399. In parallel, astrocytes have perisynaptic end-feet that
enclose synaptic clefts in order to recycle glutamate released from neurons400–402.
Therefore, astrocytes are positioned to respond to synaptic activity and supply glucose to
neurons from the blood stream. Astrocytes and neurons also display markedly different
metabolic phenotypes. Astrocytes typically present a high glycolytic rate and release
lactate in the extracellular space403–408. The glycolytic phenotype of astrocytes may be
maintained through either the low expression of PDH, or a high degree of the
phosphorylation-mediated inactivation of PDH, in order to promote the conversion of
pyruvate to lactate409,410. In contrast to astrocytes, neurons sustain a high rate of oxidative
metabolism and even prefer lactate as a fuel source over glucose when both are
present403,405,411–416. Further, neurons have a reduced capacity to perform glycolysis due
to the constant proteasomal degradation of the enzyme 6-phosphofructose-2kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), which is an activator of the rate-limiting
glycolytic enzyme PFK407. In contrast, astrocytes express high levels of PFKFB3407. In
addition, the LDH isoforms display differential cell-type specific expression in the
hippocampus and occipital cortex of post-mortem tissues: neurons exclusively express
with LDHB, while astrocytes express both LDHA and LDHB isoforms328. Thus the
enrichment of LDHB in neurons favors lactate metabolism as a fuel source, while
astrocytes are capable of both lactate metabolism and production. Perhaps the most
convincing evidence in support of the ANLSH comes from in vivo studies using
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C-

labeling of lactate and nuclear magnetic resonance (NMR) spectroscopy. These
experiments demonstrated that lactate is almost exclusively metabolized by neurons and
that lactate produced by glycolysis in astrocytes serves as a substrate for neurons413,417–
419

. In addition to these observations, it has been demonstrated that a decline in neuronal

synaptic transmission arising from glucose deprivation could be rescued by exogenous
delivery of glucose or lactate specifically to astrocytes267. This effect was abolished in the
presence of an MCT inhibitor, which indicates a role in metabolic trafficking of pyruvate
or lactate in astrocytic networks to sustain neuronal activity267.
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Controversy regarding astrocytic versus neuronal aerobic glycolysis
The role of lactate as an intermediate metabolite shuttled between astrocytes and neurons
to meet active energy requirements of the brain is still highly debated266,420–425. The
ANLSH posits that neurons preferentially consume lactate over glucose as a fuel source,
which is provided by astrocytes following activation-induced glycolytic metabolism. Yet,
both cell types are capable of consuming glucose as a fuel source and producing lactate in
vitro under various conditions425–427. Astrocytes also have a considerable capacity to
perform oxidative metabolism and rely on their mitochondria for approximately 75% of
total ATP produced428. In fact, it was estimated that astrocytes exhibit no preferential
utilization of either glycolysis or oxidative phosphorylation to support the Na+/K+
ATPase pump428,429. Neurons also have a high capacity for glycolysis and it has been
suggested from several studies using isolated synaptosomes from the adult brain that
neuronal glycolysis increases in response to cerebral activation430–433. Several lines of
evidence also suggest that lactate is not a major fuel source during normal brain
activation, yet can be used as peripheral supply from the blood when glucose availability
is inadequate such as during physical exercise434–438. Some researchers have argued that
glycogen mobilization in astrocytes may simply help to offset the energy requirements of
neurons, thereby reducing astrocytic utilization of blood-borne glucose and increasing
glucose availability for activated neurons297,439. Interestingly, alternative theories have
been proposed counter to the ANLSH called the neuron-to-astrocyte lactate shuttle. The
authors used concentration and kinetic parameters of GLUT-1 and MCTs in endothelial
cells, astrocytes, and neurons, to simulate neuronal uptake of glucose during activation
and release of lactate to be taken up by astrocytes266,440. This model was further supported
by in vivo functional magnetic resonance spectroscopy (fMRS) to demonstrate that
neurons, not astrocytes, are the primary source of glucose uptake and lactate
production424. Yet, regardless of the direction of lactate flow during cerebral activation,
these authors suggested that the overall contribution of lactate to glucose metabolism is
so small that it should be considered negligible441. Taken altogether, cerebral activation
triggers an up-regulation of aerobic glycolysis in affected brain regions with the
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associated production of lactate, yet the role of lactate as an intermediate metabolite
shuttled between astrocytes and neurons remains a contentious issue.

1.3.2

The role of lactate in memory

Memory is a complex cognitive process regulated by several different cellular and
molecular signaling cascades in the brain working together to encode and retrieve
information. Memory is often described as a process that can divided into three distinct
stages: acquisition, consolidation, and retrieval. Memory acquisition (encoding) is the
process by which an animal learns the association between a cause and effect in a given
context, while memory consolidation (storage) involves the stabilization of the
association into a long-term memory trace, and retrieval (recall) is the process by which a
memory trace is accessed to modulate future behaviour442. A large body of literature
implicates the role of different brain regions in these sequential processes: in general,
memory acquisition involves synaptic changes in the hippocampus, while memory
consolidation involves the transfer of information from the hippocampus to the frontal
and temporal cortex where it is stored for long-term retention, and memory retrieval links
neural connections between the hippocampus and cortex to elicit a recall of
information443–447. The specific transfer of information between two neurons was
originally proposed to involve cellular changes such that the repeated and persistent
activity of one neuron induces a lasting increase in efficiency of firing the other
neuron448. This mechanism is now commonly referred to as synaptic plasticity, which
describes the ability of synapses to change their strength over time in response to changes
in their activity449. The molecular changes occurring at the synapse that strengthen or
weaken the connection are referred to as long-term potentiation (LTP) and long-term
depression (LTD), respectively. While short-term changes at the synapse involve posttranslational modifications, changes associated with consolidation or stabilization of
long-term memory requires changes in gene expression and new protein synthesis450. The
role of LTP in the hippocampus associated with memory formation has been examined
extensively and reviewed in great detail451–455. On a molecular level, long-term LTP
begins with the depolarization of the post-synaptic site through the -amino-3-hydroxy5-methyl-4-isoxazolepropionate (AMPA) receptor and the coincident binding of

35

glutamate to the NMDA receptor, which stimulates an influx of Ca2+ into the cell and
triggers a signaling cascade that activates Ca2+-dependent protein kinases. This ultimately
leads to activation of the transcription factor cAMP-response element binding protein
(CREB), which promotes gene expression of proteins that remodel the actin cytoskeleton
and are required for long-term LTP and memory consolidation456–458. Several studies
have demonstrated that genetic loss of CREB impaired long-term memory formation459–
461

.

A growing body of evidence suggests that lactate participates in LTP and memory
formation. Inhibitory avoidance training in rats caused an increase in activated CREB and
its downstream targets, ARC and COFILIN. This effect was completely blocked with
administration of 1,4-dideoxy-1,4-imino-D-arabinitol (DAB), which blocks glycogen
breakdown, and led to impaired memory formation462. Exogenous lactate can rescue
CREB activation back to a level comparable to vehicle-injected rats, although glucose
was not tested. A recent meta-analysis of whole-genome microarray data revealed a
strong correlation between aerobic glycolysis and changes in gene expression associated
with synapse formation and neurite growth in the adult brain463. This observation may be
explained by results from a recent study showing that lactate can potentiate NMDA
signaling and promote the expression of synaptic plasticity-related genes downstream of
CREB by raising the cytosolic NADH/NAD+ ratio in cultured neurons and in vivo in the
mouse sensory-motor cortex464. This is in agreement with previous studies showing
redox-dependent regulation of the NMDA receptor465,466. Lactate has also been
implicated as a receptor-mediated signaling molecule independent of metabolic
coupling467. Lactate was identified as a natural ligand of a G protein-coupled receptor 81
(GPR81), also known as hydroxycarboxylic receptor 1 (HCA1)468. This receptor is
expressed on post-synaptic terminals of excitatory synapses as well as the perivascular
astrocytic processes and endothelial cells that comprise the blood-brain barrier, although
it is expressed at 100-fold levels in adipose tissues where it plays a prominent role
inhibiting lipolysis468–471. Activation of GPR81 causes an inhibition in adenylyl cyclase
activity resulting in a decline in cAMP levels, which in turn reduces calcium-spiking
activity in cortical neurons471,472. The ability of lactate to suppress neuronal activity has
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been observed previously in hippocampal slices, yet a direct role for GPR81 in synaptic
plasticity and memory has yet to be discovered473.
Perhaps the most convincing evidence that implicates a role of lactate in memory
processes is directly through metabolic coupling and fuel delivery. Given that aerobic
glycolysis is quickly up-regulated in active regions of the brain and cognitive tasks are
energetically demanding processes, lactate production and transport may simply comprise
a system of energy delivery to brain regions participating in memory processes. The first
evidence of this emerged from experiments demonstrating that glycogen is mobilized
from astrocytes in neonatal chicks following training in a taste-aversion task474,475.
Administration of DAB or 2-deoxyglucose (2DG), which impaired glycogen breakdown
and glycolysis respectively, impaired memory performance476,477. Supplementation with
lactate was sufficient to rescue memory in the presence of DAB or 2DG, while glucose
was able to rescue memory from DAB but not 2DG. These observations suggested that
mobilization of glycogen and glycolysis both play a key role in memory formation. A
similar study demonstrated that IA training in rats caused an increase in extracellular
lactate in the hippocampus that was completely blocked with DAB462. Administration of
DAB had no effect on short-term memory (tested after an hour) but blocked long-term
memory (tested after 24 hours) that was rescued with exogenous lactate462. The authors
also demonstrated that knock down of MCT1, MCT2, or MCT4 expression impaired
memory that was rescued with administration of lactate following disruption of MCT1 or
MCT4 (astrocytic) but not MCT2 (neuronal) expression. Pharmacological blockage of
MCT2 with -cyano-4-hydroxycinnamate (4-CIN) also caused an inhibition of spatial
working memory formation in rats that could not be rescued with lactate or glucose
administration296.These results have been confirmed by independent groups using a
cocaine-induced model of conditioned responses478. Ultimately, these studies
demonstrating lactate production through glycogen breakdown in astrocytes and
subsequent transport to neurons plays a key role in memory formation479. However, it
remains to be discovered how neuronal activation, aerobic glycolysis, and lactate
shuttling varies during aging and in AD and contributes to cognitive decline under
physiological conditions.
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1.4 Research questions
Aerobic glycolysis and glycogen breakdown both play a central role in long-term
memory formation through the production of lactate in astrocytes and subsequent
transport to neurons. Lactate may act as a redox-mediated signaling molecule to directly
promote the expression of synaptic plasticity genes or bind directly to a receptor to elicit
downstream signaling cascades that regulate neuronal activity. Aerobic glycolysis is upregulated in activated regions of the brain to quickly support the energy demands of firing
neurons and promote the de novo synthesis of biosynthetic building blocks for synaptic
remodeling. Aerobic glycolysis also shares a close spatial distribution to amyloid
deposition in AD patients and confers a survival advantage to neurons in culture when
exposed to A. However, the changes in aerobic glycolysis that occur with age and the
role of lactate production and transport in memory decline associated with Alzheimer’s
disease have yet to be investigated. Furthermore, the transgenic-AD mouse line used in
this study, APPswe/PS1ΔE9, develops memory loss with age, yet does not exhibit extensive
neuron loss consistent with atrophy in the human AD brain480. This has remained a
contentious issue for decades and has given rise to several research questions that I aim to
answer including:

1. Does aerobic glycolysis mediate resistance to A in vivo?
2. Does aerobic glycolysis play a role in memory performance during both normal
aging and under the conditions of high A deposition?
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1.5 Hypothesis
I hypothesize that neurons upregulate aerobic glycolysis in response to A deposition to
promote A resistance in vivo. Furthermore, I hypothesize that aerobic glycolysis
contributes to memory processes in both normal aging and under conditions of high A
deposition.

1.6 Specific aims
In order to test the hypothesis that neurons upregulate aerobic glycolysis in response to
A deposition, a mouse model of cerebral amyloid pathology, APP/PS1, and control
littermates will be treated with DCA (an inhibitor of PDK1) in the drinking water over
the course of age. I predict that APP/PS1 mice treated with DCA will undergo
neurodegeneration and succumb to memory decline at an earlier age than untreated
APP/PS1 mice. In order to test the hypothesis that aerobic glycolysis contributes to
memory, a standard memory test will be used to compare the spatial memory
performance of control mice and APP/PS1 mice to the expression of aerobic glycolysis
enzymes measured by Western blot analysis. This will determine if a correlation between
aerobic glycolysis enzyme expression and memory exists during normal and pathological
conditions. In addition, the effect of chemical inhibition of aerobic glycolysis on memory
in control and APP/PS1 mice will be assessed. I predict that the expression of aerobic
glycolysis enzymes in the brain will correlate with memory performance in both control
and APP/PS1 mice. Moreover, inhibition of aerobic glycolysis will have a more adverse
effect on memory in APP/PS1 mice due to the reliance of this metabolism to preserve
neuronal function under pathological conditions.
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Chapter 2

2

Materials and Methods

2.1 Animals
Male APPswe/PS1ΔE9 mice481 were maintained on a C57BL/6J background (Charles River
Laboratories International, Inc.) and will henceforth be referred to as APP/PS1 mice.
Age-matched male C57BL/6J littermates were used as controls and will henceforth be
referred to as control mice. All animals were housed in groups of up to 3 animals per
cage under a 12 hour light/dark cycle with ad libitum access to water and the Mouse Diet
5015 breeder chow base diet (LabDiet). A single red, transparent plastic house was
placed in each cage with cotton nesting material and corn cob bedding and that was
changed weekly. Animals were weaned at 3 weeks of age and ear punches were used for
identification and PCR-based genotyping. All animal procedures were conducted in
compliance with the Canadian Council of Animal Care (CCAC) guidelines with
approved animal protocol from the Institutional Animal Care and Use Committees at the
University of Western Ontario (protocol number 2011-079).

2.2

1

H-Magnetic resonance spectroscopy

Animals were anesthetized starting with 3.5% isoflurane and then reduced to 2%
combined with 30% oxygen. Mice were scanned using a 9.4 T small animal MRI scanner
equipped with a 30 mm millipede volume radiofrequency coil (Agilent, Palo Alto, CA,
USA). T2-weighted images were acquired using a 2-dimensional fast spin echo (FSE)
pulse sequence with parameters: repetition time (TR)/echo time (TE) = 4000/10 ms, echo
train length (ETL) = 4, effective TE = 40 ms, field of view (FOV) = 19.2 x 19.2 mm2,
matrix size = 128 x 128, slice thickness= 0.5 mm, 25 slices, 4 averages. Based on the T2image, a voxel (2 x 4 x 3 mm3) was localized to the frontal cortex for magnetic resonance
spectroscopy using a LASER pulse sequence with the following parameters:
TR/TE = 4000/270 ms, 384 averages for the metabolite spectrum with water suppressed.
An unsuppressed water spectrum (8 averages) was also acquired and a QUECC
correction was applied. Metabolite levels were measured by fitting spectra using fitMAN
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software incorporated into a graphical user interface written in the IDL (Version 5.4,
Research Systems Inc.) programming language482.

2.3 In vivo microdialysis and interstitial fluid lactate
measurements
In vivo microdialysis was performed as previously described483. Briefly, guide cannulae
(BR-style, Bioanalytical Systems, West Lafayette, IN, USA) were stereotaxically
implanted into the hippocampus and secured into place with dental cement. Twenty-four
hours post-cannulation, mice were transferred to Raturn sampling cages (Bioanalytical
Systems) and microdialysis probes (2 mm; 38 kDa molecular weight cut-off; BR-style,
Bioanalytical Systems) were inserted into the guide cannula, connected to a syringe pump
and infused with artificial cerebrospinal fluid (aCSF; 1.3 mM CaCl2, 1.2 mM MgSO4, 3
mM KCl, 0.4 mM KH2PO4, 25 mM NaHCO3 and 122 mM NaCl; pH 7.35) at a flow rate
of 1 µl/minute. Following an 8-hour habituation period, hippocampal ISF was collected
in hourly fractions and lactate measurements using a lactate oxidase method were
quantified for each hour using the YSI 2900 analyzer (YSI Incorporated, Yellow Springs,
OH, USA) per the manufacturer’s instructions.

2.4 SDS-PAGE and Western blot analysis of brain extracts
Mice were euthanized by cervical dislocation and then immediately perfused with PBS,
pH 7.4 ± 0.1. The frontal cortex and hippocampus of the right hemisphere were removed
and snap frozen in dry ice. Tissues were homogenized by hand using a pestle in an
extraction buffer containing 50 mM Tris pH 7.5, 2% SDS, 100 mM EDTA, protease
inhibitors: 2 mM leupeptin, 0.1 mM pepstatin A, and 1 mM PMSF, and the phosphatase
inhibitor 0.5 mM sodium orthovanadate. Protein extracts were separated by 10% SDSPAGE, and electroblotted onto PVDF membrane (Bio-Rad, Hercules, CA, USA).
Membranes were probed with the following antibodies: PDK1 (Enzo, Farmingdale, NY,
USA), PDH-E1 (pSer232) (Millipore, Darmstadt, Germany), PDH-E1 (pSer293)
(Millipore), PDH-E1 (AbCam, Cambridge, UK), LDHA (Cell Signaling, Danvers, MA,
USA), LDHB (AbCam), PKM2 (Cell Signaling), PKM1 (Cell Signaling), MCT2
(Millipore), MCT4 (Millipore) and -actin (Cell Signaling), followed by incubation with
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an appropriate horseradish peroxidase-conjugated secondary antibody (Bio-Rad). The
blots were developed using Pierce ECL western blotting substrate (Thermo Fisher
Scientific, Waltham, MA, USA) and visualized with a Bio-Rad Molecular Imager
(ChemiDoc XRS, Bio-Rad). Densitometric analysis was performed using Quantity One
software (Bio-Rad).

2.5 The Morris water maze
Spatial learning and memory was assessed as previously described484 using the Morris
water maze (MWM) with the following specifications: A white circular tank with
diameter 48" and height 30" (San Diego Instruments, San Diego, CA, USA) was filled
with water and maintained at a temperature of 26 ± 1 ºC using a 300 W submersible
aquarium heater (Aqueon, Franklin, WI, USA) that was removed immediately before
mice were brought into the testing room. Spatial visual cues in the form of different
shaped cardboard pictures were placed on the walls surrounding the water tank, including
a white diamond at the North position, a blue cross at the North-East, a yellow triangle at
the South-East, a green circle at the South, a pink heart at the South-West, and a red
square at the North-West (Figure 4). Visual data were collected using a HD Pro Webcam
C920 (Logitech, Romanel-sur-Morges, Switzerland) and analyzed by the video tracking
software ANY-maze v4.98 (Stoelting Company, Wood Dale, IL, USA). A circular, clear
plastic platform (diameter 10.16 cm) was submerged 1 cm below the surface of the water.
The platform was positioned in the correct quadrant according to virtual tracer lines
generated by the ANY-maze software with a radial grid from the center spaced at 45
degrees as well as a square grid spaced to the edge of the water line and a concentric grid
spaced to the edge of the square. The platform was positioned in the tank in the correct
quadrant with its center at the intersection of the radial and concentric lines.
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Figure 4: Configuration of the Morris water maze.
(Top) Virtual tracer lines in red outline the edge of the water level and
the division of the tank into four quadrants, as well as the platform in
the South-East quadrant. Virtual tracer lines in black outlining the
positioning of the platform using a radial grid from the center spaced
at 45 degrees as well as a square grid spaced to the edge of the water
line and a concentric grid spaced to the edge of the square.
Representative images are shown of cardboard pictures placed on the
walls surrounding the water tank, including a white diamond at the
North position, a blue cross at the North-East, a tallow triangle at the
South-East, a green circle at the South, a pink heart at the South-West,
and a red square at the North-West. Scale bar in the bottom right is 30
cm. (Bottom) Photograph taken of the MWM with a mouse swimming
and platform located in the South-East quadrant.
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Before the first training day, mice were acclimatized to the experimental room and water
tank. For mice naïve to the MWM, the acclimatization period lasted three consecutive
days: on the first day, mice spent 30 minutes in the experimental room in their native
cages; on the second day, mice spent 30 minutes in the experimental room in their native
cages followed by 15 seconds on the platform located in the center of the tank and
allowed 90 seconds to swim to the platform if they jumped off, or guided to the platform
if they did not find it within 90 seconds; on the third day, mice spent 30 minutes in the
experimental room in their native cages followed by 15 seconds on the platform located
in the center of the tank, then followed by a release into the water at the North release
point of the tank and allowed 90 seconds to find the platform, or guided to the platform if
they did not find it in 90 seconds. For mice that were not naïve to the MWM, an
acclimatization period of one day was performed consisting of 30 minutes spent in the
experimental room in their native cages followed by 15 seconds spent on the platform
located in the center of the tank, then followed by a release into the water at the North
release point of the tank and allowed 90 seconds to find the platform, or guided to the
platform if they did not find it in 90 seconds. For all subsequent training days mice were
first acclimatized to the experimental room for 30 minutes before the beginning of the
first trial.
Mice were then trained for 4 consecutive days with 4 trials per day to find the location of
the platform submerged in the correct quadrant. The release point of the first trial
corresponded to the cardinal directions (North, East, South, and West) rotating with each
training day (Table 1). For each of the 4 trials in one day, mice were released into the
water with a clockwise rotation of release placements for each trial that day. A trial lasted
until the mouse found the platform or until 90 seconds had elapsed, at which point the
mouse was gently guided to the platform. The mouse was then placed for 15 seconds on
the platform before it was removed and briefly dried in paper towel before placing it back
in its cage. An inter-trial interval (ITI) of 10 minutes was used to ensure consistency of
timing between trials for each mouse.
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Table 1: Release point schedule for mice training in the Morris water maze
Release Point (4 per day)
Training Day
Trial 1

Trial 2

Trial 3

Trial 4

1

N

E

S

W

2

E

S

W

N

3

S

W

N

E

4

W

N

E

S

Probe

Center

On the fifth day, mice were exposed to a probe trial in which the platform was removed
and the mouse was released in the center of the tank and given 60 seconds to attempt to
find the missing platform. After swimming in the probe trial, the mouse was then
removed from the tank and briefly dried in paper towel before placing it back into its
cage. A flag trial was then performed in which the platform was placed back into the
water in the opposite quadrant that originally held the platform and a small red plastic
pole was inserted into the platform so it was sticking out of the water. The mouse was
released in the center of the tank and given 90 seconds to find the location of the
platform. A trial lasted until the mouse found the platform or until 90 seconds had
elapsed, at which point it was gently guided to the platform. The mouse was then given
15 seconds on the platform before it was removed and briefly dried in paper towel before
placing it back into its cage.
Mice were disqualified from the data analysis of the MWM according to criteria that they
did not appear to be using visual spatial strategies to actively search for the platform, or
they appeared unable or unmotivated to escape485. This behavior could occur in the
following ways: (1) the mouse frequently swims around the edge of the pool in an
attempt to climb up the wall of the tank and does not make a clear attempt to find the
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platform; (2) the mouse frequently stops swimming and floats on the surface of the water
for long periods of time. If the mouse attempted to climb up the wall of the tank and
continued to swim on the edge of the pool, the timer continued until the end of the trial. If
at any point the mouse stopped swimming and floated in the water, the timer was paused
until it started swimming again and continued until the end of the trial. A mouse was
disqualified from analysis if it failed to demonstrate active searching behavior on
consecutive training days or on the probe trial. If a mouse was disqualified from analysis
it was removed from all training days as well as the probe and flag trials for that
particular training phase.
For acute exposure to chemical inhibitors of aerobic glycolysis, the location of the
platform was moved to different quadrants between each set of chemical treatments
(Table 2). The platform was located in the south-east quadrant for the 1st training phase
(Vehicle), the north-west quadrant for the 2nd training phase (Isosafrol), the north-east
quadrant for the 3rd training phase (DCA), and the south-west quadrant for the 4th training
phase (Saline). During the probe trial, mice were injected intraperitoneally with the
specified treatment (vehicle, Isosafrol, DCA, or saline) 30 minutes prior to the start of the
probe trial.
Table 2: Treatment schedule for mice in memory testing with Isosafrol and
dichloroacetate
Training Phase

Age (months)

Treatment

Platform Location

1

12-13

Vehicle

SE

2

13-14

Isosafrol

NW

3

14-16

DCA

NE

4

16-17

Saline

SW

Euthanization

17-18

Saline or DCA
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2.6 Preparation of mouse brain soluble and insoluble
amyloid--extracts and ELISA
Mouse brain tissue from the frontal cortex was extracted in a 50 mM Tris pH 7.5, 2%
SDS buffer with a protease inhibitor cocktail containing AEBSF (Millipore), then
sonicated briefly and centrifuged at 100,000 × g for 1 hour at 4ºC. The supernatant was
collected as the soluble A fraction and initially diluted in cold Reaction buffer BSATDPBS (Dulbecco’s phosphate buffered saline at pH7.4 containing 5% BSA and 0.03%
Tween-20), then diluted as necessary for ELISA analysis. To analyze the insoluble A
fraction, the pellet was dissolved in 70% formic acid and sonicated briefly before
centrifugation at 100,000 × g for 1 hour at 4 ºC. The supernatant was neutralized by 1 M
Tris phosphate buffer, pH 11, and then initially diluted in cold BSAT-DPBS, followed by
dilution as necessary for the ELISA. ELISAs for A40 and A42 (Thermo Fisher
Scientific) were performed according to standard protocol and measured at 450 nm using
an Infinite M1000 microplate reader (TECAN, Männedolf, Switzerland).

2.7 Cryo-immunohistochemistry and confocal microscopy
Left hemi-brains were fixed in 4% paraformaldehyde at 4 ºC overnight, then incubated in
30% sucrose at 4 ºC for 48 hours, and snap frozen in freezing microtome cassettes
containing Tissue-Tek® O.C.T. compound (Sakura Finetek USA Inc., Torrance, CA,
USA). Brain tissues were sectioned on a serial sagittal plane using a CM350 Cryostat
(Leica, Wetzlar, Germany) at a thickness of 30 m and free-floating brain slices were
stored in 25 % glycerol in PBS at 4 ºC for up to three weeks. Sections were washed in
PBS, then permeabilized using PBST (PBS and 0.1 % Triton X-100), and blocked
overnight at 4 ºC in 10% goat serum in PBST. Sections were incubated in primary
antibody solutions at a 1:100 dilution in PBST + 1% BSA overnight at 4 ºC: PDK1
(Enzo), LDHA (Cell Signaling), GFAP (AbCam), and TUJ1 (AbCam). Sections were
washed in PBS and incubated in secondary antibodies: AlexaFluor® 488 and AlexaFluor®
647 (Thermo Fisher Scientific) at a 1:1000 dilution in PBST + 1% BSA for 1 hour at
room temperature then washed with PBS and mounted with ProLong® Gold reagent with
DAPI (Thermo Fisher Scientific) on Superfrost slides (Fisher Scientific, Waltham, MA,
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USA). For staining of A plaques, sections were dehydrated with 80% ethanol then
incubated in 0.01%Thioflavin S (Sigma, St. Louis, MO, USA) for 15 min at room
temperature, followed by rehydration in PBS and mounting with ProLong® Gold antifade
reagent without DAPI (Thermo Fisher Scientific) on Superfrost slides (Fisher Scientific).

2.8 Dichloroacetate
Dichloroacetate (DCA) is an analog of acetic acid in which two of the hydrogens of the
methyl group are replaced by chlorine atoms. Humans have a long history of exposure to
DCA through chlorinated drinking water with an average daily consumption at
approximately 4 mg/kg486. DCA has been used as a metabolic treatment in laboratory
animals since 1973487 and in humans since 1980488. DCA is a selective inhibitor of PDK,
thereby preventing the phosphorylation of PDH and promoting the active form489.

2.9 Isosafrol
Isosafrol is an analog of stiripentol, an inhibitor of cytochrome P450, which has been
used for the treatment of severe myoclonic epilepsy in infancy (SMEI), a rare congenital
form of epilepsy called Dravet syndrome490. Isosafrol lacks the hydroxyl group and
tertiary-butyl group of stiripentol. It was recently discovered that isosafrol is a potent
inhibitor of LDHA and strongly prevented pyruvate-to-lactate conversion in vitro491.

2.10 Chronic exposure to dichloroacetate through oral
administration in drinking water
DCA (Sigma) was orally administered to mice at a daily dose of 200 mg/kg (pH 7.4 ±
0.1) by changing the drinking immediately water after weaning (3 weeks of age), based
on an average daily water consumption of 5mL per mouse. Mice were weighed twice
weekly and the average weight of mice in each cage was used to calculate the amount of
DCA to add to drinking water of each bottle per cage. Drinking water was replaced twice
per week with freshly prepared DCA.
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2.11 Acute exposure to Isosafrol and dichloroacetate
through intraperitoneal injection
The chemical inhibitor of LDH, Isosafrol (Sigma) was prepared fresh the day of injection
at a concentration of 15mg/mL in a sterile solution of 1% Carboxymethylcellulose
(CMC) (Sigma) in 0.9% NaCl (saline). Mice were weighed and then injected
intraperitoneally with the correct volume of Isosafrol solution for a dosage of 300 mg/kg
(1 mL for a 50 mg animal). The vehicle injection was a sterile solution of 1% CMC
(Sigma) in saline. Mice were weighed and then injected intraperitoneally with the correct
volume of vehicle assuming a dosage of 300 mg/kg of Isosafrol from a 15 mg/mL
concentration. DCA (Sigma), was prepared fresh the day of injection at a concentration
of 10 mg/mL in a sterile solution of saline and neutralized to pH 7.4 ± 0.1 with NaOH.
Mice were weighed and then injected intraperitoneally with the correct volume of DCA
solution for a dosage of 200 mg/kg (1 mL for a 50 mg animal). For saline injections, mice
were weighed and injected intraperitoneally with the correct volume of sterile saline
assuming a dosage of 200 mg/kg of DCA from a 10 mg/mL solution.

2.12 Preparation of mouse brain extracts and LDHA/LDHB
enzyme activity assay
Mice were injected intraperitoneally with vehicle (1% CMC) or Isosafrol (300 mg/kg)
and euthanized 30 minutes later by cervical dislocation. The hippocampus was dissected
and snap frozen in dry ice. Tissues were homogenized in PPB buffer (100 mM Potassium
Phosphate Buffer, pH 7.0 ± 0.1, with 0.1% Triton X-100 (Sigma), 2 mM EDTA, 2 mM
leupeptin, 0.1 mM pepstatin A, 1 mM PMSF, and 0.5 mM sodium orthovanadate).
Protein extracts were added to a standard reaction formula for either LDHA (pyruvate to
lactate) or LDHB (lactate to pyruvate). The LDHA reaction formula included 30 mM
sodium pyruvate (Sigma), 0.192 mM NADH (Sigma), and approximately 3 g of protein
extract in 500 mM PPB, pH 7.4 ± 0.1 for a total volume of 50 L in a single well of a
Nunc™ Black Polystyrene 96-well plate (Thermo Fisher Scientific). The LDHB reaction
formula included 90 mM sodium lactate (Sigma), 1.287 mM NAD+ (Sigma), 218.4 M
Hydrazine (Sigma), and approximately 3 g of protein extract in a buffer containing 0.5
M Glycine and 2.5 mM EDTA, pH 9.5 ± 0.1 for a total volume of 50 L in a single well
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of a Nunc™ Black Polystyrene 96-well plate (Thermo Fisher Scientific). The rate of
NADH consumption or production (LDHA and LDHB reactions, respectively) was
determined by measuring NADH fluorescence at excitation/emission of 340/460 nm
using a Infinite M1000 microplate reader (TECAN) at 20 second intervals for 5 minutes.
Concentration of NADH was determined at each time point by comparing each
fluorescence value to a NADH fluorescence standard curve. One Unit of enzyme is
defined as the amount of enzyme that catalyzes conversion of 1μmol of substrate per
minute. A line-of-best-fit was modeled from a linear regression analysis and enzyme
activity was expressed in Units per mg of protein, calculated using the slope
(ΔNADH(μM)/min) of the reaction and the volume of the reaction (50 L) according to
the following equation:

2.13 Hyperpolarized 13C-pyruvate magnetic resonance
spectroscopy
Images were acquired using a GE MR750 3.0T MRI (GE, Fairfield, CT, USA). A
custom-built dual-tuned 13C-1H solenoid radiofrequency coil was used as and 1H and 13C
images were inherently registered. A hyperpolarized [1-13C]-pyruvate buffered solution
was prepared using a dynamic nuclear polarizer, Hypersense (Oxford Instruments,
Abingdon, UK). The solution had a final concentration of 150 mM pyruvate with pH 7.4
at 37 °C and with ~10% polarization at 3 T with T1 of ~60 seconds. The imaging session
consisted of fast imaging employing steady-state acquisition (FIESTA) imaging and
hyperpolarized 13C-MRS imaging. FIESTA images were acquired with the following
imaging parameters: 30 x 30 mm field of view (FOV), 0.2 mm isotropic in-plane
resolution, 0.4 mm slice thickness, repetition time (TR) = 10.3 ms, echo time (TE) = 5.2
ms, bandwidth = 12.58 Hz, and phase cycling = 8. For hyperpolarized 13C-MRS imaging,
a ~0.3 ml bolus of the hyperpolarized [1-13C]-pyruvate buffered solution was injected via
a tail vein catheter. 15 seconds after the injection, 2D 13C-spectra were acquired using
free induction decay chemical shift imaging (FID-CSI) with the following parameters: 30
x 30 mm FOV, 2.5 mm isotropic in-plane resolution, slice thickness = 10~15 mm, TR =
80 ms, spectral width = 5000 Hz and number of points = 256. DCA was freshly prepared

51

at a concentration of 40 mg/mL in sterile saline and neutralized to pH 7.4 ± 0.1 using
NaOH. Mice were given 30 minutes to recover following hyperpolarized

13

C-pyruvate

injection before injection of DCA at 200 mg/kg via tail vein catheter. Mice were then
given another 30 minutes to recover and another bolus of hyperpolarized

13

C-pyruvate

was injected and mice were scanned again as previously described.

2.14 Statistical analysis
Two-way ANOVA and Tukey’s post hoc comparisons were used for the following
analyses: the difference between the genotypes over the course of aging for lactate levels
deduced by 1H-MRS analysis, the difference between genotypes over the course of aging
for band density derived from western blot analysis, as well as the levels of soluble and
insoluble A(1-40) and A(1-42) from cortical extracts of APP/PS1 mice. A Bonferroni
correction for multiple comparisons was used to adjust the significance value for western
blot analysis. A two-way ANOVA with repeated measures was used to analyze the
difference between genotypes for the latency to find the platform over the course of
training days in the MWM. A Welch’s T-test was used to evaluate the difference between
genotypes for individual measures of the MWM: total distance traveled, percent time
spent in the correct quadrant, and latency to find the flag platform. A multiple linear
regression model and ANCOVA was used to analyze the difference between genotypes
for correlation of memory performance in the MWM and the relative band density by
western blot analysis, in addition to the correlation of soluble and insoluble A levels
with the relative band density by western blot analysis. A one-way ANOVA with
repeated measures was used to analyze the difference between genotypes for each
training phase of injected chemicals Isosafrol and DCA. Two-way ANOVA and Tukey’s
post hoc comparisons were used to analyze the difference between the genotypes and
chemical treatments on memory performance with the MWM. A Welch’s t-test with a
Bonferroni correction for multiple comparisons was used to analyze the difference
between saline- and DCA-injected control mice on band densitometry from western blot
analysis. A Welch’s paired t-test was used to evaluate the difference between lactate-topyruvate ratios for

13

C-pyruvate MRS measurements of before and after DCA injection.

A Welch’s t-test with a Bonferroni correction for multiple comparisons was used to
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evaluate the difference between control mice injected saline and DCA for measures of
memory performance in the MWM. A multiple linear regression model was used to
analyze the difference between saline- and DCA-injected mice for the correlation of
memory performance in the MWM and relative band density by western blot. Statistical
evaluation was performed with Microsoft Excel 2007, RStudio v0.99.891, and GraphPad
Prism v6.01.
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Chapter 3

3

Results

3.1 Examination of lactate levels in the frontal cortex and
hippocampus of APP/PS1 mice over the course of age
To examine changes to brain lactate levels over the course of normal aging, in vivo 1Hmagnetic resonance spectroscopy (1H-MRS) was performed on the frontal cortex and
hippocampus of control and APP/PS1 mice (Figure 5A). Lactate was identified as a peak
at 1.33 ppm (Figure 5B) and quantified as a ratio to the metabolite, N-acetylaspartate
(NAA). Lactate was measured at 3, 6, 9, and 12 months of age in the frontal cortex
(Figure 6A). A two-way ANOVA (age × genotype) was performed, which revealed a
significant effect of age (F(3,47) = 4.200, p = 0.010), and genotype (F(3,47) = 4.575, p =
0.037). A Tukey’s post hoc comparison test determined that cortical lactate levels
progressively declined starting at 9 months of age (p = 0.008) to 12 months of age (p =
0.002).

In contrast, lactate levels did not significantly change for APP/PS1 mice

throughout the course of aging. In order to ensure that the standard reference metabolite
did not change over the course of age, NAA was measured as a ratio to creatine at 3, 6, 9,
and 12 months of age in the frontal cortex (Figure 6B). A two-way ANOVA (age ×
genotype) was performed, which revealed no significant effect for age (F(3,48) = 2.561,
p = 0.066) or genotype (F(3,48) = 0.082, p = 0.776), which indicated that NAA levels did
not change and was suitable as a reference metabolite for measuring lactate over the
course of aging. In addition to the frontal cortex, lactate levels in the hippocampus of
control and APP/PS1 mice was assessed by 1H-MRS and expressed as a ratio to NAA at
6 and 12 months of age (Figure 7A). A two-way ANOVA (age × genotype) was
performed and revealed no significant effect of genotype on lactate levels in the
hippocampus for age (F(1,54) = 3.863, p = 0.055) or genotype (F(1,54) = 0.349, p =
0.557). The same analysis for levels of NAA/creatine (Figure 7B) revealed no significant
effect of treatment for age (F(1,54) = 3.323, p = 0.074) or genotype (F(1,54) = 0.005, p =
0.941), which indicated that NAA was a good reference metabolite for measuring lactate
over the course of aging.
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Figure 5: Representation of lactate levels in the frontal cortex and
hippocampus of APP/PS1 mice measured by 1H-magnetic
resonance spectroscopy.
(A) Volume of interest in frontal cerebral cortex (left) and
hippocampus (right) in the coronal plane. (B) Representative spectrum
showing the raw data (red line) obtained from the frontal cortex of a
6-month-old APP/PS1 mouse, the fitted result (green line), and the
residual line (blue line), which is the difference between the fit and the
spectrum. Cho, choline; Cr, creatine; Lac, lactate (highlighted by
vertical red lines between 1.2 and 1.4 ppm); NAA, N-acetylaspartate.
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Figure 6. Lactate levels remain unaltered in APP/PS1 mice from 3
to 12 months of age, but decline in aged control mice.
(A) 1H-MRS spectra were quantified and average lactate levels in the
frontal cortex from 3 to 12 months of age were expressed as a ratio to
total NAA for control mice and APP/PS1 mice. (B) Quantification of
average NAA levels in the frontal cortex expressed as a ratio to total
creatine for control mice and APP/PS1 mice. Data are shown as mean
+ SEM, **p < 0.01, n = 5 and 12, respectively, for control and
APP/PS1 mice at ages 3 - 9 months; n = 4 and 3, respectively, for
control and APP/PS1 mice at age 12 months.
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Figure 7. Lactate levels remain constant in the hippocampus over
the course of age in both control and APP/PS1 mice.
(A) 1H-MRS spectra were quantified and average lactate levels in the
hippocampus at 6 and 12 months of age were expressed as a ratio to
total NAA for control mice and APP/PS1 mice. (B) Quantification of
average NAA levels in the frontal cortex expressed as a ratio to total
creatine for control mice and APP/PS1 mice. Data are shown as mean
+ SEM, n = 16 and 11, respectively, for control and APP/PS1 mice.
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To rule out the possibility that the anesthetic isoflurane might influence brain metabolism
during MRS analysis, in vivo microdialysis was performed in awake, freely moving mice
to assess lactate levels in the hippocampal ISF (Figure 8). A one-way ANOVA followed
by a Tukey’s post-hoc test revealed a significant age-dependent rise in lactate levels in
APP/PS1 mice from 3 to 18 months of age (F(2,84) = 20.53, p < 0.001). Furthermore,
hippocampal ISF lactate levels were significantly elevated in APP/PS1 mice at 12 months
of age compared with control mice as determined by a two-way ANOVA (age ×
genotype) followed by a Bonferroni’s post-hoc test (F(1,75) = 5.870, p < 0.05). These
observations reveal an age-dependent elevation in lactate levels within the cortex and
hippocampal ISF of APP/PS1 mice compared with control mice.

Figure 8. Interstitial lactate levels in the hippocampus are elevated
in older APP/PS1 mice.
Hippocampal ISF lactate levels in APP/PS1 mice are significantly
elevated at 12 and 18 months of age compared with 3-month-old mice
(left). A significant difference in hippocampal ISF lactate levels
between control and APP/PS1 mice was detected at 12 months of age
(right). *p < 0.05, **p < 0.01, ***p < 0.001. Data are shown as mean
+ SEM.
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3.2 Age-dependent changes in expression of lactate
metabolism and transporting proteins in the frontal
cortex and hippocampus of APP/PS1 mice
To explore the mechanism by which lactate levels can change in the brain with age, I
next examined the expression of proteins responsible for lactate metabolism and transport
(Figure 9). Protein extracts from the frontal cortex of control and APP/PS1 mice
euthanized at 6 and 12 months of age were resolved by SDS-PAGE and then
immunoblotted using the antibodies indicated (Figure 10). The band density was
quantified using -actin as a loading control and measurements were expressed as a ratio
of density relative to control mice at 6 months of age (Figure 11). A two-way ANOVA
(age × genotype) with a Bonferroni correction for multiple comparisons ( = 0.00625)
revealed a significant age-dependent decline for proteins involved in lactate metabolism,
including the following: PDK1 (F(1,12) = 39.677, p <0.001), LDHA (F(1,12) = 24.008, p
< 0.001), and PKM1 (F(1,12) = 22.118, p < 0.001). An age-dependent decline was
observed in several markers of aerobic glycolysis markers, including PDH-p/PDH
(F(1,12) = 9.006, p = 0.011), LDHB (F(1,12) = 4.720, p = 0.050), and PKM2 (F(1,12) =
7.168, p = 0.020), yet these did not reach the threshold set by the Bonferroni correction
( = 0.00625). In contrast, expression of the lactate transporters was elevated with age:
MCT2 (F(1,12) = 5.590, p = 0.036) and MCT4 (F(1,12) = 38.685, p < 0.001). A
significant effect of genotype was found for PDK1 (F(1,12) = 9.718, p = 0.009), LDHB
(F(1,12) = 7.960, p = 0.015), PKM1 (F(1,12) = 5.083, p = 0.044), and MCT4 (F(1,12) =
6.237, p = 0.028). In addition, a significant interaction between age and genotype was
found for PDK1 (F(1,12) = 13.417, p = 0.003) and PKM1 (F(1,12) = 5.181, p = 0.042).
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Figure 9. Proposed metabolic pathway of lactate metabolism and
transport in the brain.
Glucose is broken down via glycolysis into phosphoenol pyruvate
(PEP). PEP is then converted to pyruvate via pyruvate kinase M2
(PKM2) or pyruvate kinase M1 (PKM1). Pyruvate can be metabolized
to acetyl-CoA and used as a substrate for oxidative phosphorylation in
the mitochondria, or converted to lactate as a by-product of aerobic
glycolysis. Pyruvate dehydrogenase kinase 1 (PDK1) phosphorylates
and inhibits the pyruvate dehydrogenase complex (PDH), which is
responsible for converting pyruvate to acetyl-CoA. Lactate
dehydrogenase A (LDHA) converts pyruvate to lactate primarily in
astrocytes, while lactate dehydrogenase B (LDHB) catalyzes the
reverse reaction of lactate to pyruvate mainly within neurons.
Monocarboxylate transporter 4 (MCT4) and monocarboxylate
transporter 2 (MCT2) are involved in shuttling lactate between
astrocytes and neurons, respectively.
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Figure 10. Age-dependent decline in expression of aerobic
glycolysis proteins in the frontal cortex.
Western blot analysis of mouse frontal cortex extracts from 6-monthold and 12-month-old control mice and APP/PS1 mice using indicated
antibodies as markers of aerobic glycolysis and lactate metabolism.
The upper -Actin panel was used as a loading control for all
indicated proteins above this panel whereas the lower -Actin panel
was used as loading control for MCT2 and MCT4 protein levels. n = 4
for each set of control mice and APP/PS1 mice at 6 and 12 months of
age.
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Figure 11. Age-dependent decline in expression of aerobic
glycolysis proteins in the frontal cortex: Band densitometry
analysis.
Quantification of band densitometry for western blots of extracts from
the frontal cortex of 6-month-old and 12-month-old control mice and
APP/PS1 mice probed with the indicated antibodies. Relative band
density was calculated relative to -actin. Data are shown as mean ±
SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n = 4 for each set of
control mice and APP/PS1 mice at 6 and 12 months old.
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Western blot analysis was also performed using extracts from the hippocampus of control
and APP/PS1 mice euthanized at 6 and 12 months of age (Figure 12). Band densitometry
measurements of proteins involved in lactate metabolism and transport were measured
relative to -actin and a two-way ANOVA (age × genotype) with a Bonferroni correction
for multiple comparisons ( = 0.00625) (Figure 13). This analysis revealed a significant
age-dependent decline in markers of lactate metabolism, including the following: PDHp/PDH (F(1,19) = 23.106, p < 0.001), LDHA (F(1,19) = 28.244, p < 0.001), and PKM1
(F(1,19) = 20.912, p < 0.001). Interestingly, in contrast to the measurements in the frontal
cortex, there was an age-dependent increase in expression of certain lactate metabolism
enzymes in the hippocampus including LDHB (F(1,19) = 19.496, p < 0.001) and PKM2
(F(1,19) = 13.746, p = 0.002). In contrast to expression patterns in the cortex, a decrease
in the lactate transport protein MCT4 (F(1,19) = 17.068, p < 0.001) was found in the
hippocampus of both control and APP/PS1 mice with age. These data indicated that there
is an age-dependent change in proteins involved in lactate metabolism and transport in
the hippocampus that is distinct from that of the frontal cortex.
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Figure 12. Differential expression of aerobic glycolysis proteins in
the hippocampus with age.
Western blot analysis of mouse hippocampal extracts from 6-monthold and 12-month-old control mice and APP/PS1 mice probed with
the indicated antibodies. n = 6 for each set of control mice and
APP/PS1 mice at 6 and 12 months old.

65

66

Figure 13. Differential expression of aerobic glycolysis proteins in
the hippocampus with age: Band densitometry analysis.
Quantification of band densitometry for western blots of extracts from
the hippocampus of 6-month-old and 12-month-old control mice and
APP/PS1 mice probed with the indicated antibodies. Relative band
density was calculated relative to -actin. Data are shown as mean ±
SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n = 6 for each set of
control mice and APP/PS1 mice at 6 and 12 months old.
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3.3 Correlation analysis of aerobic glycolysis enzyme
expression in the frontal cortex and amyloid- dynamics
Considering that a tight spatial correlation exists between A deposition and areas of
high aerobic glycolysis in both the resting normal brain, it has been suggested that
aerobic glycolysis may contribute to A processing262. In order to determine if aerobic
glycolysis influences the production of A or if the deposition of A influences the
expression of aerobic glycolysis enzymes, soluble and insoluble fractions of A were
extracted from the frontal cortex of APP/PS1 mice at 12 months of age. The levels of
unique A species, A(1-40) and A(1-42), were quantified by ELISA selective for A
peptides with C-termini ending at residue 40 or 42, respectively. The average amount of
A in each brain extract was calculated as a ratio to total protein and a two-way ANOVA
was performed (fraction × A species). This analysis revealed a significant interaction
between the type of fraction and A species suggesting that the burden of amyloid in the
frontal cortex exists predominantly as insoluble A(1-42) (F(1,20) = 22.00, p < 0.001)
(Figure 14). A multiple linear regression was then performed for relative band density of
aerobic glycolysis enzymes and amount of A(1-40) or A(1-42) in either soluble or
insoluble fractions (Figure 15). This analysis revealed no correlation between levels of
soluble A(1-40) and A(1-42) with expression of aerobic glycolysis proteins: LDHA/LDHB
(R2 = 0.418, p = 0.125), PDK1 (R2 = 0.269, p = 0.513), PDH-p/PDH (R2 = 0.352, p =
0.220), and PKM2/PKM1 (R2 = 0.512, p = 0.055). The same analysis was performed for
relative band density with insoluble A species and revealed no significant correlation
with expression of aerobic glycolysis enzymes: LDHA/LDHB (R2 = 0.779, p = 0.075),
PDK1 (R2 = 0.765, p = 0.564), PDH-p/PDH (R2 = 0.755, p = 0.896), or PKM/PKM1 (R2
= 0.808, p = 0.419). These data suggested that expression of aerobic glycolysis enzymes
likely has no influence on the tendency of A peptides to form insoluble species.
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Figure 14. Soluble and insoluble A(1-40) and A(1-42) in the frontal
cortex of APP/PS1 mice at 12 months old.
Levels of A(1-40) and A(1-42) were quantified with ELISA using
extracts from the frontal cortex of APP/PS1 mice at 12 months old in
both soluble and insoluble fractions. Amount of A was expressed as
a ratio to the total amount of protein as measured by Lowry assay.
Data are shown as individual animals with mean as horizontal line,
***p < 0.001, n = 6 mice.
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Figure 15. Deposition of A in APP/PS1 mice does not correlate
with expression of aerobic glycolysis enzymes.
Levels of A(1-40) and A(1-42) in both soluble (left) and insoluble
(right) cortical extracts from APP/PS1 mice at 12 months old were
correlated with expression of aerobic glycolysis enzymes: the ratio of
LDHA/LDHAB, PDK1, the ratio of phosphorylated-PDH/PDH, and
the ratio of PKM2/PKM1. n = 6 mice. No significant associations
were detected.
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3.4 Determining the cell-specific localization of aerobic
glycolysis enzyme expression in control and APP/PS1
mice
To identify which cell types are expressing the enzymes responsible for aerobic
glycolysis, frozen brain sections from control and APP/PS1 mice at 12 months of age
were immunostained using antibodies specific for PDK1 and LDHA and co-stained with
glial fibrillary acidic protein (GFAP) antibodies for reactive astrocytes and Class III Tubulin (TUJ1) for neurons. The sections were also stained with Thioflavin S (ThioS),
which stains amyloid plaques. Within the frontal cortex of control mice, PDK1 and
LDHA were exclusively expressed in the soma of TUJ1+ neurons (Figure 16). Within the
frontal cortex of APP/PS1 mice, the expression of PDK1 and LDHA were observed
primarily in the soma of TUJ1+ neurons and also in GFAP+ reactive astrocytes
surrounding amyloid plaques. The same staining pattern was observed within the dentate
gyrus of the hippocampus: PDK1 and LDHA expression was limited to the soma of
TUJ1+ neurons in control mice and expression also observed in GFAP+ reactive
astrocytes surrounding amyloid plaques in APP/PS1 mice (Figure 17). These
observations indicate that PDK1 and LDHA are expressed primarily in the cell bodies of
neurons, suggesting that this cell type is also capable of producing lactate through aerobic
glycolysis.
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Figure 16. PDK1 and LDHA are expressed in neurons of the
frontal cortex of control and APP/PS1 mice and astrocytes colocalized to A plaques of APP/PS1 mice.
Fluorescence micrographs of the frontal cortex in control mice (top)
and APP/PS1 mice (bottom) at 12 months old. Thioflavin S was used
to visualize A plaque deposits (blue), while immunofluorescence
was used to colocalize expression of PDK1 (red) and LDHA (red)
with markers for astrocytes (GFAP +, green) and neurons (TUJ1 +,
green). Merged images indicate that PDK1 and LDHA are primarily
expressed in the soma of neurons in control mice and also in reactive
astrocytes surrounding A plaques of APP/PS1 mice (bottom). White
arrows indicate co-localized expression of PDK1 and LDHA in
cortical GFAP + cells in APP/PS1 mice. Scale bar, 100 m.
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Figure 17. PDK1 and LDHA are expressed in both neurons and
astrocytes co-localized to A plaques in the dentate gyrus of the
hippocampus.
Fluorescence micrographs of the dentate gyrus of the hippocampus in
control mice (top) and APP/PS1 mice (bottom) at 12 months old.
Thioflavin S was used to visualize A plaque deposits (blue), while
immunofluorescence was used to colocalize expression of PDK1 (red)
and LDHA (red) with markers for astrocytes (GFAP +, green) and
neurons (TUJ1 +, green). Merged images indicate that PDK1 and
LDHA are primarily expressed in the soma of neurons in control mice
and also in reactive astrocytes surrounding A plaques of APP/PS1
mice (bottom). White arrows indicate co-localized expression of
PDK1 and LDHA in cortical GFAP + cells in APP/PS1 mice. Scale
bar, 100 m.
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3.5 Determining the age of onset for visual-spatial memory
deficit in APP/PS1 mice
The MWM was used as a test of visual-spatial learning and memory at 12 months of age.
Control mice and APP/PS1 mice were evaluated on their ability to learn the location of a
hidden platform in the North-West quadrant of the water tank over the course of 4
training days with 4 trials per day (Figure 18A). The latency time to find the platform
was measured as an average of the 4 trials for each mouse and a two-way ANOVA with
repeated measures (training day × genotype) was performed. This analysis revealed a
significant effect of training day on the ability of mice to find the platform (F(3,72) =
20.08, p < 0.001), but there was no significant effect with genotype (F(3,72) = 2.709, p =
0.1128), or the interaction between training day and genotype (F(3,72) = 0.114, p =
0.952). This analysis revealed that there is no difference between control mice and
APP/PS1 mice in their ability to learn the location of the hidden platform during training.
On the fifth day of testing, the hidden platform was removed and a probe trial was
performed in which mice were allowed to swim for 60 seconds. The swim path of each
mouse was used to compile a heat map representation of swimming behavior of each
group of control and APP/PS1 mice during the probe trial (Figure 18B). The total
distance covered during the probe trial was measured in order to determine if genotype
had an effect on the physical ability of mice to swim in the tank of water (Figure 18C). A
Welch’s t-test revealed no significant effect on total distance covered (t(21) = 1.516, p =
1.445). The ability of mice to remember the location of the platform was assessed as the
percent time spent in the correct quadrant (Figure 18D). A Welch’s t-test revealed a
significant effect between genotypes (t(21) = 2.688, p = 0.007), which indicated that
APP/PS1 mice have worse memory performance than control mice at 12 months of age.
After the probe trial, a flag trial was performed to assess the ability of mice to use a
visual cue to find the platform. Mice were allowed to swim in the tank for 90 seconds and
the latency to find the flag-marked platform was recorded (Figure 18E). A Welch’s t-test
revealed no significant effect between genotypes (t(22) = 1.301, p = 0.207), which
indicated that both control mice and APP/PS1 mice were able to use the flag as a visual
cue to determine the location of the hidden platform.
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Figure 18. APP/PS1 mice have impaired visual-spatial memory at
12 months of age.
Memory performance in control mice and APP/PS1 mice at 12 months
of age was assessed using the Morris water maze. (A) Mice were
trained for 4 consecutive days to find the location of a hidden platform
in the NW quadrant and the latency to escape was recorded. On day 5
a probe trial was performed in which the platform was removed and
mice were allowed to swim for 60 seconds (B-E). (B) The swim path
for each group of mice was recorded and compiled into heat map
representations. Measurements were taken for the total distance
traveled (C) and the percentage of time spent in the correct quadrant
(D). Immediately after the probe trial, a flag trial was performed to
assess the ability of mice to use visual cues to find the platform. The
platform was placed back in to the tank in the opposite quadrant and
the latency to find the flag was recorded (E). Data shown are mean ±
SEM, **p < 0.01, n = 12 and 11 for control and APP/PS1 mice,
respectively.
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3.6 Correlation analysis of aerobic glycolysis enzyme
expression and memory performance in APP/PS1 mice
at 12 months of age
To determine whether aerobic glycolysis in the frontal cortex affects memory, the
expression of aerobic glycolysis enzymes in the frontal cortex was compared with
individual performances in the MWM at 12 months of age (Figure 19). A one-way
ANCOVA was conducted on the linear regression of relative band density and percent
time spent in the correct quadrant, controlling for genotype. This analysis revealed that
genotype was a significant covariate for the enzymes involved in lactate production:
LDHA (F(1,9) = 12.467, p = 0.008), PDH-p/PDH (F(1,9) = 5.588, p = 0.046), and
PKM2/PKM1 (F(1,9) = 7.119, p = 0.028). This suggests that higher expression of these
proteins correlates with better memory performance in control mice and worse
performance in APP/PS1 mice. Genotype was not a significant covariate for the linear
regression of LDHB expression on memory performance (F(1,9) = 2.161, p = 0.180).
These data suggest that metabolism toward lactate production in the frontal cortex may
be beneficial for memory processes in control mice and may in fact be detrimental to
APP/PS1 mice.
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Figure 19. Inverse relationship between expression of aerobic
glycolysis enzymes in the frontal cortex and memory performance
in APP/PS1 mice.
Memory performance in the Morris water maze, as measured by
percent time spent in the correct quadrant during the probe trial, was
correlated with the expression of aerobic glycolysis enzymes in the
frontal cortex of both control mice and APP/PS1 mice at 12 months of
age. Higher expression of enzymes involved in lactate production,
including LDHA, the ratio of PKM2/PKM1, and the ratio of
phosphorylated-PDH/PDH, correlated with better memory
performance in control mice, but not for APP/PS1 mice. Higher
expression of LDHB, the enzyme that catalyzes the reverse reaction of
LDHA, correlated with decreased memory performance for control
mice, but an increase in memory performance for APP/PS1 mice. *p <
0.05, **p < 0.01, n = 6 for each group of control and APP/PS1 mice.
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A similar analysis examining the relationship between expression of aerobic glycolysis
enzymes and memory was performed on extracts from the hippocampus (Figure 20). A
one-way ANCOVA was conducted on the linear regression of relative band density and
percent time spent in the correct quadrant, controlling for genotype. This analysis
revealed that genotype was not a significant covariate for any of the markers of lactate
metabolism: LDHA (R2 = 0.374, p = 0.073), LDHB (R2 = 0.148, p = 0.738), PDH-p/PDH
(R2 = 0.141, p = 0.416), and PKM2/PKM1 (R2 = 0.168, p = 0.737). Altogether, these data
indicate that aerobic glycolysis in the frontal cortex, and the concomitant production of
lactate, may play a key role in memory processes. In contrast, the role of lactate
metabolism in the hippocampus is less clearly defined.
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Figure 20. Correlation analysis between expression of aerobic
glycolysis enzymes in the hippocampus and memory performance
in APP/PS1 mice.
Memory performance in the Morris water maze, as measured by
percent time spent in the correct quadrant during the probe trial, was
correlated with the expression of aerobic glycolysis enzymes in the
hippocampus of both control mice and APP/PS1 mice at 12 months
old. n = 6 for each group of control mice and APP/PS1 mice. No
significant interactions were detected.
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3.7 Examining the effect of chronic oral administration of
dichloroacetate on memory at 12 months of age
Dichloroacetate (DCA) is a chemical inhibitor of PDK and is used in the treatment of
congenital lactic acidosis492. DCA-mediated inhibition of PDK results in increased PDH
activity and more glycolytic flux through the mitochondria with a concomitant decrease
in lactate production239. Animal and clinical experiments indicate that a single oral dose
of DCA has excellent bioavailability and can induce a lactate-lowering effect within 30
minutes of administration492. In order to determine if DCA caused an effect on the
memory performance, mice were exposed to 200 mg/kg of DCA in the drinking water
from the time of weaning to 12 months of age when they were memory tested with the
MWM. During the training phase of the MWM, mice were tasked with finding the
location of a hidden platform in one of the quadrants of the tank. Mice were given 4 trials
a day over 4 consecutive training days and the average time required to find the platform
for each day was recorded (Figure 21A). A two-factor repeated measures ANOVA
(genotype x treatment) was performed and revealed no significant interaction between
genotype, treatment, and training day (F(3,123) = 0.106, p = 0.370). This indicated that
the DCA in the drinking water did not have a preferential effect on one genotype over
another in their ability to learn the location of the platform over the course of four
training days. There was no effect from the interaction between treatment and training
day (F(3,123) = 0.038, p = 0.999), indicating that DCA had no effect on mice of either
genotype to learn the location of the platform. There was also no effect between genotype
and training day (F(3,123) = 1.046, p = 0.375), indicating that control mice did not learn
the location of the platform any faster than APP/PS1 mice. This analysis did reveal a
significant effect from training day (F(3,123) = 35.743, p < 0.001), demonstrating that all
mice from both genotypes and treatments found the platform faster over the course of
four training days. In addition, there was a significant effect from genotype (F(1,41) =
8.258, p = 0.006), suggesting that APP/PS1 mice took longer to find the platform on
average for each training day regardless of DCA treatment. This indicated that the
APP/PS1 mice have an impaired ability to learn the location of the platform at 12 months
of age.
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During the probe trial, the platform was removed from the tank and the mice were given
60 seconds to swim and attempt to find the platform. The swimming path of the animals
was recorded along with the time spent in the correct quadrant and the total distance
covered during the swim. In order to visualize the memory performance of each group of
mice, a heat map analysis was constructed that compiles the swimming path of each
mouse into a collective representation of areas covered by the swimming group (Figure
21B). The percentage of time spent in the correct quadrant was recorded during the probe
trial as a measure of memory performance (Figure 21C). A two-way ANOVA (genotype
× treatment) revealed a significant effect of genotype on memory performance (F(1,37) =
10.63, p = 0.002), while there was no effect from DCA treatment (F(1,37) = 0.103, p =
0.751) or interaction between genotype and treatment (F(1,37) = 0.028, p = 0.867). This
indicated that chronic DCA treatment had no effect on memory performance for either
genotype. The total distance covered during the probe trial was measured to evaluate the
physical ability of mice to swim in the MWM (Figure 21D) and a two-way ANOVA
(genotype × treatment) was performed. This analysis revealed no significant difference
between genotypes (F(1,37) = 1.330, p = 0.256) or DCA treatment (F(1,37) = 0.085, p =
0.772). These results suggest that the chronic treatment of DCA in the drinking water at
200 mg/kg had no effect on the memory performance of either control or APP/PS1 mice
at 12 months of age. Further, the only variable contributing to a difference in memory at
this age was genotype of the animals.
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Figure 21. Chronic exposure to dichloroacetate does not affect
memory performance at 12 months of age.
Memory performance of 12-month-old control mice and APP/PS1
mice provided either normal water or DCA-water (200 mg/kg) was
assessed by the Morris water maze. (A) Mice were trained for 4
consecutive days (4 trials per day) to find the location of a hidden
platform in the NW quadrant and the latency to escape was recorded.
On day 5 a probe trial was performed in which the platform was
removed and mice were allowed to swim for 60 seconds (B-D). (B)
The swim path for each group of mice was recorded and compiled into
heat map representations. Measurements were taken for the percentage
of time spent in the correct quadrant (C) and the total distance traveled
(D). The dashed horizontal line at 25% represents the amount of time
spent in the correct quadrant by random chance. Data shown are mean
± SEM, **p < 0.01, n = 12 and 11 for control and APP/PS1 mice
provided normal water, respectively, and n = 10 and 9 for control and
APP/PS1 mice provided DCA water, respectively.
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3.8 Determining the effect of chronic oral dichloroacetate
administration on PDH phosphorylation in the brain
Although short-term oral administration of DCA has been shown to diminish cortical
lactate levels493, the effect of chronic oral DCA administration on PDH phosphorylation
and metabolism in the brain has never been examined.

The expression of aerobic

glycolysis enzymes was examined at 12 months of age by western blot analysis in the
frontal cortex of control mice provided either normal water or DCA-water (Figure 22).
Band densitometry analysis was then performed (Figure 23) and a Welch’s t-test
(treatment) revealed no significant effect on the ratio of phosphorylated-PDH to total
PDH (t(12) = 0.204, p = 0.842), or the protein expression of PDK1 (t(12) = 1.042), p =
0.327), LDHA (t(12) = 1.480, p = 0.167), LDHB (t(12) = 1.020, p = 0.3348, PKM2 (t(12)
= 2.081, p = 0.060), or PKM1 (t(12) = 0.211, p = 0.837). These observations collectively
suggest that chronic exposure to 200 mg/kg of DCA in the drinking water had no effect
on the phosphorylation level of PDH or the expression of lactate metabolism enzymes at
12 months of age.
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Figure 22. Chronic exposure to dichloroacetate in the drinking
water does not affect phosphorylation levels of PDH or expression
of aerobic glycolysis enzymes in the frontal cortex of control mice.
Western blot analysis of extracts from the frontal cortex of 12 month
old control mice drinking either normal water or DCA water (200
mg/kg) using indicated antibodies as markers of aerobic glycolysis
and lactate metabolism. n = 6 and 8, respectively, for control mice
with normal water and DCA water.
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Figure 23. Chronic exposure to dichloroacetate in the drinking
water does not affect phosphorylation levels of PDH or expression
of aerobic glycolysis enzymes in the frontal cortex of control mice:
Band densitometry analysis.
Quantification of band densitometry for western blots of extracts from
the frontal cortex of 12 month old control mice drinking either normal
water or DCA water (200 mg/kg) using indicated antibodies as
markers of aerobic glycolysis and lactate metabolism. Relative band
density was calculated relative to -actin. Data are shown as mean ±
SEM, n = 6 and 8, respectively, for control mice with normal water
and DCA water.
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3.9 Determining the effect of acute dichloroacetate injection
on PDH phosphorylation in the brain
Due to the inability of chronic oral administration of DCA to inhibit PDH
phosphorylation, alternative strategies were considered to deliver chemical inhibitors. I
decided to perform an acute injection of both Isosafrol and DCA. Isosafrol is a specific
inhibitor of LDHA that has been shown to cross the blood-brain barrier and prevent
chemically induced seizures in mice491. To determine if acute exposure to DCA had an
effect on brain metabolism, the expression of aerobic glycolysis enzymes was examined
at 17 - 18 months of age by western blot analysis in the frontal cortex of control mice
injected with either saline or DCA (200 mg/kg) 30 minutes before euthanization (Figure
24A). Band densitometry analysis was then performed and expressed as standardized
ratio to saline-injected mice relative to -actin (Figure 24B). A Welch’s t-test revealed a
significant effect on the ratio of phosphorylated-PDH to total PDH at Serine-232 (t(10) =
9.083, p < 0.001) and Serine-293 (t(10) = 16.261, p < 0.001) in DCA-injected mice
compared to saline-injected mice. This analysis also revealed a significant effect of
treatment on PDK1 levels (t(10) = 2.837), p = 0.018). These data indicated that
intraperitoneal injection of DCA at 200mg/kg inhibited phosphorylation of PDH in the
frontal cortex. In addition, extracts from the hippocampus of mice injected
intraperitoneally with either vehicle or Isosafrol were tested for LDHA or LDHB activity
with a fluorescence-based enzyme activity assay (Figure 24C). A decrease in LDHA
activity was observed in the hippocampus of mice injected with Isosafrol (14.31 ± 1.340
Units/mg) as compared to mice injected with vehicle (21.23 ± 4.712 Units/mg). A
Welch’s t-test revealed that this difference was not significant (p = 0.09). Injection of
Isosafrol caused no difference in LDHB activity (p = 0.405). These findings demonstrate
that both DCA and Isosafrol affect their protein targets in the brains of mice within 30
minutes of injection.
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Figure 24. Acute exposure to dichloroacetate decreases
phosphorylation of PDH and Isosafrol may alter enzyme activity in
the frontal cortex.
(A) Western blot analysis of frontal cortex extracts from 18-month-old
control mice euthanized 30 minutes after intraperitoneal injection with
either saline or DCA (200 mg/kg). Levels of phosphorylated-PDH at
Serine-232 or Serine-293, total PDH, and PDK1 were measured using
indicated antibodies. (B) Quantification of band densitometry for western
blots of extracts. Relative band density was calculated relative to -actin.
n = 6 for each set of saline- and DCA-injected mice. (C) Isosafrol
decreases LDHA, but not LDHB activity in the frontal cortex. Mice
injected intraperitoneally with either vehicle or Isosafrol (300 mg/kg).
After 30 minutes mice were sacrificed, perfused with PBS and brains were
snap frozen. Hippocampal extracts were analyzed for LDHA and LDHB
activity. n = 1 mouse with 6 technical repeats. Data are shown as mean ±
SEM, *p < 0.05, ***p < 0.001.
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3.10 Examining the effect of acute Isosafrol and
dichloroacetate injection on memory performance
A single cohort of control mice and APP/PS1 mice were assessed using the MWM over
the course of 12 to 18 months of age in four consecutive training and probe trial
experiments. The location of the platform was moved after each exposure so the mice had
to re-learn the location at each training session. All mice were injected with the treatment
on the day of the probe trial, 30 minutes before entering the pool. The treatments for each
probe trial were as follows: (1) the vehicle of Isosafrol (1% carboxymethylcellulose) with
platform location South-East, (2) Isosafrol (300 mg/kg) with platform location NorthWest, (3) DCA (200 mg/kg) with platform location North-East, and (4) the vehicle of
DCA (saline) with platform location South-West. During the training phase, the mice
were given 4 trials a day over 4 consecutive days to find the location of the hidden
platform and the average latency time for each day was recorded (Figure 25). A one-way
ANOVA with repeated measures (genotype x training day) revealed a significant delay in
the latency time for APP/PS1 mice to find the platform for the first three training sessions
compared to control mice: Vehicle (F(1,23) = 12.920, p = 0.002), Isosafrol (F(1,22) =
21.100, p < 0.001), and DCA (F(1,21) = 5.631, p = 0.0273). However, there was no
significant difference in latency times between control and APP/PS1 mice in the fourth
training session: Saline (F(1,16) = 2.185, p = 0.159). This analysis indicated that the
APP/PS1 mice were slower at learning to find the platform than the control mice during
the first three training periods, yet by the fourth training session they performed equally
to control mice. These data suggest that APP/PS1 mice at an age of up to 18 months are
capable of learning the location of the platform just as well as control mice following
repeated training.
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Figure 25. Overview of training program in the Morris water
maze for mice treated with Isosafrol and dichloroacetate.
The effect of metabolic inhibitors on memory performance in control
mice and APP/PS1 mice starting at 12 months of age was repeatedly
tested using the Morris water maze. Mice were given four training
trials a day to find the location of a hidden platform in one quadrant of
the water tank (position indicated on bottom left of each training
phase). On the fifth day, the platform was removed from the tank and
a probe trial was performed 30 minutes after intraperitoneal injection
of the indicated treatment (indicated by syringe). Mice were given a
two week recovery period between training phases and the location of
the platform changed for each treatment. Data shown are mean ±
SEM, asterisks indicate a significant difference between genotype for
a particular training phase as determined by a two-way ANOVA with
repeated measures, *p < 0.05, **p < 0.01, ***p < 0.001, n = 17 and 8,
respectively, for control mice and APP/PS1 mice for vehicle phase, n
= 16 and 8, respectively, for control mice and APP/PS1 mice for
Isosafrol phase, n = 15 and 8, respectively, for control mice and
APP/PS1 mice for DCA phase, and n = 13 and 5, respectively, for
control mice and APP/PS1 mice for saline phase.
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The memory performance of each mouse on the probe trial was then compared over the
course of treatments to determine if there was an observable effect from acute exposure
to Isosafrol or DCA. The ability of mice to remember the location of the platform was
measured as the percent time spent in the correct quadrant (Figure 26A). A two-way
ANOVA analysis (genotype × treatment) of the time spent in the correct quadrant
revealed a significant effect associated with genotype (F(1,81) = 4.280, p = 0.042), and
treatment (F(3,81) = 5.651, p = 0.001), as well as the interaction between genotype and
treatment (F(3,81) = 3.453, p = 0.021). In order to compare the memory of control mice
over the course of different treatments, a Tukey’s post-hoc test was performed and
revealed no significant difference between vehicle and Isosafrol treatment (p = 0.236),
but there was a significant difference between vehicle and DCA treatment (p < 0.001), as
well as the difference between DCA and saline treatment (p = 0.004). This analysis
revealed no significant difference in memory for control mice between vehicle and saline
treatments (p = 0.999), which indicated that these mice are just as capable of
remembering the location of the platform at an older age than when they started the first
training session. Interestingly, the APP/PS1 mice exhibited better memory (43.9% ±
5.4%) than the control mice (37.8% ± 2.0%) with the DCA treatment, although this
difference was not significant (p = 0.698). This analysis also revealed that memory
performance in APP/PS1 mice were unaffected by acute exposure to metabolic inhibitors
of aerobic glycolysis. The total distance covered during the probe trial was measured in
order to determine if genotype or treatment had an effect on the physical ability of mice
to swim in the tank of water (Figure 26B). A two-way ANOVA (genotype × treatment)
revealed no significant effect of genotype (F(1,81) = 0.004, p = 0.952) or treatment
(F(3,81) = 1.606, p = 0.195), or the interaction between genotype and treatment (F(3,81)
= 2.213, p = 0.093) on swimming distance. Thus, neither the genotype nor chemical
treatment had any effect on locomotor activity in mice. Altogether, these data collected
from the MWM suggested that acute exposure to chemical inhibitors of aerobic
glycolysis had a significant effect on the memory performance of control mice, yet had
no effect on APP/PS1 mice. Further, acute exposure to DCA appeared to exert a more
pronounced effect on memory processes than Isosafrol in control mice.
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Figure 26. Acute exposure to dichloroacetate impairs memory
performance in control mice.
The Morris water maze was used to evaluate memory performance, as
measured during a 60 second probe trial by the percent time spent in the
quadrant that contained the hidden platform during training (A). Mice
were exposed to the probe trial 30 minutes after intraperitoneal injection
of the indicated treatment. Horizontal dotted line at 25% represents the
percent of time spent in the correct quadrant by random chance. Control
mice injected with DCA (200 mg/kg) performed significantly worse
than when injected with vehicle or saline. (B) Total distance covered
during the probe trial was used as a measure of locomotor ability. Data
shown are mean ± SEM, asterisks indicate a significant difference
between treatments as determined by a two-way ANOVA followed by
Tukey’s post-hoc test, **p < 0.01, ***p < 0.001, n = 17 and 8,
respectively, for control mice and APP/PS1 mice for vehicle phase, n =
16 and 8, respectively, for control mice and APP/PS1 mice for Isosafrol
phase, n = 15 and 8, respectively, for control mice and APP/PS1 mice
for DCA phase, and n = 13 and 5, respectively, for control mice and
APP/PS1 mice for saline phase.
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3.11 Replicating the effect of acute dichloroacetate injection
on memory performance in control mice
In the initial study, we attempted to determine the effect of the aerobic glycolysis
inhibitors Isosafrol and DCA on memory performance using a single group of mice with
repeated memory testing under different treatment conditions. This experimental design
introduces the confounding factor of repeated testing, which could influence the outcome
of successive memory tests. Previous studies have shown that repeated memory testing
influence the successive behavior outcome on the MWM494. Thus, it was important to test
the effect of aerobic glycolysis inhibitors on mice that had no previous exposure to any
agent. Considering that DCA had a more pronounced effect on memory performance in
the MWM than Isosafrol (Figure 26), DCA was selected as a single experimental
treatment with saline as a negative control.
A new group of 20 control mice aged 9-months was randomly divided into saline and
DCA treatment groups. The mice were given 2 weeks to acclimatize to their environment
before beginning memory testing as described above with the platform located in the
south-west quadrant. The latency to find the location of the platform during the training
phase was recorded and a two-way ANOVA with repeated measures (training day ×
treatment) was performed (Figure 27A). This analysis revealed no significant effect on
memory by DCA treatment (F(1,17) = 0.525, p = 0.478), or the interaction between
treatment and training day (F(3,51) = 0.880, p = 0.458), which suggested that there was
no difference in the ability of the two treatment groups to learn the location of the
platform during training. On the fifth day of training, the platform was removed and the
mice were injected intraperitoneally with either saline or DCA (200 mg/kg) 30 minutes
before entering the pool for a probe trial. The swimming path of each mouse was
recorded and a heat map representation of swimming behaviour was constructed for the
two treatment groups (Figure 27B). The total distance covered during the probe trial was
recorded (Figure 27C), and a Welch’s t-test revealed no significant effect of DCA
treatment on total distance covered (t(18) = 0.805, p = 0.4331). Several different
measures of memory performance were collected during the probe trial and a Welch’s ttest with a Bonferroni correction for multiple comparisons ( < 0.01) was performed to
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determine if there was a difference between the two treatment groups. There was no
significant effect on the following measures of memory performance: (Figure 27D) the
percent of time spent in the correct quadrant (t(18) = 0.516, p = 0.307), (Figure 27E) the
number of entries to the platform location (t(18) = 0.766, p = 0.227), and (Figure 27F) the
latency to the first entry to the platform location (t(18) = 1.322, p = 0.102). The latency to
the first entry to the platform location during the probe trial was then compared to the
average latency of each mouse to find the platform during the last day of training (Figure
27G). This analysis was performed to determine if there was an effect of DCA exposure
on the ability of mice to continue learning the location of the platform. On average, mice
injected with saline before the probe trial crossed the boundary of the platform 4.88 ±
1.09 seconds faster than the average of their previous attempts on the last day of training.
In contrast, mice injected with DCA before the probe trial crossed the boundary of the
platform on average 0.16 ± 1.96 seconds slower than the average of their previous
attempts on the last day of training. A Welch’s t-test was performed on the difference in
latency to the platform between the probe trial and the final day of training. This analysis
revealed a potential effect (t(18) = 2.241, p = 0.021), yet it did not reach the threshold
determined by the Bonferroni correction for multiple comparisons (a = 0.01). Although
this result should be interpreted with caution, it suggested that DCA may have had an
effect on the ability of mice to continue learning the location of the hidden platform.
After the probe trial, the platform was placed back into the tank in the opposite quadrant
and a red flag was attached to the platform as a visual cue of its location. Mice were
allowed to swim in the tank for 90 seconds and the latency to find the flag-marked
platform was recorded (Figure 27H). A Welch’s t-test revealed no significant effect (t(18)
= 0.158, p = 0.438), which indicated that the ability of mice to use the flag as a visual cue
to determine the location of the hidden platform was not compromised by DCA
treatment. Altogether, these data suggested that acute exposure to DCA did not have an
observable effect on the memory performance of mice, yet may impair the ability of mice
to continue learning the location of the platform.
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Figure 27. Acute exposure to dichloroacetate does not alter spatial
memory performance in naïve mice.
Naïve control mice were intraperitoneal injected with saline or DCA
(200 mg/kg) at 9 months of age followed by memory assessment using
the Morris water maze. (A) Mice were trained for 4 consecutive days (4
trials per day) to find the location of a hidden platform in the SW
quadrant and the latency to escape was recorded. On day 5 a probe trial
was performed in which the platform was removed and mice were
allowed to swim for 60 seconds (B-H). (B) The swim path for each
group of mice was recorded and compiled into heat map
representations. Measurements were taken for the total distance traveled
(C), the percentage of time spent in the correct quadrant (D), the
number of times crossing the boundary of the platform (E), the latency
to the first platform entry (F), and the difference in latency between the
average of training day 4 and the first platform entry during the probe
trial (G). Immediately after the probe trial, a flag trial was performed to
assess the ability of mice to use visual cues to find the platform. The
platform was placed back in to the tank in the opposite quadrant and the
latency to find the flag was recorded (H). Data shown are mean ± SEM,
*p < 0.05, n = 9 and 10 for saline and DCA treatments, respectively.
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3.12 Assessing the efficacy of acute dichloroacetate injection
to reduce the conversion of pyruvate to lactate in the
brain
In order to determine if DCA injection had a metabolic effect on the brain, mice were
scanned with a 3T-MRI after injection with hyperpolarized

13

C-pyruvate (Figure 28A).

Hyperpolarized 13C-pyruvate MRS measures the kinetic conversion of pyruvate to lactate
in vivo.

13

C-substrates can be highly magnetized (hyperpolarized) by dynamic nuclear

polarization (DNP) in vitro and then used as injectable agents to probe in vivo
metabolism495. This hyperpolarization technique provides signal-to-noise enhancements
on the order of 10,000-fold over non-hyperpolarized

13

C-imaging methods495.

In

addition, the metabolic rate of conversion of pyruvate to lactate in the brain can be
measured over the course of ~1 minute following injection of hyperpolarized
pyruvate. Mice were injected with

13

13

C-

C-pyruvate and its conversion to lactate was

measured 30 minutes before and 30 minutes after injection of DCA (200 mg/kg) using an
intravenous tail-vein catheter and the ratio of lactate-to-pyruvate peaks was quantified as
an indication of pyruvate breakdown to lactate in the mouse brain (Figure 28B). This
analysis revealed that the ratio of lactate-to-pyruvate peaks was reduced from 0.104 ±
0.013 before DCA exposure to 0.056 ± 0.196 after DCA exposure (Figure 28C).
However, due to variability in the conversion rate, a paired Welch’s t-test revealed that
there was no significant difference between before and after DCA injections (t(4) =
2.010, p = 0.069). These data indicate that DCA may reduce the conversion of pyruvateto-lactate in the brain, although there was variability in the degree to which DCA
interfered with this conversion and additional mice need to be tested.
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Figure 28. Hyperpolarized 13C-pyruvate magnetic resonance
spectroscopy revealed a potential decrease in conversion of
pyruvate to lactate in DCA-injected mice.
Control mice at 9 months old were injected with a 0.3 mL bolus of
hyperpolarized [1-13C]-pyruvate via tail vein catheter and the
conversion of pyruvate-to-lactate was measured using free induction
chemical shift imaging (FID-CSI). (A) 1H-MRI image of the brain in
the coronal field overlaid with voxels of 13C-pyruvate spectra (yellow).
(B) Conversion of pyruvate-to-lactate was measured as a ratio of the
observed lactate peak to pyruvate peak. A pyruvate hydrate peak was
also recorded. 30 minutes after the first 13C-pyruvate injection was
measured (before), DCA (200 mg/kg) was injected using the tail vein
catheter followed by a 30 minute recovery time, after which another
injection of 13C-pyruvate was performed (after). The difference in the
ratio of lactate-to-pyruvate peaks from before DCA injection (blue line)
and after (red dashed line) was used to evaluate the effect of DCA on
pyruvate conversion to lactate in the brain. (C) The ratio of lactate-topyruvate peaks was measured following hyperpolarized 13C-pyruvate
injection before and after DCA (200 mg/kg) exposure in control mice at
9 months old. Data shown are mean ± SEM, p = 0.068, as calculated by
paired Welch’s t-test, n = 5 mice.
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3.13 Replicating the effect of acute dichloroacetate injection
on PDH phosphorylation in the brain
In order to evaluate the physiological effect of DCA injection on the brain of affected
mice, mice were euthanized 30 minutes after injection of saline or DCA. Brain extracts
from the frontal cortex were analyzed by western blotting using antibodies targeting key
proteins involved in lactate metabolism and transport (Figure 29). The band density was
quantified using -Actin as a loading control and a Welch’s t-test was performed with a
Bonferroni correction for multiple comparisons ( = 0.00625) to determine the difference
between saline- and DCA-injected mice (Figure 30). This analysis revealed a significant
effect for the phosphorylation level of PDH (t(14) = 8.198, p < 0.001), which indicated
that phosphorylation levels were reduced in DCA-injected mice. A significant effect was
also revealed for the expression of PDK1 (t(14) = 3.362, p = 0.005), indicating an
increase in expression in DCA-injected mice. There was no effect on the expression of
the following enzymes: LDHA (t(14) = 1.647, p = 0.122), LDHB (t(14) = 0.966, p =
0.350), PKM2 (t(14) = 1.680, p = 0.115), and PKM1 (t(14) = 0.321, p = 0.753). This
analysis also revealed a significant effect for the expression of the astrocyte-specific
lactate transporting protein: MCT4 (t(14) = 3.468, p = 0.004). Mice injected with DCA
had lower expression of MCT4 than saline-injected mice. There was no effect for
expression of the neuron-specific MCT2 (t(14) = 0.636, p = 0.535). These observations
indicated that the injection of DCA caused a significant decline in phosphorylation levels
of PDH in the frontal cortex, and may also influence expression of PDK1 and the lactate
transporter protein, MCT4.
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Figure 29. Acute exposure to dichloroacetate
phosphorylation levels of PDH in the frontal cortex.

reduces

Western blot analysis was performed on extracts from the frontal cortex
of control mice intraperitoneal injected with either saline or DCA (200
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were
used to detect proteins involved in aerobic glycolysis and lactate
metabolism. n = 10 and 9, respectively, for saline- and DCA-injected
mice.
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Figure 30. Acute exposure to dichloroacetate reduces
phosphorylation levels of PDH in the frontal cortex: Band
densitometry analysis.
Quantification of band densitometry for western blots of extracts from
the frontal cortex of control mice injected with saline or DCA (200
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were
used as markers of aerobic glycolysis and lactate metabolism. Relative
band density was calculated relative to -actin. A significant decline in
phosphorylation levels of PDH was measured following DCA injection.
Data are shown as mean + SEM, *p < 0.05, **p < 0.01, ***p < 0.001, n
= 10 and 9, respectively, for saline- and DCA-injected mice.
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Extracts from the hippocampus were also analyzed by western blotting with antibodies
for lactate metabolism and transport (Figure 31). Band densitometry analysis was
performed using -actin as a loading control and a Welch’s t-test with a Bonferroni
correction for multiple comparisons ( = 0.00625) was used to evaluate the effect of
DCA injection (Figure 32). This analysis revealed a significant effect for the
phosphorylation levels of PDH (t(14) = 4.493, p < 0.001), which indicated that
phosphorylation of PDH was reduced in DCA-injected mice. This analysis also revealed
a potential effect for the expression of LDHA (t(14) = 2.249, p = 0.041) and the neuronspecific lactate transporter MCT2 (t(14) = 2.276, p = 0.039), yet these did not reach the
threshold determined by the Bonferroni correction for multiple comparisons. There were
no other significant effects for any of the following lactate metabolism or transporting
proteins: PDK1 (t(14) = 0.910, p = 0.379), LDHB (t(14) = 1.790, p = 0.095), PKM2
(t(14) = 2.002, p = 0.065), PKM1 (t(14) = 0.524, p = 0.609), or the astrocyte-specific
lactate transporter MCT4 (t(14) = 1.373, p = 0.191). Altogether, these analyses indicated
that injection of DCA caused a reduction in phosphorylation of PDH in the frontal cortex
and hippocampus of affected mice.
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Figure 31. Acute exposure to dichloroacetate
phosphorylation levels of PDH in the hippocampus.

reduces

Western blot analysis was performed on extracts from the hippocampus
of control mice intraperitoneal injected with either saline or DCA (200
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were
used to detect proteins involved in aerobic glycolysis and lactate
metabolism. n = 10 and 9, respectively, for saline- and DCA-injected
mice.
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Figure 32. Acute exposure to dichloroacetate reduces
phosphorylation levels of PDH in the hippocampus: Band
densitometry analysis.
Quantification of band densitometry for western blots of extracts from
the hippocampus of control mice injected with saline or DCA (200
mg/kg) 30 minutes prior to euthanization. Indicated antibodies were
used as markers of aerobic glycolysis and lactate metabolism. Relative
band density was calculated relative to -actin. A significant decline in
phosphorylation levels of PDH was measured following DCA injection.
Data are shown as mean + SEM, *p < 0.05, ***p < 0.001, n = 10 and 9,
respectively, for saline- and DCA-injected mice.
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3.14 Replicating the correlation analysis of PDH
phosphorylation and memory performance in control
mice
Considering that there was an inverse correlation between expression of aerobic
glycolysis enzymes in the frontal cortex and memory performance of control mice and
APP/PS1 mice (Figure 19), the expression of these same proteins was compared to
memory performance of saline-injected and DCA-injected mice. Band densitometry
measurements in the frontal cortex were correlated to the individual measures of percent
time spent in the correct quadrant during the MWM probe trial and a multiple linear
regression model (relative band density x treatment) was performed (Figure 33). This
analysis revealed a significant positive correlation for the level of phosphorylation of
PDH in saline-injected mice (R2 = 0.7443, p = 0.006), which indicated that mice with
higher phosphorylation levels performed better in the memory task. There was no
correlation for phosphorylated-PDH in DCA-injected mice (R2 = 0.049, p = 0.600). A
correlation was also detected in saline-injected mice for the expression of PKM1 (R2 =
0.528, p = 0.041), indicating that mice with higher PKM1 performed better in memory
testing. This analysis also revealed a significant correlation in DCA-injected mice for
expression of the astrocyte-specific lactate transporter MCT4 (R2 = 0.746, p = 0.012), yet
there was no correlation for MCT4 expression in saline-injected mice (R2 = 0.004, p =
0.883). A one-way ANCOVA was conducted on the linear regression of relative band
density and percent time spent in the correct quadrant, controlling for treatment. This
analysis revealed that DCA treatment was not a significant covariate for any of the
measured proteins. The memory performance of mice injected with saline or DCA was
also correlated with the expression of lactate metabolism and transport enzymes in the
hippocampus. The same analysis was performed on relative band densitometry and
percent time spent in the correct quadrant for saline- and DCA-injected mice (Figure 34).
A multiple linear regression model (relative band density x treatment) was then
performed and revealed only one significant correlation for expression of PKM1 (R2 =
0.625, p = 0.020) in saline-injected mice. This analysis suggested that mice with higher
expression of PKM1 in the hippocampus performed worse on the memory task.
Interestingly, this is opposite to the trend observed in the frontal cortex.
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Figure 33. Memory performance correlates with phosphorylation of
PDH in saline-injected mice and MCT4 expression in
dichloroacetate-injected mice within the frontal cortex.
Band densitometry measurements using indicated antibodies in the
frontal cortex were compared with memory performance of control
mice injected with saline (open diamond) and DCA (closed diamond) in
the Morris water maze probe trial as a measure of percent time spent in
the correct quadrant. Lines-of-best-fit are overlaid for saline-injected
mice (solid) and DCA-injected mice (dashed). A significant positive
correlation was observed for phosphorylated-PDH in saline-injected
mice and also for MCT4 in DCA-injected mice. Horizontal dotted line
at 25% represents the probability of spending the same amount of time
in the correct quadrant by chance. n = 8 for each group of saline- and
DCA-injected mice.
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Figure 34. Correlations of memory performance with band
densitometry in the hippocampus.
Band densitometry measurements using indicated antibodies in the
hippocampus were compared with memory performance of control
mice injected with saline (open diamond) and DCA (closed diamond) in
the Morris water maze probe trial as a measure of percent time spent in
the correct quadrant. Lines-of-best-fit are overlaid for saline-injected
mice (solid) and DCA-injected mice (dashed). Horizontal dotted line at
25% represents the probability of spending the same amount of time in
the correct quadrant by chance. n = 8 for each group of saline- and
DCA-injected mice.
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In order to further validate the correlation between phosphorylation of PDH in the frontal
cortex and memory performance in saline-injected mice, the relative band density was
correlated to several other measures of memory performance in the MWM (Figure 35). A
multiple linear regression (relative band density x treatment) was performed on the
number of platform entries with phosphorylation of PDH and revealed a significant
positive correlation for saline-injected mice (R2 = 0.546, p = 0.036). This correlation was
not observed for DCA-injected mice (R2 = 0.003, p = 0.900). This indicated that salineinjected mice with higher phosphorylation of PDH crossed the platform boundary more
often. A one-way ANCOVA was conducted on the linear regression of relative band
density and number of platform entries, controlling for treatment. This analysis revealed
that DCA treatment was not a significant covariate. The latency to the first entry of the
platform boundary was then compared to phosphorylation of PDH using an exponential
decay equation. This analysis revealed a strong correlation (R2 = 0.967), which suggested
that saline-injected mice with higher phosphorylation of PDH were able to find the
platform boundary faster. This correlation was not observed in DCA-injected mice (R2 =
0.227). Finally, the difference in latency to the first platform entry between the probe trial
and the final training day was correlated to phosphorylation of PDH using a multiple
linear regression (relative band density x treatment). This analysis revealed no correlation
for saline-injected mice (R2 = 0.324, p = 0.182) and no correlation for DCA-injected mice
(R2 = 0.057, p = 0.570). Altogether, these data indicate that phosphorylation level of PDH
in the frontal cortex was positively correlated to several measures of memory
performance in the MWM.
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Figure 35. Phosphorylation of PDH correlates with memory
performance in control mice.
Band densitometry measurements of phosphorylated PDH in the frontal
cortex of control mice injected with either saline (open diamond) or
DCA (closed diamond) were compared with memory performance in
the Morris water maze probe trial for measures of (A) percent time
spent in the correct quadrant, (B) number of platform entries, (C)
latency to the first platform entry, and (D) the difference in time
between average latency to find the platform on training day 4 and the
latency to the first entry of the platform on the probe trial. Lines-ofbest-fit are overlaid for saline-injected mice (solid) and DCA-injected
mice (dashed). Levels of phosphorylated PDH in control mice correlate
with all measures of memory performance. n = 9 and 10 for saline and
DCA treatments, respectively.
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Chapter 4

4

Discussion

This work produced several novel observations, which gave rise to some conclusions that
need to be addressed. This chapter is split into two main categories of discussion:
examining the temporal and spatial expression of aerobic glycolysis enzymes and lactate
levels, and examining the relationship between cerebral aerobic glycolysis and memory
performance. Each conclusion is addressed independently by interpreting the results and
determining how they fit into the context of the greater research field.

4.1 Examining the temporal and spatial expression of
aerobic glycolysis enzymes and lactate levels
4.1.1

Cerebral lactate levels decline with age

Lactate production, consumption, and transport between astrocytes and neurons has been
examined extensively425, yet little emphasis has been placed on examining changes in this
metabolism with age. In vivo 1H-MRS is a powerful tool to detect metabolic signatures of
different brain regions non-invasively over the course of normal aging. In this study, 1HMRS was used to measure lactate in the frontal cortex and hippocampus of control mice
and APP/PS1 mice from 3 to 12 months of age. This analysis revealed a decline in lactate
levels from 6 to 12 months of age in the frontal cortex of control mice (Figure 6),
whereas the hippocampus revealed no significant decline in lactate levels between 6 and
12 months of age (Figure 7). Consistent with this finding, a 1H-MRS longitudinal study
of metabolites in healthy C57BL/6 mice between 3 and 24 months of age also revealed a
progressive decline in lactate levels in the cortex but not hippocampus496. However, in
contrast to our findings, a study using 1H-MRS reported that cortical lactate levels
increased with age in a mitochondrial DNA mutator mouse model of advanced aging330.
However, it is not clear if brain metabolism in mutant advanced-aging mice is an accurate
reflection of brain metabolism that occurs during normal aging. Collectively, these
observations suggest that a decline in glycolytic metabolism occurs with advanced age in
the frontal cortex, whereas the hippocampus appears to be less affected.
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Examination of lactate levels by 1H-MRS revealed a decline in the frontal cortex of aged
control mice and no change in APP/PS1 mice. In addition, there was found to be no
significant change with age or genotype in the hippocampus. Maintained lactate in the
frontal cortex of aged APP/PS1 mice could be attributed to an increase in regional
glucose uptake and glycolytic metabolism. An increase in glucose uptake in the cortex
and hippocampus, as measured by 18F-FDG-PET, was reported in 12-month-old APP/PS1
mice when compared to control animals234. The authors ruled out the contribution of
cerebral blood flow by demonstrating that cerebral perfusion is reduced in APP/PS1 mice
at this age. A similar study measured an increase in glucose utilization in the frontal
cortex and hippocampus of APP/PS1 mice at 3.5 and 5 months of age, which correlated
with improved performance in the MWM497. Increased glucose uptake has also been
measured using

18

F-FDG-PET in the cortex, hippocampus, and striatum of 7- and 9-

month old APP(Tg2576) mice498, in 12-month old PDAPPV717F mice499,500, in 16-month-old
APP(Tg2576)/PS1M146L mice501and in 12-month-old 5xFAD mice502. However, a decline in
glucose uptake has also been measured by
AD, including 18-month-old 3xTG mice
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F-FDG-PET in several animal models of

. Hypometabolism is a common pathological

feature of AD indicating a reduction in neuronal energy demand from loss of synaptic
activity at later stages of the disease, yet inconsistencies in glucose uptake measurements
using 18F-FDG-PET have been noted in AD animal models504. Different states of glucose
uptake have been reported, even among the same transgenic strains, including APP(Tg2576)
mice498,505 and 5xFAD mice502,506. However, in APP/PS1 mice, only increases in glucose
uptake have been measured at 3.5, 5, and 12 months of age234,497.
The majority of 1H-MRS studies of AD in rodent models do not report lactate
measurements507–509. This is because the lactate peak is largely obscured by lipid signals
with similar resonance frequencies and is difficult to measure510,511. In many cases, brain
extracts from post-mortem tissue are analyzed instead of in vivo longitudinal
measurements over the course of age. A 1H-MRS metabolomics study of extracted brain
samples revealed an elevation in lactate levels in the hippocampus and frontal cortex of
the TgCRND8 mice compared to controls at both 2-3 months of age and 12-13 months of
age512. However, a recent high-throughput metabolomics study on 6-month-old APP/PS1
mice using ultra performance liquid chromatography followed by gas chromatograph
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mass spectrometry measured a decline in lactate, creatine, and NAA in the hippocampus
and cortex compared to controls513. These observations highlight the need for consistency
in measuring metabolites, including lactate, across animal models of AD to reliably
evaluate the age-associated changes in brain metabolism. The concentration of
metabolites detected by 1H-MRS can be quantified using an unsuppressed water signal
from the same volume of interest as an internal reference496, yet in this study lactate was
measured using NAA as a reference metabolite and has been previously reported514.
Second only to the neurotransmitter glutamate, NAA is the most abundant metabolite in
the brain and is mainly produced in neurons where it is shuttled to oligodendrotyes and is
used for myelin production515. In order to determine if NAA levels change with age,
NAA in the frontal cortex and hippocampus was quantified as a ratio to total creatine,
which is frequently used as a reference metabolite in 1H-MRS studies508,514. We found
that the ratio of NAA to creatine in both the frontal cortex and hippocampus did not
change over the course of age in control mice or APP/PS1 mice (Figure 5 and Figure 6),
which is consistent with the findings of other groups496,507–509. Therefore, NAA was a
suitable metabolite to standardize lactate measurements over the course of aging.
Although we did not detect a difference in hippocampal lactate levels using 1H-MRS
analysis, we did observe an increase in hippocampal ISF lactate levels using
microdialysis analysis in awake mice (Figure 8). The discrepancies in measured lactate
levels using the two methods may be due to the low level of sensitivity for the detection
of lactate by 1H-MRS and the small size of the hippocampus. In contrast, microdialysis
has higher detection capabilities for lactate and was performed in awake mice. The use
of isoflurane anesthetic during 1H-MRS analysis may have influenced lactate levels in the
hippocampus and obscured genotype-specific differences516. These findings underscore
the need to develop more sensitive and non-invasive techniques for measuring lactate
levels in vivo.

4.1.2

The expression of lactate metabolism and transport proteins
declines with age in both control mice and APP/PS1 mice

Maintained lactate levels in the APP/PS1 brain is indicative of higher levels of aerobic
glycolysis and resembles the metabolic profile of the Warburg effect in cancer cells 243. It
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has been previously demonstrated that nerve cells selected for resistance to A toxicity
up-regulate aerobic glycolysis as a protective mechanism239. Chemical or genetic
disruption to key aerobic glycolysis enzymes PDK1 or LDHA resulted in re-sensitization
of resistant lines, while over-expression of PDK1 or LDHA conferred resistance to A
and other neurotoxins in naïve lines240. Elevated lactate in the frontal cortex and
hippocampus of APP/PS1 mice at this age may indicate the up-regulation of glucose
uptake or a metabolic shift from oxidative phosphorylation to aerobic glycolysis as a
protective resistance to A toxicity. Nerve cell lines and primary cortical neurons that are
resistant to Atoxicity had enhanced glucose consumption, increased activity of
glycolytic

enzymes

including

HK,

glyceraldehyde

3-phosphate

dehydrogenase

(GAPDH), and PK, and increased flux through the PPP260. The A-induced changes to
metabolism were found to be due to activation of the transcription factor HIF-1, which
regulates cellular responses to low oxygen by up-regulating glycolytic metabolism,
including enzymes PDK and LDHA. It was anticipated that western blot analysis of brain
extracts would reveal an increase in aerobic glycolysis enzyme expression in APP/PS1
mice compared to control mice at the same age. A two-way ANOVA identified an
increase in expression of PDK1 at 6 months of age in the frontal cortex of APP/PS1 mice
when compared to controls, indicating a possible up-regulation of aerobic glycolysis.
However, these mice also had an increase in PKM1 (non-glycolytic isozyme) and no
significant difference in expression of LDHA, PKM2, or the phosphorylation levels of
PDH (Figure 11). These observations indicate a lack of collective up-regulation of
enzymes involved in aerobic glycolysis in APP/PS1 mice. Interestingly, this analysis
revealed a significant age-dependent decline in all proteins involved in glucose
metabolism for both control and APP/PS1 mice from 6 to 12 months of age indicating a
general decline in glucose metabolism with age. The cerebral CMRglc can be estimated
using
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F-FDG PET imaging as a marker of glucose uptake and metabolism. Several

studies have demonstrated that CMRglc declines significantly in older individuals in
several brain regions

including the parietal, temporal, and frontal cortex, with the

greatest reduction observed in the frontal cortex517–520. Furthermore, the metabolism of
ketones, the brains’ major alternative fuel source, can be measured using 11C-AcAc PET
as a marker of cerebral metabolic rate of acetoacetate (CMRa). In contrast to CMRglc,
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the CMRa does not decline with age in the same brain regions521. It has been suggested
that the decline in CMRglc may be due to brain atrophy and lower cortical thickness in
cognitively normal individuals519,522, yet even after correction for partial volume effects,
the same trends in CMRglc and CMRa were observed523. These studies suggest that a
general decline in cerebral glucose uptake and metabolism occurs with age that may not
be adequately compensated by the metabolism of ketones as an alternative fuel source,
and is consistent with the age-dependent decline in expression of glycolytic enzymes
observed in the frontal cortex of both control and APP/PS1 mice in this study.
If we assume that glucose influx and metabolism is elevated in aged APP/PS1 mice, then
an increase in lactate levels measured by 1H-MRS in the frontal cortex of 9-12-month-old
APP/PS1 mice supports the hypothesis that aerobic glycolysis is up-regulated in neurons
in order to promote A resistance. Yet, given a general decline in expression of
glycolytic enzymes with age in both control and APP/PS1 mice, an alternate explanation
may be that lactate efflux from the brain is diminished in APP/PS1 mice. Western blot
analysis of brain extracts revealed an age-dependent increase in expression of the lactate
transporters: MCT2 (neuronal-specific) and MCT4 (astrocyte-specific), in the frontal
cortex of control mice, but not in APP/PS1 mice. At 12 months of age, the expression of
MCT4 was found to be significantly elevated in the frontal cortex of control mice
compared to APP/PS1 mice (Figure 11). This indicates that lactate transport may be
compromised in APP/PS1 mice. During neuronal activation, a high energy demand is
placed on astrocytes, which need to rapidly clear glutamate from the synapse and
necessitating aerobic glycolysis for rapid energy production. As a result, the majority of
lactate released from astrocytes is beyond the metabolic need of activated neurons, and
thus is expelled from the brain524. There is substantial evidence that suggests astrocytes in
the AD brain become “reactive” or “activated” in response to inflammatory cytokines
produced by microglia, including Interleukin-1 (IL-1) and IL-6525,526. Reactive astrocytes
change their phenotype by interweaving themselves within amyloid plaques and upregulating expression of several marker proteins including GFAP and the S100 calciumbinding protein B (S100)527,528. Yet it was recently discovered in APP/PS1 mice that
reactive astrocytes do not migrate to plaques; instead they respond to plaque-induced
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injury by changing phenotype and function529. Consequently, reactive astrocytes may
provide less support to neurons because they are functionally different and can no longer
fulfill their normal roles530,531. The data presented here suggest that a decline in glycolytic
metabolism occurs in the cortex during normal aging while a concurrent increase in MCT
expression arises as a possible compensatory response to maintain neuronal activity. In
contrast, while a decline in glycolytic metabolism occurs in the APP/PS1 brain, no
increase in MCT expression was detected. Thus, in the absence of enhanced lactate
transport, lactate may accumulate either within reactive astrocytes or in the extracellular
space.

4.1.3

The interaction between the frontal cortex and the
hippocampus

In this study, both the frontal cortex and the hippocampus were examined in parallel as
both these brain regions play key roles in memory. It is understood that the hippocampus
and the frontal cortex both participate in memory consolidation and retrieval. Many of the
pioneering studies investigating the involvement of specific brain regions in memory
come from lesion studies in humans. The most famous of these cases being the patient
H.M., who had most of his medial temporal lobe (which includes the hippocampus)
bilaterally removed in an attempt to cure his epilepsy. Following surgery, H.M.
developed severe anterograde amnesia, meaning he could not develop any new memories
or consolidate newly acquired memories532. This evidence strongly implicated the
hippocampus as the central mediator of episodic memory formation and has encouraged
decades of research detailing the interaction of the hippocampus with other brain regions
to support memory consolidation and retrieval533. In a similar study of brain lesions using
paired-associate learning tasks, in which two lists of cue words are paired with different
response words, patients with damage to the frontal cortex have difficulty with the
second-list learning534. This suggests that the frontal cortex is responsible for control of
memory associations as part of a memory-filtering mechanism. Several studies using
animal models have shown that damage to the frontal cortex impairs the ability of the
brain to alter behaviour in response to stimuli with different emotional significance535,
learn the association of different perceptual stimuli with a food reward536, or to switch

122

between memory associations of odor or place stimuli537. These studies demonstrate that
the frontal cortex is involved in memory consolidation and retrieval by associating
incoming stimuli with a context of familiar experiences within related memories. The
association between hippocampus and frontal cortex is best understood using the railroad
metaphor in which the hippocampus is responsible for placing new railroad tracks
(memory formation), while the frontal cortex is responsible for flexibly switching
between tracks that have already been laid (memory association)538,539.
The frontal cortex and hippocampus also have dramatically different metabolic profiles.
The regional distribution of aerobic glycolysis can be measured using multimodal PET by
comparing the cerebral metabolic rate for oxygen (CMRO2) using [15O-H2O] and
CMRglc using [18F-FDG]. Aerobic glycolysis is estimated as the oxygen-glucose index
(OGI), which compares the molar ratio of oxygen-to-glucose. An OGI of 6 indicates that
all glucose is converted to carbon dioxide and water, and an OGI of less than 6 indicates
that non-oxidative glucose metabolism (aerobic glycolysis) is occurring. In a recent study
measuring the OGI from different brain regions of normal young adults at rest, aerobic
glycolysis was found to be elevated in the DMN and in areas of the frontal and parietal
cortex, while the cerebellum and the hippocampus had reduced aerobic glycolysis relative
to the brain average351. In a follow up study, the authors demonstrated that the brain
regions with high aerobic glycolysis in young healthy adults strongly correlated with the
regions of high A deposition, as measured by PET using [11C-PiB] retention540. Yet, the
age-associated metabolic changes in the frontal cortex and hippocampus of the AD brain
have yet to be investigated. In this study, 1H-MRS analysis of the hippocampus revealed
that lactate levels decline with age for both control mice and APP/PS1 mice, although not
significantly, and there was no difference between control mice and APP/PS1 mice. In
contrast, microdialysis sampling revealed elevated extracellular lactate in the
hippocampus of aged APP/PS1 mice compared to controls. These data suggest that either
aerobic glycolysis declines with age in the hippocampus, or lactate export increases, and
is counter to the hypothesis that aerobic glycolysis is promoted in neurons in response to
A deposition.

123

Western blot analysis of brain extracts from the hippocampus revealed a significant
change in expression of aerobic glycolysis enzymes from 6 to 12 months in both control
and APP/PS1 mice. A two-way ANOVA revealed a significant age-dependent decline in
phosphorylated PDH levels, LHDA and PKM1 expression, along with an increase in
expression of LDHB and PKM2 (Figure 13). The decline in phosphorylated PDH levels
suggests an increase in PDH activity, while a decline in LDHA and an increase in LDHB
suggest an increase in lactate oxidation with age. This analysis also revealed a significant
interaction between age and genotype for PDK1 and LDHB, indicating that PDK1
increases in control mice and decreases in APP/PS1 mice with age, while LDHB
expression increases in control mice and does not change in APP/PS1 mice with age.
These changes indicate a shift in metabolism toward oxidative phosphorylation in both
control and APP/PS1 mice. The age-dependent decline in PKM2 and increase in PKM1 is
unexpected since expression of PKM2 is closely associated with aerobic glycolysis in
cancer cells301,336,541,542. Expression of PKM2 is induced by insulin signaling and mTOR
activation336, as well as epidermal growth factor receptor (EGFR) activation543. Elevated
PKM2 expression is also found in adult stem cells while PKM1 is expressed in
differentiated cells of the brain544,545. Western blot expression analysis of the lactate
transporters MCT2 (neuron-specific) and MCT4 (astrocyte-specific) in the hippocampus
revealed an age-dependent decline in MCT4 for both control and APP/PS1 mice, but no
difference in age or genotype for MCT2. These findings suggest that lactate efflux may
decline within hippocampal astrocytes with a concomitant metabolic shift toward
oxidative phosphorylation with age. Further investigation is warranted to discern how
expression of aerobic glycolysis enzymes is regulated over the course of age and in
different regions of the AD brain.
The 1H-MRS analysis of cerebral lactate levels was complemented by microdialysis
measurements of hippocampal ISF of control and APP/PS1 mice performed by Macauley
and colleagues. This analysis revealed an age-dependent increase in ISF lactate for
APP/PS1 mice from 3 to 18 months of age, as well as a significant increase at 12 months
of age compared to control mice (Figure 8). These results appear counter to the unaltered
hippocampal lactate levels in APP/PS1 mice as measured by 1H-MRS (Figure 7), as well
as the age-dependent decline in expression of aerobic glycolysis enzymes and lactate
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transporters in the hippocampus as measured by western blot analysis (Figure 13). One
important distinction between these experiments is the physiological condition of the
animal. During in vivo microdialysis sampling of ISF lactate, mice are awake and freely
moving, while 1H-MRS measurements of lactate was performed under isoflurane
anesthesia. Isoflurane has been shown to influence brain metabolism516. In addition, in
vivo 1H-MRS has a low level of sensitivity for the detection of lactate, a limitation that is
further compounded by the small size of the hippocampus.
It is well established that aerobic glycolysis is upregulated during neuronal activation
with a concomitant increase in ISF lactate concentration346,349,361,363,377,546. The agedependent increase in hippocampal ISF lactate concentrations in APP/PS1 mice may be
indicative of an increased capacity to perform aerobic glycolysis during neuronal
activation, which is supportive of my hypothesis that neurons upregulate aerobic
glycolysis in response to A deposition. Moreover, MCT2 expression levels did not
decline with age, suggesting that neuronal-generated lactate may be exported at a higher
level in APP/PS1 mice relative to control aged mice. These findings underscore the need
to develop more sensitive and non-invasive techniques for measuring lactate levels in
vivo.

4.1.4

Aerobic glycolysis does not influence amyloid- processing

The interplay between A production and glycolytic metabolism may occur through
neuronal activity. Regional ISF measurements using in vivo microdialysis in APP(Tg2576)
transgenic mice at 3 months of age demonstrated that neuronal activity increases ISF A
and lactate concentrations547. The acute injection of glucose increases hippocampal ISF
lactate concentration, A levels, and neuronal activity in both 3-month-old and 18-month
old APP/PS193,483,548. Interestingly, 1H-MRS measurements of lactate levels in the frontal
cortex of 24-month-old PS2APP mice correlated significantly with higher plaque
levels514. Neuronal activation may also promote A production through altered APP
processing. In a study that used primary neuronal cultures harvested from APP(Tg2576)
embryos, neuronal activation was found to promote A production while neuronal
inhibition decreased A production by mediating the interaction between APP and
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PS1549. In a similar study, activation of the NMDA receptor increased the production and
secretion of A by shifting APP processing from the -secretase to the -secretase550.
Perhaps the most compelling evidence linking neuronal activation to aerobic glycolysis
and A production comes from PET imaging. The regional distribution of aerobic
glycolysis in the resting human brain is predominantly in the DMN, a region that
correlates spatially with deposition of A in the AD brain540. The authors suggest this
may be due to a persistent level of neuronal activity in the DMN when individuals are not
engaged in specific goal-directed behaviours352,551,552. The DMN is also active during
light sleep553,554 and persists in deep sleep yet connectivity between frontal and posterior
regions is lost during this time555. ISF lactate and A levels exhibit diurnal fluctuation
that are co-regulated and consistent with neuronal activity during sleep/wake cycles in
both normal mice and APP/PS1 mice; A production increases during wakefulness and
decreases with sleep547,556–558. Furthermore, A plaque formation can interrupt the normal
sleep-wake cycle of 9-month-old APP/PS1 mice resulting in increased wakefulness and
decreased sleep in a feed-forward loop that promotes A production557. This is consistent
with diurnal fluctuations in CSF A levels and disrupted sleep-wake cycles observed in
humans556,559–561. These observations indicate a possible feed-forward mechanism
between regional neuronal activity and increases in glucose uptake, aerobic glycolysis,
and A production, but it is currently unknown if aerobic glycolysis promotes A
production or whether it is merely a consequence of neuronal activity.
In order to measure A dynamics in the APP/PS1 mouse brain, an ELISA was performed
on extracts from the frontal cortex of 12 month-old mice. The relative concentrations of
A(1-40) and A(1-42) were measured as a ratio to total protein in either soluble or insoluble
fractions from the frontal cortex of APP/PS1 mice. This analysis revealed that the
majority of A in the brains of these mice was insoluble A(1-42) (Figure 14). This finding
is in agreement with the genetic elements of APP/PS1 mice: the Swedish mutation
(K670N:M671L) in APP increases production and secretion of both A(1-40) and A(1562–566
,
42)

while expression of PSEN1 lacking exon 9 (ΔE9) shifts the cleavage of APP to

favor A(1-42) over A(1-40)96. The levels of A in APP/PS1 mice have been examined
extensively and the majority of A burden in the brain is consistently the A(1-42) species
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in insoluble (plaque) fractions96,481,567–570. Interestingly, the levels of soluble A(1-40) and
A(1-42) in the cortex and hippocampus both correlate negatively with measures of spatial
learning and memory in the MWM, but not insoluble A(1-40) and A(1-42)570. In order to
test the hypothesis that aerobic glycolysis influences A production, the levels of soluble
and insoluble A(1-40) and A(1-42) were correlated with the expression of aerobic
glycolysis enzymes in the frontal cortex (Figure 15). There were significant relationships
detected for levels of soluble A(1-40) and A(1-42) with PDK1, LDHA/LDHB, PDHp/PDH, or PKM2/PKM1. In addition, there were no significant interactions between
levels of insoluble A(1-40) and A(1-42) with expression of any of the aerobic glycolysis
enzymes investigated. This analysis indicates that aerobic glycolysis in the frontal cortex
does not influence the production of A or the cleavage of APP to favor A(1-40) or A(142).

Further studies using neuronal cell culture models evaluating the effect of altered

aerobic glycolysis enzyme expression on A dynamics would help elucidate the interplay
between these two processes.

4.1.5

Aerobic glycolysis enzymes are expressed primarily in
neurons and reactive astrocytes surrounding plaques

The cell-specific spatial expression of enzymes responsible for aerobic glycolysis and
lactate production in the mouse brain has not previously been investigated. Several lines
of evidence support distinct metabolic phenotypes between neurons (mainly oxidative)
and astrocytes (mainly glycolytic)378. Measurements of cerebral lactate by 1H-MRS or
western blot analysis of protein extracts do not distinguish between these two
predominant cell types. To identify which cell types are expressing the enzymes
responsible for aerobic glycolysis, frozen brain sections from control and APP/PS1 mice
at 12 months of age were immunostained using antibodies specific for PDK1 and LDHA
and co-stained with antibodies for astrocytes (GFAP) and neurons (TUJ1). Within the
frontal cortex and hippocampus of control mice, PDK1 and LDHA expression was
localized primarily to the soma of TUJ1+ neurons (Figure 16 and Figure 17). This
observation demonstrates that neurons are capable of using aerobic glycolysis in both
control mice and APP/PS1 mice. In support of this observation, LDHA has been found to
be expressed in the cytosol of rat primary cortical neurons and astrocytes, while LDHB
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expression was prevalent in synaptosomes329. In contrast, previous studies have found
neurons exclusively immunoreactive with LDHB antibodies, while astrocytes were
immunoreactive with both LDHA and LDHB antibodies in the human hippocampus and
occipital cortex328,409. In a similar study of primary astrocyte and neuron cultures from
chick embryos, astrocytes were found to predominantly express LDHA and neurons were
found to predominantly express LDHB571. Interestingly, in this study PDK1 and LDHA
were also expressed in GFAP+ reactive astrocytes surrounding amyloid plaques in the
frontal cortex and hippocampus of APP/PS1 mice. It was surprising to find an absence of
PDK1 or LDHA expression in astrocytes of control mice. The GFAP antibody used for
this experiment may not have been sensitive enough to visualize astrocytes in control
mice and future experiments should make use of an antibody that reliably stains native
astrocytes. However, if PDK1 and LDHA were expressed in astrocytes of the control
mouse brain then fluorescence signal would have labeled these cells red in the merged
confocal image, and this was not detected. The expression of PDK1 and LDHA in
reactive astrocytes, but not in native astrocytes, may indicate that these cells up-regulate
aerobic glycolysis as a consequence of disease pathogenesis. A similar staining pattern
has been characterized in TgCRND8 mice at 12 months of age showing coimmunostaining of reactive astrocytes with PFKFB3 expression, a main regulator of
glycolysis572. Up-regulation of aerobic glycolysis in reactive astrocytes may be
responsible for the increase in lactate observed in the frontal cortex of APP/PS1 at 9 and
12 months of age. Further investigation is warranted to test if reactive astrocytes display
metabolic reprogramming toward aerobic glycolysis. Collectively these observations
indicate that PDK1 and LDHA are expressed primarily in the cell bodies of neurons, yet
both cell types may be capable of producing lactate through aerobic glycolysis.

4.2 Examining the relationship between cerebral aerobic
glycolysis and memory performance
4.2.1

Expression of aerobic glycolysis enzymes in the frontal
cortex correlates with memory performance

Previous work has demonstrated that both the hippocampus and the frontal cortex are
involved in spatial memory retrieval using the MWM573–576. More recently, it was
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demonstrated that lesions to the frontal cortex impaired memory in a partial-cue
environment, showing that an interaction between the frontal cortex and hippocampus
was required for pattern completion during memory retrieval577. However, it has yet to be
determined if aerobic glycolysis in the frontal cortex or hippocampus plays a role in
spatial memory recall. In order to test the hypothesis that aerobic glycolysis contributes to
memory processes, a correlation analysis was performed comparing expression of aerobic
glycolysis proteins in extracts from the frontal cortex and hippocampus at 12 months of
age (Figure 19 and Figure 20). A multiple linear regression model was then fit on the
percentage of time spent in the correct quadrant during the probe trial. This analysis
revealed a significant interaction with memory for enzymes involved in lactate
production including LDHA, the ratio of phosphorylated PDH to total PDH, and the ratio
of PKM2 to PKM1, suggesting that higher expression, or phosphorylation, of these
proteins correlates with better memory performance in control mice and worse
performance in APP/PS1 mice. These observations support the hypothesis that aerobic
glycolysis contributes to memory processes in control mice, but not in APP/PS1 mice. It
stands to reason that if neuronal activity is linked to a focal elevation of aerobic
glycolysis and lactate efflux578, then a higher expression of aerobic glycolysis would
enhance neuronal activation.
It is currently unknown why higher aerobic glycolysis may be detrimental to memory in
the AD brain. In the context of AD in humans, elevated lactate levels correlate negatively
with memory performance. Increased lactate within the precuneus/posterior cingulate of
individuals with MCI is associated with poorer memory performance579. AD patients also
show a significant increase in CSF lactate levels compared with age-matched nondemented individuals or patients with vascular dementia580,581. In addition, intravenous
lactate infusion does not improve semantic memory in AD patients582. These findings
suggest that perturbed lactate metabolism may be involved in the pathophysiological
processes in AD. One possible explanation may be that enhanced aerobic glycolysis and
neuronal activation promote A deposition leading to interference with synaptic
transmission and memory processes570. However, the ELISA analysis of soluble and
insoluble levels of A(1-40) and A(1-42) demonstrated no such relationship in the frontal
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cortex (Figure 15). The same multiple linear regression analysis in the hippocampus
revealed no significant interaction between relative band intensity and genotype on
percent time spent in the correct quadrant for any of the markers of aerobic glycolysis
(Figure 20). This finding suggests that aerobic glycolysis may play a role in memory
processes in the frontal cortex but not the hippocampus.

4.2.2

Chronic oral administration of dichloroacetate does not affect
memory at 12 months of age

The behaviour of APP/PS1 mice is well characterized but the age of cognitive decline
varies between laboratories and husbandry conditions. In the MWM, impairment in
spatial memory has been reported as early as 3.5 months of age583 and 6 months of age584,
yet 8-14 months of age is the most commonly reported age for onset of spatial memory
impairment in APP/PS1 mice when using the MWM97,569,570,585,586. In order to test the two
central hypotheses, that neurons upregulate aerobic glycolysis to promote A resistance,
and aerobic glycolysis contributes to memory processes, a chemical inhibitor of aerobic
glycolysis, DCA, was orally administered to control and APP/PS1 mice at a dose of 200
mg/kg per day via drinking water, beginning at the age of weaning. It was anticipated that
APP/PS1 mice exposed to DCA would lose a protective resistance mechanism and
succumb to neurodegeneration at an earlier age than APP/PS1 mice exposed to normal
drinking water. Spatial learning and memory was assessed using the MWM at 12 months
of age (Figure 18). The ability of mice to learn the location of the platform was measured
as the change in latency time required to find the platform over the course of 4 training
days. APP/PS1 mice showed a delay in finding the platform on each training day
compared to control mice. This is in agreement with similar studies demonstrating a
spatial learning impairment at this age97,584, yet disagrees with one report showing no
difference between genotypes585. Interestingly, a study using the visual platform water
maze demonstrated that APP/PS1 mice have a significant increase in thigmotaxis, or
tendency to cling to or follow the wall instead of actively search for the platform, and
also demonstrated more excessive floating in the pool than control mice587. This indicates
that stress may be a confounding factor for spatial memory performance for these mice.
In order to account for this possibility, mice that displayed excessive thigmotaxis or
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floating in either genotype were eliminated from analysis in both the training phase and
probe trials.
On day 5 a probe trial was performed in which the platform was removed and mice were
tested on their ability to remember the location of the platform, as measured by the
percent time spent in the correct quadrant. A two-way ANOVA revealed that APP/PS1
mice have a significant decrease in the percent time spent in the correct quadrant,
regardless of DCA exposure. There was no effect from treatment or the interaction
between genotype and treatment, suggesting that DCA had no effect on the ability of
mice of either genotype to remember the location of the platform. This indicated that
either chronic exposure to DCA had no physiological effect on the brain, or that aerobic
glycolysis did not participate in A resistance and memory performance. As a measure of
physical ability to perform the task, the total distance covered during the probe trial was
measured and a two-factor ANOVA was performed. This analysis revealed no significant
effect from genotype or treatment, or the interaction between genotype and treatment,
indicating that all mice swam a comparable distance. This suggests that impairment in
memory performance of APP/PS1 mice is reflective of impaired spatial memory and not
altered physical ability. It also demonstrates that chronic oral exposure to DCA does not
have a negative consequence to physical ability.

4.2.3

Chronic oral administration of dichloroacetate does not have
a physiological effect on the brain at 12 months of age

The effect of DCA exposure has been well documented in humans due to its ability to
reduce lactate levels in patients with congenital forms of MELAS (mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke-like episodes)588 and preclinical
evidence that it might be beneficial in cancer

589

. Acute administration of DCA at 35-50

mg/kg increases PDH activity by 3-6 fold and reduces lactate levels by more than 60% in
muscle tissue590,591. It has been estimated that the maximal reduction in circulating lactate
levels is achieved at an acute dose of DCA at 100 mg/kg, yet a dose-dependent reduction
in lactate continues beyond 200 mg/kg493. In order to confirm the physiological effect of
DCA, brain extracts were harvested at 12 months of age from the frontal cortex of control
mice exposed to chronic DCA and compared to mice that were provided normal drinking
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water. DCA is a specific inhibitor of PDK, the kinase that phosphorylates and inhibits the
PDH complex489,592. It was expected that mice exposed to DCA would have a decline in
PDH phosphorylation levels when compared to mice that were provided normal drinking
water. However, this analysis revealed that there was no difference in PDH
phosphorylation between these two groups (Figure 23). In addition, there was no
difference in expression levels of any other marker of aerobic glycolysis between the two
treatment groups. This indicates that chronic exposure to DCA at an oral dose of
200mg/kg daily since the age of weaning does not have a physiological effect on the
mouse at 12 months of age.
Despite several studies demonstrating the effectiveness of acute DCA exposure activating
PDH and lowering lactate levels, the physiological effect of chronic DCA exposure is
less clear. In one study of four MELAS patients, chronic oral exposure to DCA at a daily
dose of 25 mg/kg appeared to maintain lower serum lactate levels, yet there was no
change in CSF lactate levels over a course of 5 years593. In a larger study of 30 MELAS
patients given a chronic daily DCA dose of 25 mg/kg, there was no significant difference
between DCA and placebo groups in 1H-MRS estimation of cerebral lactate, CSF lactate,
or venous lactate, over the course of 24 months594. In addition, all 15 of the patients
randomly assigned to DCA had to prematurely discontinue the study due to side effects
from peripheral nerve toxicity. DCA is cleared more efficiently from plasma after an
initial acute dose than after 6 months of 25 mg/kg daily exposure595. Moreover, older
subjects aged 14 – 33.9 years were less efficient at clearing DCA from plasma than
younger subjects aged 2.2 – 7.1 years after 6 months of 25 mg/kg daily exposure595. This
finding has also been recapitulated in rats, demonstrating an age-associated effect on
DCA plasma clearance after chronic exposure for 6 months at 25 mg/kg daily596. These
studies demonstrate a lack of knowledge on the physiological effect between acute and
chronic DCA exposure. In this study, one control mouse and 3 APP/PS1 mice were
euthanized after approximately 5 months of 200 mg/kg daily oral DCA exposure due to
tissue damage to the ends of their tails and hind feet. All other mice appeared to tolerate
DCA well up to 12 months of age. During the probe trial of the MWM, there was no
significant effect of DCA treatment on the total distance covered, suggesting that there
was no physical impairment due to DCA exposure on the ability of these mice to swim.
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In summary, these observations indicate that chronic oral administration of DCA at 200
mg/kg daily for 12 months has no discernible effect on lactate levels or phosphorylation
levels of PDH in the frontal cortex. This suggests that chronic oral DCA administration
may be unsuitable for the long-term modulation of aerobic glycolysis in the brain.

4.2.4

Acute inhibition of aerobic glycolysis impairs memory

In order to further test the hypothesis that aerobic glycolysis contributes to memory
processes, the chemicals DCA and Isosafrol were used to inhibit the activity of PDK and
LDHA, respectively. Instead of a chronic exposure to these chemicals, an acute
intraperitoneal injection was used to deliver the treatment 30 minutes before entering the
MWM on the probe trial. The ability of these agents to target their intended protein in the
CNS after a single intraperitoneal injection was confirmed by western blot and enzyme
activity analysis (Figure 24). A single cohort of control mice and APP/PS1 mice starting
at 12 months of age was selected for this experiment and all mice were injected with the
same treatment at each of the probe trials (Figure 25). Mice were trained to learn the
location of the platform over the course of 4 training days and the latency to find the
platform was recorded for each training phase. This analysis revealed a significant
difference in latency time to find the platform between genotypes for the vehicle phase,
Isosafrol phase, and the DCA phase, but not the final saline phase of training. This
suggests that APP/PS1 mice may show an improvement in memory over the course of
repeated memory testing. However, the pre-exposure to the test agents might also have
had a differential effect on memory in the APP/PS1 mice. Future studies using naïve
APP/PS1 mice would help resolve this issue.
The difference between genotypes for latency to find the platform in the first three phases
may be accounted by the tendency of APP/PS1 to display thigmotaxis and excessive
floating as a stress response587. This behaviour was observed in some of the APP/PS1
mice over the course of the experiment and these mice were removed from analysis if the
behaviour persisted across consecutive training days (Table A2). However, these mice
were allowed to swim in subsequent training phases and were included in analysis if they
did not display excessive stress behaviour. Interestingly, there was no difference in
latency to find the platform during training between control mice and APP/PS1 mice for
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the final training phase indicating that these mice are capable of spatial learning at 18
months of age given repeated testing. This analysis also showed no overt toxicity from
acute injection of Isosafrol or DCA given that all mice were able to recover 2 weeks after
chemical administration and perform just as well during the next training phase.
At each individual phase of the experiment, the chemical treatment of vehicle, Isosafrol,
DCA, or saline, was given to the mice 30 minutes before entering the probe trial. This
time point was chosen due to previous reports showing a physiological effect on the brain
at this time for both Isosafrol at 300 mg/kg491 and DCA at 200 mg/kg493. During each
probe trial, the percent time spent in the correct quadrant was recorded as a measure of
memory and the total distance covered was recorded as a measure of physical ability to
swim in the water tank (Figure 26). A two-way ANOVA revealed a significant effect of
genotype and treatment, as well as an interaction between genotype and treatment. When
compared to the initial injection of the vehicle (1% Carboxymethylcellulose), Isosafrol
had no effect on the ability of control mice or APP/PS1 mice to remember the location of
the platform. In contrast, DCA administration had a significant effect on control mice, yet
had no effect on APP/PS1 mice, when compared to either the first injection with vehicle
or the last injection with saline. The same analysis was performed on the total distance
travelled during the probe trial and this revealed no significant effect from genotype or
treatment, suggesting that all mice were equally capable of physically performing the
memory task. These observations suggest that DCA may influence memory for control
mice and support the hypothesis that aerobic glycolysis contributes to memory processes.
These results also complement the earlier correlation analysis, which demonstrated an
inverse relationship between expression of aerobic glycolysis enzymes in the frontal
cortex and memory performance in control mice and APP/PS1 mice. There appeared to
be no effect from chemical administration in APP/PS1 mice, indicating that aerobic
glycolysis may not contribute to memory recall in these mice.

4.2.5

Acute injection of dichloroacetate has a physiological effect
on the brain

Considering that chronic exposure through drinking water did not exhibit a physiological
response in the brains of affected mice at 12 months of age, it was important to determine
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if acute injection of DCA had a measurable effect. Western blot analysis was performed
on extracts from the frontal cortex of control mice euthanized after injection of either
saline or DCA at 200 mg/kg (Figure 24A). This analysis revealed that mice injected with
DCA had a significantly lower ratio of phosphorylated PDH to total PDH. This suggests
that acute DCA exposure resulted in a physiological response in the brains of affected
animals and is in agreement with other reports showing DCA causes a decline of
phosphorylated PDH levels in mouse liver extracts597, and isolated mitochondria from the
mouse brain598. Intraperitoneal injection of DCA has also been shown to increase PDH
activity in the brain599,600, yet to the best of my knowledge this is the first report of DCA
intraperitoneal injection demonstrating a reduction in phosphorylation levels of PDH in
the brain. The relative band density of PDK1 was also measured to determine if there was
any difference in the levels of the target of DCA. A significant decrease in PDK1
expression was detected in animals injected with DCA compared to saline. It is unclear if
a 30 minute exposure to DCA is long enough to induce changes in transcription and
translation, but long-term exposure to DCA has been shown to reduce PDK4 expression
through the Forkhead box protein O1 (FOXO1) transcription factor601. In addition to the
direct chemical inhibition of PDK, DCA exposure may also promote a decline in PDK1
expression further potentiating the decrease in PDH phosphorylation and promoting
oxidative phosphorylation. Altogether, these results demonstrate that an acute injection
of DCA causes an observable reduction in phosphorylation levels of PDH in the frontal
cortex of affected mice.

4.2.6

The inhibition of memory performance from acute injection of
dichloroacetate is not reproducible

One of the main goals of scientific experimentation is to ensure that the outcomes are
reproducible. In animal behaviour experiments, there may be several confounding
variables that influence the outcome of a particular test. One possible confounding factor
is repeated testing, in which a previous experience influences the outcome of subsequent
tasks. Animals that have been exposed to a behavioural test often perform differently than
naïve animals494, although the relative influence of repeated testing depends on the
specific test being administered602, the strain of the animal603, and time interval between
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behavioural tests604. One study using C57BL/6J and 129S2/Sv strains in the MWM
reported that mice who had previously experienced the test did not perform any
differently than naïve mice during training or during the probe trial605. Another study
using C57BL/6J and NMRI strains showed that training at 2 months of age did not
improve performance in the MWM at 10 months of age compared to naïve mice, and also
did not affect from their performance when they were tested again at 18 months of age606.
A similar study using C57BL/6J and NMRI strains showed that training at 2 months of
age improved performance at 6 and 10 months of age in NMRI mice when compared to
naïve mice, but this effect was not observed in C57BL/6J mice who showed no difference
to naïve mice603. However, in the case of this study the time interval between training
was approximately 2 weeks, and it is unclear if previous experiences changed the
outcome of subsequent trials with a different chemical treatment. Another confounding
variable that may have influenced the outcome of these tests is age. Control mice and
APP/PS1 mice started the first training phase at approximately 12 months of age and
finished the last probe trial at approximately 16 months of age. It is unclear if aging
negatively affected mice at later experimental phases. In an attempt to address these
confounding variables and determine if repeated trials or age had an influence on
subsequent outcomes, a saline injection phase was performed as the final treatment
(Figure 26). This analysis revealed no difference between either control mice or APP/PS1
mice injected with saline at the very end of the study or vehicle at the very beginning of
the study. Although these results need to be taken with caution, they suggest that these
confounding variables did not impair the ability of these mice to perform during the final
probe trial.
In order to further test the hypothesis that aerobic glycolysis contributes to memory
processes, a new experiment was conducted where each of the previous confounding
variables was removed. DCA was selected as the treatment instead of Isosafrol because
control mice showed a greater impairment in memory from DCA injection than Isosafrol
treatment in the previous study. The latency time required to find the platform was
recorded over the course of four training days and a one-way repeated measure ANOVA
revealed no difference between mice assigned to saline or DCA treatments (Figure 27).
This indicated that there was no inherent difference in the ability of mice from either
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treatment group to learn the location of the hidden platform. Several measures of
performance were recorded during the probe trial including the total distance traveled, the
percent time spent in the correct quadrant, the number of platform entries, the latency to
the first platform entry, and the difference in latency to the platform between the probe
trial and the average of the final training day (Figure 27). Mice injected with DCA
travelled the same total distance as mice injected with saline, suggesting that DCA had no
effect on the ability of mice to swim in the tank. Mice injected with DCA spent the same
percent of time in the correct quadrant as mice injected with saline, and crossed the
boundary of the platform the same number of times. These measures suggest that there
was no significant difference in memory performance between saline and DCA-injected
mice at 9 months of age. The latency to the first platform entry was also recorded and
there was no difference between DCA-injected mice and saline-injected mice. In contrast,
the difference between the latency to find the platform boundary during the probe trial
and the average latency to find the platform on training day 4 revealed that saline mice
found the platform boundary faster than their previous average time (-4.88 ± 1.09
seconds), while the DCA mice did not find the platform any faster than their previous
average time (0.16 ± 1.96 seconds). There was a considerable difference between these
two groups (p = 0.042), yet it did not reach the significance threshold set by the
Bonferroni correction for multiple comparisons ( < 0.01). This finding should be
interpreted with caution, but suggests that DCA may cause a delay in memory recall and
could have had an effect on the ability of mice to continue to learn the location of
platform. Future experiments should examine the effect of DCA injection before each
training day in order to determine if DCA impairs learning ability in these mice.
Moreover, the previous study was performed with mice at 12 months of age. The effect
of DCA on mice at different ages should also be considered.
Following the probe trial, a flag trial was performed where the platform was placed back
into the tank in the opposite quadrant and a red flag was attached as a visual cue. The
latency to find the platform during this trial found no difference between DCA-injected
mice and saline-injected mice, suggesting that DCA did not interfere with the ability of
mice to use visual cues to find the platform. Altogether, these data indicate that acute
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exposure to DCA does not impair memory performance in naïve mice, which is counter
to the previous study showing a significant decline in memory performance of DCAinjected mice. However, there was indication that learning might be compromised by
DCA exposure. Further studies using different ages of mice and repeated injection
strategies will be required to formally determine the effect of DCA-mediated inhibition of
aerobic glycolysis on learning and memory.

4.2.7

Acute injection of dichloroacetate may reduce conversion of
pyruvate to lactate in the brain

Recent advances in MRI technology have enabled the monitoring of brain metabolism
non-invasively with the use of hyperpolarized

13

C-labelled metabolites coupled with

13

MRS. Injection of hyperpolarized C-pyruvate generates pyruvate and lactate peaks that
are linearly proportional to their concentration, and thus can be used to quantify the
conversion of pyruvate-to-lactate in the brain607. Considering that acute exposure to DCA
had no effect on memory performance of naïve mice, DCA was tested for a physiological
response on the brain using hyperpolarized

13

C-pyruvate MRS. The target of DCA is

PDK, which phosphorylates and inhibits the PDH complex resulting in higher activity
and a drop in brain lactate levels600. In order to measure the conversion of pyruvate to
lactate in the brain, 9-month-old naïve mice (n = 5) were injected via tail vein with

13

C-

pyruvate and the resulting peaks of pyruvate and lactate were measured 30 minutes
before and 30 minutes after tail vein injection of DCA (200 mg/kg). The whole brain
was imaged by 1H-MRI and individual

13

C-pyruvate spectra were overlaid to a coronal

field of view (Figure 28). The average of all spectra for each individual mouse was
calculated for both before and after DCA injection and the average of all mice in the
experiment was then compiled. This analysis revealed a decline in the ratio of lactate-topyruvate from before (0.10 ± 0.01) to after (0.06 ± 0.02) DCA injection (Figure 28). A
paired Welch’s t-test revealed that this difference was not statistically significant (p =
0.07), however, only five mice were analyzed and there was considerable variability in
lactate levels detected using this scanning technique. Further

13

C-pyruvate MRS

experiments should be completed to improve the sample size and increase the power of

138

the analysis in order to conclusively determine that DCA causes a decline in brain lactate
production.

4.2.8

Acute injection of dichloroacetate causes a decline in
phosphorylated PDH levels in the brain

To determine if DCA injection in these mice caused a change in phosphorylation levels
of PDH, mice were euthanized 30 minutes after intraperitoneal injection with either
saline or DCA (200 mg/kg) and brain extracts from the frontal cortex and hippocampus
were examined by western blotting (Figure 30 and Figure 32). This analysis revealed that
DCA caused a significant reduction in levels of phosphorylated PDH to total PDH in both
the frontal cortex and the hippocampus, indicating that DCA caused a physiological
response in the affected animals. This analysis also revealed a significant increase in
PDK1 expression and a significant decrease in MCT4 expression in the frontal cortex of
DCA-injected mice. There was no significant difference between saline- and DCAinjected mice for any of the proteins investigated in the hippocampus. A decrease in
expression of LDHA and MCT2 was noted but these differences did not pass the
significance threshold as determined by the Bonferroni correction for multiple
comparisons. Altogether, these results confirm the previous observations that DCA
injection causes a decline in levels of phosphorylated PDH in the frontal cortex and
hippocampus of affected mice.

4.2.9

The correlation between the expression of aerobic glycolysis
enzymes in the frontal cortex and memory performance is
reproducible

In order to further examine the relationship between aerobic glycolysis and memory, the
percent time spent in the correct quadrant during the probe trial of the MWM was
correlated to the band density from western blots of aerobic glycolysis and lactate
transporter proteins in the frontal cortex and hippocampus of saline- and DCA-injected
mice (Figure 33 and Figure 34). A multiple linear regression revealed that the ratio of
phosphorylated PDH to total PDH in the frontal cortex positively correlated with memory
performance for saline-injected mice. This suggests that mice with higher
phosphorylation of PDH in the frontal cortex performed better on the memory task than
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mice with lower phosphorylation of PDH. It is intriguing that DCA-injected mice had a
significant reduction in levels of phosphorylated-PDH and yet this did not confer
impairment in memory performance. This suggests that compensatory responses may
have been activated to maintain energetic demand during memory testing despite the drop
in PDH phosphorylation. A significant positive correlation was also observed between
memory performance and the expression of the astrocyte-specific lactate transporter,
MCT4, in the frontal cortex of DCA-injected mice. This indicates that mice with higher
MCT4 expression performed better on the memory test than mice with lower expression.
Previous reports have demonstrated that inhibition of MCT4 leads to amnesia, which can
be rescued by lactate but not equicaloric glucose, yet the inhibition of MCT2 leads to
amnesia that cannot be rescued by lactate or glucose462. Assuming that DCA caused a
decline in lactate levels by inhibiting PDK and thus reducing phosphorylation of PDH, an
increase in lactate transport may have arisen to maintain neuronal activity. The positive
correlation between memory performance and levels of phosphorylated-PDH in the
frontal cortex is consistent with previous observations in control mice (Figure 19).
However, these mice also displayed a positive correlation for lactate-producing enzymes
LDHA and PKM2/PKM1, suggesting a relationship between lactate production and
improved memory. This collective trend is absent from saline-injected mice in this
analysis, which showed no correlation for LDHA, LDHB, PKM2, or PKM1. In
agreement with previous observations, there were no significant correlations between
memory and expression of aerobic glycolysis proteins or lactate transporters in the
hippocampus. These results indicate that aerobic glycolysis in the frontal cortex may play
a more fundamental role than it does in the hippocampus.
It is also possible that aerobic glycolysis does not contribute to memory processes. Mice
injected with DCA did not exhibit impaired memory despite a decline in levels of
phosphorylated-PDH in both the frontal cortex and hippocampus. In addition, memory
performance did not correlate with expression of any marker of aerobic glycolysis other
than phosphorylation of PDH. However, earlier results from the correlation analysis of
control and APP/PS1 mice demonstrated a clear positive correlation between memory
and expression of lactate producing enzymes whereas the opposite effect was observed
for the lactate consuming enzyme (Figure 19). Furthermore, a significant decline in
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memory performance was measured from DCA-injected control mice when compared to
vehicle-injected and saline-injected control mice (Figure 26). These observations
highlight the need to reproduce experiments and test the hypothesis under different
conditions. In order to further examine the relationship between memory and aerobic
glycolysis, each measure of memory performance from the MWM was correlated to
levels of phosphorylated PDH in the frontal cortex of saline- and DCA-injected mice
(Figure 35). As previously demonstrated, a multiple linear regression revealed a
significant correlation between levels of phosphorylated PDH and percent time spent in
the correct quadrant.
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Chapter 5

5

Conclusions

There are two main conclusions that can be drawn from this work: (1) the deposition of
A in the AD brain perturbs lactate metabolism as indicated by the maintained lactate
levels with age in the frontal cortex of APP/PS1 mice, which interferes with memory
processes normally beneficial to the healthy aging brain, and (2) aerobic glycolysis plays
a role in spatial memory as demonstrated by the correlation analysis between protein
expression and memory performance, yet is not explicitly required for proper memory
function. There are several strengths and limitations to this study that are addressed in
this chapter, as well as future directions for further addressing these emergent hypotheses.

5.1 Thesis summary
Alzheimer’s disease is a neurodegenerative disorder characterized by the accumulation of
intracellular amyloid plaques and extracellular neurofibrillary tangles. The amyloid
plaques are comprised of aggregated A peptides that cause mitochondrial dysfunction
and neuronal death. Nerve cells can become resistant to A-toxicity by up-regulating
aerobic glycolysis, a metabolic phenotype that predominantly uses glycolysis for energy
production despite the availability of oxygen. Yet, it is currently unknown if neurons are
capable of escaping A-mediated toxicity by up-regulating aerobic glycolysis in vivo, and
whether aerobic glycolysis contributes to memory. The studies outlined in this
dissertation tested the hypotheses that neurons upregulate aerobic glycolysis to promote
A resistance, and that aerobic glycolysis contributes to memory processes. In vivo 1HMRS revealed an age-dependent decline in lactate levels within the frontal cortex of
control mice, whereas lactate levels remained unaltered in APP/PS1 mice from 3 to 12
months of age. In the hippocampus, lactate levels declined with age for both genotypes,
but sampling of ISF found elevated levels of lactate in APP/PS1 mice. An age-dependent
decline in levels of aerobic glycolysis enzymes in both control mice and APP/PS1 mice
was detected along with a concomitant increase in lactate transporter expression in
control mice. Immunofluorescence microscopy revealed the expression of aerobic
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glycolysis enzymes PDK1 and LDHA primarily in neurons within the frontal cortex and
hippocampus, and also in activated astrocytes in APP/PS1 mice. These findings suggest
that aerobic glycolysis plays an important role in memory in control mice but may be
detrimental in AD mice.
In order to test the hypothesis that aerobic glycolysis contributes to memory processes, a
single cohort of mice were injected with an acute dose of Isosafrol, an inhibitor of
LDHA, and also DCA, an inhibitor of PDK, in consecutive independent trials
immediately before entering the MWM. Control mice exposed to DCA performed worse
in the memory task compared to vehicle or saline injections, while APP/PS1 mice were
unaffected. A second experiment was performed to confirm these observations using two
independent groups of randomly assigned naïve control mice. In this case, mice injected
with DCA were found to have similar memory performance to mice injected with saline.
In vivo hyperpolarized 13C-pyruvate MRS was used to validate the effectiveness of DCA
by demonstrating a reduction in conversion of pyruvate to lactate in the brain. Western
blots from extracts of the frontal cortex and hippocampus of DCA-injected mice revealed
a significant decline in phosphorylation of PDH. In support of previous findings,
phosphorylation of PDH correlated with better memory performance in saline-injected
mice. These observations support the hypothesis that aerobic glycolysis contributes to
memory, yet is likely not the only contributing factor. Together, this evidence indicates
that production of lactate, via aerobic glycolysis, is beneficial for memory function
during normal aging. A deposition may perturb lactate processing and contribute to
cognitive decline in AD.

5.2 Strengths and limitations of the study
5.2.1

Disparity between human patients and the APP/PS1 mouse
model of Alzheimer’s disease

Transgenic mouse models of AD offer a unique opportunity to examine pathogenic
mechanisms and test novel therapeutics. However, given the high failure rate of clinical
trials, several questions have arisen about the validity of using laboratory animals to
model a complex age-related neurodegenerative disease in humans608,609. All transgenic
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mouse models of AD carry autosomal dominant mutations identified from early-onset
variants of the disease in humans, yet this accounts for less than 1% of all AD cases,
while the vast majority of AD cases are sporadic in nature and arise as a consequence of
age and genetic or lifestyle risk factors610. This means that these animals are good models
of a small subset of AD patients, but do not accurately represent the pathophysiological
changes associated with sporadic AD in the general public. In addition, most transgenic
mouse models only recapitulate amyloid accumulation, yet fail to develop other
pathological hallmarks including neurofibrillary tangles and neuronal loss611. Transgenic
mice that do carry mutations driving both amyloid plaques and neurofibrillary tangles
develop neurodegeneration and early cognitive deficits in a supra-physiological
manner612. These models are efficient for experimental purposes because of the rapid
onset of pathology and early cognitive decline, yet the progression of pathophysiology in
humans with sporadic AD occurs over the course of decades and this cannot be
accurately recapitulated in experimental models.
All of my experiments were performed using the APP/PS1 mouse model of AD. These
mice carry the Swedish mutation (K670N:M671L) in the APP gene that results in
increased production and secretion of the A peptide562–566, while expression of PSEN1
lacking exon 9 (ΔE9) shifts the cleavage of APP to favor A(1-42) over A(1-40)96. I chose
this model for several reasons: (1) the resistance mechanism in immortalized nerve
cultures was identified in A toxicity independent of tau pathology260; (2) these mice
develop cognitive impairment between 8 and 14 months of age481, which is suitable for
the purposes of finishing experiments within a doctoral timeline; and (3) these mice do
not develop neurodegeneration at the age of cognitive impairment613, suggesting that a
resistance mechanism to A may exist in order to facilitate neuron survival despite the
widespread accumulation of plaque at this age. Yet, if these mice do not experience
neurodegeneration, then why do they develop cognitive impairment? It was recently
discovered that APP/PS1 mice have impaired synaptic rewiring of cholinergic
interneurons in the hippocampus that is required for fear-conditioned learning614. In
addition, hippocampal pyramidal cells of APP/PS1 mice have early deficits in long-term
potentiation (LTP) that are independent of altered dendritic spine morphology615. These
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studies highlight a key disparity between these mice and human AD patients, where
cognitive decline is highly correlated with neurofibrillary tangles and neuron loss616–619.
The results of this dissertation suggest that memory deficit in APP/PS1 mice may also lie
in altered lactate metabolism, although further experiments are needed to confirm this
hypothesis.

5.2.2

Protein expression may not reflect enzyme activity

Western blot analysis of protein expression levels and phosphorylation of PDH may not
accurately reflect enzyme activity or the direction of metabolic pathways. A recent 1HMRS study demonstrated that brain lactate levels increase with age and this is
characterized by a shift in the ratio of LDH isozyme expression of high LDHA and low
LDHB330. This change in the ratio of LDHA to LDHB has also been described in
different tissues of the rat, including brain, in response to hypoxia620. However,
considering that the equilibrium constant is the same for all isozymes, because it is the
same reaction being catalyzed, it can be assumed that the LDH reaction is a nearequilibrium reaction and steady state conditions apply. This means that the isozyme
pattern cannot have an influence on the equilibrium lactate concentration331. If non-steady
state conditions apply, such as a rapid glycolytic flux or lactate export from the cell, then
the isozyme pattern may influence lactate concentration. In support of the expression
analysis of LDH isozyme pattern, Ross and colleagues also performed LDH activity
assays and demonstrated a significant increase in LDH activity in the direction of the
reaction from pyruvate to lactate330. In this dissertation, the ratio of LDHA to LDHB was
measured using western blot analysis from brain extracts, yet the activity of this reaction
was not measured and it was assumed that a shift in the ratio of LDHA/LDHB would
translate to a change in the direction of the pyruvate to lactate reaction.
By the same measure, it was assumed that a change in the level of PDH phosphorylation
was an indication of the activity of the enzyme, yet this is not always the case. Purified
PDH from bovine kidney mitochondria could be inactivated in a dose-dependent manner
by incubating the reaction mixture in ATP independent of PDH kinases or
phosphatases592. The regulation of PDH by phosphorylation is also site-specific. In an
elegant study by Korotchikina and Patel, the three phosphorylation sites of mammalian
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PDH were mutated from Serine to Alanine either individually or in combination. The
activity of these PDH mutants demonstrated little decline in activity for mutations in 2 of
the 3 phosphorylation sites, yet a 50-70% decline in activity of the mutant at Serine293621. One study using human mitochondria from muscle found that the phosphorylation
of PDH at two independent sites, Serine-293 and Serine-300, were negatively correlated
with PDH activity using an exponential model (R2 = 0.43 and 0.46, respectively), yet this
accounts for only 43% and 46% of the variation in PDH activity suggesting alternate
regulatory mechanisms may be present622. Furthermore, elevated phosphorylation of
PDH did not compromise the regulation of PDH activity during exercise. Dynamic
changes to the concentrations of substrates (pyruvate, NAD+, CoA) or products (acetylCoA, CO2, NADH) may also influence the activity of PDH independent of the PDH
kinases or phosphatates623. Considering that the acute exposure to DCA reduced
phosphorylation levels of PDH at both sites Serine-232 and Serine-293 in the brains of
affected mice (Figure 24), it was assumed that PDH activity was increased. However, this
was not measured and it is possible that the change in phosphorylation level was not
reflective of activity. If phosphorylation does not accurately reflect PDH activity, it is
possible that DCA failed to inhibit memory performance because PDH activity was
maintained following DCA exposure. Future experiments should measure activity of
PDH from these samples to confirm that DCA exposure affects the activity of the enzyme
in vivo.
Western blot analysis of protein expression and phosphorylation of PDH were correlated
to memory performance in the MWM. Interestingly, the expression of lactate-producing
enzymes in the frontal cortex correlated with better memory whereas expression of
LDHB correlated with worse memory in control mice. In addition, saline-injected mice
showed a positive correlation between phosphorylation of PDH in the frontal cortex and
memory. Correlations of gene expression in the brain and behavioural changes have
previously been described624–627, indicating a relevant relationship between expression of
certain proteins in the brain and behavioural phenotype. It was assumed that the protein
levels from brain extracts of euthanized mice were reflective of actual protein expression
during the memory test. However, it is currently unknown how stable these expression
patterns are during stressful conditions of memory testing or over the course of time.
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Several different factors are known to influence gene expression of glycolytic enzymes,
including physical exercise628, hypoxia629, glucose availability630, circadian rhythm631,
and neuronal activation632. Protein phosphorylation is an especially labile regulatory
mechanism that changes rapidly in response to cellular environment633. In terms of
metabolic signaling, phosphorylation is especially sensitive to changes in nutrient
availability and energetic status of the cell considering that ATP is the donor of
phosphate groups634. Phosphorylation of PDH can occur as quickly as 2 minutes in
response to glucose stimulation in pancreatic -cells635. In response to hypoxia, PDH
phosphorylation occurs within 30 minutes, while transcriptional upregulation of HIF-1
target genes occurs after 4-6 hours636. Given that protein expression and phosphorylation
is constantly changing in response to a dynamic cellular environment, future experiments
should aim to euthanize mice immediately following memory testing to ensure accurate
correlations are made.

5.2.3

Off-target effects and increased variability with chemical
modulation from Isosafrol and dichloroacetate

In order to modulate the activity of key aerobic glycolysis enzymes, the chemicals DCA
and Isosafrol were used to inhibit the aerobic glycolysis enzymes PDK and LDHA,
respectively. Chemical modulation is a simple, effective, and inexpensive way to test the
effect of target molecules on a biological system. Chemical modulation is used
extensively in vitro in part due to the simplicity of the cell culture system, yet there are
certain challenges associated with in vivo biological systems. The single largest limitation
discovered in this work was the loss of effect in chronic exposure to DCA. Thus the
ability to test the hypothesis that aerobic glycolysis is upregulated in neurons to promote
A resistance, could not be properly investigated. Other main limitations of chemical
modulation in laboratory animals are potential off-target effects and variable
bioavailability and clearance of these agents.
Despite several studies demonstrating the high affinity of DCA for PDK599 and Isosafrol
for LDHA491, these chemicals have several additional off-target effects. DCA is
transported across the plasma membrane by the MCT family of transporters that are also
responsible for shuttling lactate, pyruvate, and ketone bodies637. This means that DCA
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could interfere with transport of metabolites within the brain and across the blood-brain
barrier by directly competing with these substrates. The primary site of DCA metabolism
is the liver, where it is dehalogenated to glyoxylate in a reaction that requires glutathione
and eventually converted to glycine, oxalate, and CO2637,638. Yet, a minority of DCA may
also undergo reductive dechlorination to monochloracetate, which is highly neurotoxic596.
Peripheral neuropathy is a common side effect of DCA in humans595 and laboratory
animals639. This likely occurs via reduction in expression of myelin-related proteins in
Schwann cells640. Over the course of this dissertation, several mice had to be euthanized
after months of chronic exposure to DCA due to tissue damage to the ends of their tails
and hindfeet. While all other mice appeared to tolerate DCA during the course of
exposure, and there was no observable effect of DCA on the ability of mice to swim in
the MWM, it was assumed that nerve toxicity did not have an effect on cerebral lactate
metabolism. Isosafrol has a shorter history than DCA and so less is known about its
pharmacology or pharmacotoxicology. Oral administration of isosafrol in rats resulted in
89% of the dose excreted in urine after 72 hours suggesting it has less bioavailability than
DCA641. Isosafrol is an analog of stiripentol, which indirectly inhibits cytochrome P450
enzymes642 and may affect detoxification reactions in the liver or synthesis of hormones,
cholesterol, or vitamin D643.
Chemical modulation also introduces a source of individual variability between animals
of the same treatment. The mode of delivery of chronic DCA exposure was oral
administration in the drinking water. The dosage of DCA was calculated based on an
average weight of all animals in the same cage and an assumed daily consumption of 5
mL per animal. Given that animals in the same cage had different weights and likely
consumed different amounts of water, the specific dose of each animal would have been
slightly different. Precise dosages of DCA and Isosafrol were achieved by intraperitoneal
injection. The dose of each injection was calculated by weight of each individual animal,
which was more accurate than oral administration, yet there were likely subtle differences
in the site of injection of each animal that introduced variability in biological
measurements. In addition, mice that were injected with DCA or Isosafrol were memory
tested or euthanized 30 minutes after delivery, yet the half-life of the drug is dependent
on its detoxification in the liver or clearance in the kidney and would be slightly different
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for each animal. For these reasons, the introduction of chemicals to a biological system as
a means to study the effect of inhibiting an enzyme introduces addition sources of
variability between individuals within a treatment group.

5.3 Future directions
Due to technical limitations of chemical-induced inhibition of enzymes, future work
should be aimed at using more reliable and robust methods of modifying the expression
or activity of these enzymes in order to reduce off-target effects and limit additional
sources of variation. Genetic manipulation allows precise temporal and spatial control
over expression of gene targets. This gives researchers the tools for examining the
biological consequence of altered expression within a given age of an animal’s lifespan
and within specific tissues of interest.
Future projects will be aimed at over-expressing or knocking-out LDHA in either neurons
or astrocytes and testing the behavioural outcome at an appropriate age. In addition,
crossing these mice to a mouse model of AD would greatly help towards identifying the
role of LDHA expression, and associated lactate production, on AD progression. Some of
this work has already been accomplished. In consultation with Christopher Pin and the
London Regional Transgenic and Gene Targeting Facility (LRTGT), I created a new
transgenic mouse line over-expressing mouse LDHA with a C-terminal HA tag. Founder
mice for this transgenic line are currently in our colony. The Ldha gene was cloned into
the pTRE-Tight (Clontech) tetracycline-inducible expression vector, which contains a
minimal CMV promoter (PminCMVΔ) immediately downstream of a tetracycline response
element (TREmod) consisting of seven direct repeats of a 36 bp sequence containing the
19 bp tetracycline operator sequence (tet-O). In order to test the efficiency of expression
in response to tetracycline, the mLDHA-HA-pTight construct was transfected into HeLa
cells that stably express the reverse tetracycline transactivator (rtTA). The HeLa-rtTA
cells were kindly provided by Dr. Nina Jones of Guelph University. A dose-dependent
increase in mLDHA-HA protein level was found with a 24 hour exposure to tetracycline
as determined by western blot analysis of cell lysates using anti-HA antibodies (Figure
A1B). The mLDHA-HA-pTight construct was then digested with the Xho1 restriction
enzyme to isolate the fragment containing the Ptight promoter and the mLDHA-HA gene
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with a polyadenylation tail. This fragment was used for pronuclear injection into
fertilized embryos for the creation of a novel transgenic mouse at the LRTGT facility.
Tail samples from weaned pups were tested for the presence of the mLDHA-HA
transgene using primers within the Ptight promoter and the first exon of the LDHA gene.
This analysis identified two female mice positive for the mLDHA-HA transgene. These
founders were bred to male C57BL/6J mice and the litters were tested for the presence of
the transgene using ear punch tissue from weaning. One of the founder females produced
a single female pup that was positive for mLDHA-HA, indicating that the transgene was
within the germline and could be passed through breeding (Figure A1C).
This mLDHA-HA transgenic mouse line will be crossed to mice containing the reverse
tetracycline transactivator (rtTA) under control of the neuron-specific CaMKII
promoter in order to drive expression of mLDHA-HA specifically in neurons in response
to oral administration of doxycycline644. In order to drive expression in astrocytes, tet-OmLDHA-HA transgenic mice will be crossed to mice containing the rtTA element under
control of the astrocyte-specific Gfap promoter645,646. In a preliminary experiment to
confirm the tight inducible expression of the mLDHA-HA construct, 1-month-old mice
that express either the mLDHA-HA alone or rtTA alone, or mice expressing both
mLDHA-HA and rtTA will be switched to a doxycycline chow for a time course of 2
weeks and then euthanized. Western blot analysis using HA-specific monoclonal
antibodies will be used to confirm the expression of the mLDHA-HA construct in double
transgenic mice alone. A sub-cohort of double transgenic mice will be treated with
doxycycline for 2 weeks and removed from doxycycline for 2 weeks to demonstrate that
removal of doxycycline after induction can suppress expression of the transgene. Once
the regulation of transgene expression has been confirmed, double-transgenic mice will
be allowed to age to 12 months and exposed to doxycycline chow for 2 weeks that will
activate mLDHA-HA expression in either neurons or astrocytes.
In order to knock-out LDHA expression in either neurons or astrocytes, an alternate
approach will be taken. Transgenic mice containing loxP sites flanking exon 2 in the
Ldha alleles (LDHAfl/fl) will be crossed to mice containing Cre-recombinase under
control of the tet-O promoter (tet-O-Cre)647. The LDHAfl/fl mouse line is commercially
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available and has successfully been used to conditionally knockout the Ldha gene only in
bone marrow stem cells648. These double-transgenic mice will be crossed to mice
containing the tetracycline-transactivator (tTA) cassette under control of the CaMKII
promoter to drive expression in neurons649 or the Gfap promoter to drive expression in
astrocytes650. The tTA element will repress expression of Cre in the presence of
doxycycline and activate Cre when doxycycline is removed. Considering that complete
knockout of LDHA is embryonic lethal651, pregnant mothers will be put on doxycycline
chow to prevent the expression of Cre during gestation and neonatal development in
triple-transgenic mice. In a preliminary experiment to confirm the absence of LDHA
expression, 1-month-old triple-transgenic mice will be switched from a doxycycline
chow to a normal chow for a time course of 2 weeks and then euthanized. Western blot
analysis of brain extracts using LDHA-specific antibodies will be used to determine the
expression of LDHA protein relative to double-transgenic mice that lack the tet-O-Cre
cassette. A sub-cohort of triple transgenic mice will be switched to normal food for 2
weeks and then back to doxycycline for 2 weeks to demonstrate that removal of
doxycycline induces a permanent excision of the floxed Ldha gene. Once the regulation
of the transgenic elements have been established, triple-transgenic mice will be
maintained on doxycycline until 12 months of age and switched to normal chow to
remove LDHA expression in either neurons or astrocytes.
These genetic mouse lines allow for convenient temporal and spatial control over
expression of LDHA response to doxycycline chow. Transgenic mice that are either not
exposed to doxycycline chow (for over-expression line) or exposed to doxycycline chow
(for knock-out line) can be conveniently used as littermate controls. The behaviour of
LDHA over-expression mice or LDHA knock-out mice will be evaluated using several
different memory tests, including the MWM, the Barnes maze652, and the novel object
recognition test653. In order to assess stress and anxiety of these animals, the open-field
test654, the elevated plus maze655, and the light-dark exploration test656 will be used. All of
these behavioural tests are available to our laboratory. The amount of lactate will be
measured in vivo using 1H-MRS examining different brain regions including the frontal
cortex, the hippocampus, and the cerebellum. Mice will be euthanized and brain tissue
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harvested for western blot analysis of the frontal cortex, the hippocampus, and the
cerebellum, in order to confirm the expression of the mLDHA-HA construct using HAspecific antibodies or the deletion of LDHA using LDHA-specific antibodies. The tissuespecific expression or knock-out of LDHA in neurons or astrocytes will be evaluated
using cryo-immunofluorescence microscopy with TUJ1 antibodies to target neurons and
GFAP antibodies to target astrocytes with co-immunostaining using HA-specific
antibodies and LDHA-specific antibodies. It is predicted that mice over-expressing
mLDHA-HA in neurons or astrocytes will display higher levels of cerebral lactate and
have enhanced memory performance. In contrast, mice that lack LDHA expression will
display decreased levels of cerebral lactate and will have memory deficits. These results
will offer robust evidence to accept or reject the hypothesis that aerobic glycolysis
contributes to memory processes. Any differences between the genetic manipulations of
LDHA in neurons or astrocytes will indicate a functionally distinct role of aerobic
glycolysis in these two different cell types.
In order to test the hypothesis that aerobic glycolysis promotes A resistance in AD,
double-transgenic LDHA over-expression mice and triple-transgenic LDHA knock-out
mice will each be crossed to the 5xTg mouse line. These mice contain 5 different
mutations targeting the A pathway: APPKM670/671NL (Swedish), APPI716V (Florida),
APPV7171 (London), PSEN1M146L, and PSENL286V. This mouse model of AD has several
benefits over the APP/PS1 mouse line; including deficits in spatial learning that occur at
4-5 months of age and apparent neurodegeneration at 9-12 months of age657. Considering
that these mice exhibit dramatic rises in A(1-42) levels beginning at 1.5 months of age,
the induction of LDHA over-expression or knock-out will be initialized immediately after
weaning. These mice will be monitored over the course of age and behavioural testing
will be administered at 4 months of age. The progression of amyloid pathology will be
examined over the course of aging by euthanizing mice at regular intervals of age. Brain
cryo-sections will be stained with Thioflavin S to visualize amyloid plaques via
immunofluorescence, while cerebral levels of A(1-40) and A(1-42) will be measured using
ELISAs. Synaptic dysfunction and neurodegeneration will be evaluated by western blot
analysis measuring levels of syntaxin and post-synaptic density protein 95 (PSD-95),
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both synaptic markers, and p25 as a marker for the neurodegeneration pathway657. It is
anticipated that over-expression of LDHA in neurons or astrocytes will maintain neuron
survival in 5xTg mice at 9 months of age, while the opposite trend is expected with
LDHA knock-out mice. These experiments will provide sufficient evidence to accept or
reject the hypothesis that aerobic glycolysis promotes Aresistance in AD.

5.4 Concluding remarks
A number of significant and novel findings were realized in this study. First, lactate
levels in the frontal cortex decline with age, yet are maintained in APP/SP1 mice. A
significant correlation exists between expression of lactate producing enzymes and
memory performance in control mice, but not in APP/PS1 mice. These findings suggest
that lactate production plays a beneficial role in memory in the healthy aging brain but
might contribute to memory decline in the AD brain. Second, expression of PDK1 and
LDHA, two central regulators of aerobic glycolysis was found primarily in the soma of
neurons, but also in reactive astrocytes surrounding amyloid plaques. These observations
indicate that neurons can also generate lactate, and that reactive astrocytes may play a
role in the elevated lactate levels detected in the AD brain. Finally, chemical inhibition of
aerobic glycolysis appeared to inhibit learning in mice whereas it had little to no effect on
spatial memory. Thus, aerobic glycolysis may play a more prominent role in different
regions of the brain affecting other cognitive processes and behaviours independent of
memory. Each of these observations need to be examined further in order to provide a
more complete mechanistic overview of cerebral lactate metabolism in the healthy brain
and its role in memory. This work will also lead to a better understanding of how aerobic
glycolysis and cerebral A interact in the AD brain and could lead to the development of
novel metabolic strategies to treat this devastating disease.
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Appendix A: Supplementary Figures and Tables

Figure A1. Creation of novel transgenic mouse line containing
mLDHA-HA-pTight expression cassette.
(A) Western blot analysis of cell lysates probed using HA- and
GAPDH-antibodies showing tetracycline-inducible expression of
mLDHA-HA in HeLa-rtTA cells. (B) PCR-based genotyping of ear
punch from litter of female founder mouse #849 with positive pup #6
demonstrating germline transmission of the mLDHA-HA-pTight
transgene.
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Table A2. List of mice removed from analysis due to stress effects in a particular
training phase.
Mice could be removed from analysis if they display behaviour that clearly demonstrates
no attempt to actively search for the platform during the training phase. The number of
control mice and APP/PS1 mice out of the total for each training phase is displayed.

Number of mice removed from analysis due to stress
Training Phase

Control

APP/PS1

Vehicle

0 / 17

3 / 11

Isosafrol

0 / 16

1/9

DCA

0 / 15

1/9

Saline

0 / 13

1/7
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